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Abstract 
 
Complex secondary metabolites display a wealth of biological activities and, together with 
their derivatives, have provided over 60% of new pharmaceutical agents over the past 40 years. 
Despite their clinical success, limitations in isolation yields as well as the synthetic challenges 
posed by these scaffolds often hinders the medicinal chemistry efforts necessary to overcome 
suboptimal pharmacological properties, highlighting the need for alternative methods. A 
promising strategy for generating libraries of natural product analogues is through the use of 
biosynthetic enzymes. These systems have long been hypothesized to be capable of producing 
almost unlimited structural diversity, due to their modular nature, however to date, efforts towards 
PKS engineering have mostly met with failure. Despite notable successes, decreased product 
yields and/or failure to produce the desired structures entirely have stymied these efforts. Recent 
studies focusing on the interrogation of single modules or module domains via biochemical 
analysis coupled with structural determination have begun to shed light on these complex systems 
and give us insight into the reasons for the initial failures.  
The studies presented in this thesis focus on investigations into the structural and 
mechanistic parameters that govern selectivity in the biosynthetic enzymes of interest from two 
key natural products, the PKS/NRPS derived cryptophycin family of anticancer agents, and the 
PKS antibiotic Pikromycin. In the cryptophycin system, synthetic chain elongation intermediates 
have been coupled with the Crp TE macrocyclizing catalyst to produce a library of heterocyclic 
unit A analogues. This was met with remarkable success as all the analogues were processed by 
the TE with similar or greater efficiency than that seen with the native substrate. Current efforts 
are focused on gaining an NMR structure of this TE with hopes of shedding light on the underlying 
catalytic mechanism that makes this enzyme so versatile. This facilitated the biological evaluation 
of these analogues, allowing us to identify one that displays remarkable activity without the 
presence of an epoxide group that was previously thought to be necessary for maximum efficacy.  
Utilizing the same strategy in the Pikromycin system, five new pentaketides analogues 
were generated that could be used with three separate intact PKS modules, the PikAIII-TE and the 
 xiii 
coupled PikAIII/AIV system. These synthetic intermediates have continued to lend credence to 
the hypothesis that in PKS systems, the TE tends to be the deciding factor on whether hydrolytic 
byproducts are formed or macrocycles. Utilizing our biocatalytic platform we have been able to 
show that the TE can more effectively produce 14 membered macrolactones containing unnatural 
functionality than 12, leading to the isolation of three new macrolactone products. Altered alkyl 
chain substituents on these pentaketides substrates have also shed light on the likelihood of a size 
restriction for the loading of these substrates onto the KS domain of the initial module. The 
continued investigation of these substrates as well as others continues to build the groundwork for 
future engineering campaigns aimed at generating more flexible catalysts for the production of 
novel natural product analogues.  
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Chapter 1 
Introduction and Background 
 
 
1.1  Natural Products as Therapeutic Agents 
1.1.1   History of Natural Products in Medicine  
Natural products, or secondary metabolites, are chemical compounds derived from all 
kingdoms of life, that are not required for primary survival (i.e. growth, reproduction, or 
metabolism), but confer a selective advantage to a given organism within their niche.1 These 
compounds have been used in the treatment of human illnesses since before the advent of modern 
medicine and continue to play a vital role in combating major diseases.2 The first recorded reports 
of natural product usage stem from ancient civilizations including Mesopotamia (2600 BC) and 
the ancient Egyptians (1550 BC) who used plant derived medicines to formulate oils, ointments, 
pills, and gargles to treat a variety of ailments including colds and inflammation.2-4 The early 
1800’s saw a renaissance of drug development and natural product exploration with the isolation 
of morphine and other alkaloids (including quinine and nicotine) from a variety of plant sources5 
and by 1853 salicylic acid, the active metabolite in aspirin, became the first natural product to be 
made by chemical synthesis with the advent of the Kolbe-Schmitt reaction.6 In 1928, natural 
product medicines were again a sensation as one of the most profound medical discoveries came 
when Alexander Flemming discovered a molecule, penicillin, with antibacterial activity from a 
fungus, Penicillium chrysogenum, changing the course of modern medicine.2  
1.1.2 Natural Products in Clinical Drug Discovery and Development   
The field of natural product drug discovery continued to expand through the early 1900s and 
with the onset of the “golden age of antibiotics”, all major pharmaceutical companies initiated 
natural products discovery teams, looking for not only antimicrobials, but anti-fungals and anti-
cancer agents.3 The wide variety of chemical diversity seen in these molecules makes them 
effective agents in all areas of clinical medicine, with over 60% of all drugs approved from 1981 
 2 
to 2014 being direct natural products or natural product derivatives. The significance of these 
molecules is even more pronounced in the area of antibiotics and anticancer agents, with the 
number of compounds being derived from natural sources being above 70% for these classes of 
drugs.1 Some examples of clinically used natural products are antibiotics like penicillin and 
erythromycin A, anti-cancer agents like Taxol, antiparasitics like avermectin, analgesics like 
morphine, cholesterol lowering agents like lovostatin, insecticidal agents like spinosyn A, and 
immunosuppressant’s like cyclosporine (Figure 1.1).7  
Despite the clinical success of natural products, the early 2000’s saw a decline in 
pharmaceutical company involvement. With the advent of combinatorial synthesis and high 
throughput screening (HTS) technology, large libraries of compounds could be chemically 
synthesized and screened for activity over a variety of targets. These initial hit identifications could 
then be translated into promising leads through structure activity relationship (SAR) campaigns, 
 
 
 
Figure 1.1 Natural Products as Drug Leads. Examples of well-known natural products with clinical 
significance, demonstrating the vast array of scaffolds and assorted therapeutic applications of these 
types of compounds.  
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circumventing the need to pursue natural products which historically have been plagued with 
lengthy, complex chemical syntheses and high production costs.8 In recent years however, interest 
in natural products has been reinvigorated as combinatorial synthesis, despite many successes, 
cannot compete with the chemical diversity found in nature. These “privileged scaffolds” have 
developed over thousands of years to interact specifically with a variety of biological targets,9 
making their structural diversity an unavoidable necessity, and thus providing an advantage over 
traditional synthetic libraries. 
 
1.2 Polyketide Synthase and Non-Ribosomal Peptide Natural Products  
Polyketides (PKs), non-ribosomal peptides (NRPs), and their hybrids (PK/NRP) are a large 
sub-class of natural products which historically possess a wealth of pharmacological activates, 
specifically in the areas of anticancer and antibiotics.10-12 These molecules are formulated in an 
analogous manner by megasynthase enzymes that are organized into biosynthetic pathways. 
Polyketides are comprised of multiple, two carbon ketide units, that are joined together to form 
the growing polyketide chain.  Non-ribosomal peptides are also formulated by multidomain 
proteins, except these are responsible for the joining of amino acids or amino acid derivatives via 
peptide bond formation to produce the complex structures seen in nature (e.g. Figure 1.1). A subset 
of these PK and NRP natural products contain a macrocyclic core, formulated via an 
intramolecular ester or amide bond, which serves to lock these otherwise flexible molecules into 
their precise, biologically relevant, conformation. The biosynthesis of these is terminated by a 
thioesterase, the enzyme responsible for effecting, regio- and stereo- specific macrocyclization.13  
1.2.1 General Biosynthetic Machinery of Polyketide Synthases   
The enzymatic systems responsible for the production of polyketide natural products are 
termed Polyketide Synthases (PKS) and utilize a similar mechanistic strategy as Fatty Acid 
Synthases (FAS) found in primary metabolism. Based on their architecture, PKSs can be classified 
into three different types, Type I, Type II,14 and Type III,15with Type I being covered here. Type 
I PKS, like FAS, select for two carbon units in the form of malonyl Coenzyme A (CoA) derivatives 
that are then joined together through a series of Claisen Condensation reactions. Each module of 
a polyketide synthase is comprised of three necessary domains, the ketosynthase (KS), the acyl 
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transferase (AT), and the acyl carrier protein (ACP) seen in Figure 1.2. 16-17 During elongation, 
the AT selects an appropriate malonyl derivative and loads it onto the ACP. The KS, containing 
the growing polyketide chain from the previous module, catalyzes decarboxylation of the ACP 
bound malonyl derivative. This generates a transient nucleophile that reacts with the growing chain 
in a Claisen Condensation type reaction, increasing the backbone length by two carbons with each 
cycle.  
In addition to the necessary domains, there are three “optional” domains, the ketoreductase 
(KR), dehydratase (DH), and enoyl reductase (ER) which are responsible for reductions of the 3-
keto group to either a hydroxyl, alkene, or alkane functionality (Figure 1.2: 2, 3, and 4). In FAS 
there are a single copy of all six of these which iteratively act upon each ketide unit, producing the 
relatively simple, unsaturated chains seen in these systems. In PKS systems, the necessary domains 
are organized into modules, each capable of accepting potentially different extension units 
(malonyl, methyl malonyl, and ethyl malonyl, etc.). Each module will contain all three necessary 
domains and can be complemented with one, two, or all three optional domains, producing the 
vast diversity seen in polyketide chains (Figure 1.2).10  
Once a single module has completed its extension, the growing polyketide chain is then passed 
off to the downstream module via protein-protein interactions. These are modulated by a non-
 
 
Figure 1.2 Schematic of a generic PKS module. The cycle starts when the AT selects an appropriate 
extender unit and loads it to the ACP. Decarboxylation and subsequently Claisen Condensation is 
catalyzed by the KS which produces the b keto substrate 1. Optional domains present in the different 
modules can then act upon the newly extended product. These include the KR which performs a keto 
reduction (2), DH which performs dehydration (3), and the ER which reduces the double bond to a 
saturated alkane (4).  
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covalent association of “docking domains”, short helical segments that are fused to the C-terminus 
of the upstream module and the N-terminus of the downstream.18 The interaction of these two 
dimerization elements facilitates effective and specific transfer of growing polyketide chain.   
1.2.2 General Biosynthetic Machinery of Non-Ribosomal Peptide Synthetases 
 Non-ribosomal peptides are formulated by a separate set of multi-modular enzymes termed 
Non-Ribosomal Peptide Synthetases (NRPS). These systems utilize amino acids or amino acid 
derivatives, instead of malonyl derivatives, and join them together via peptide bond formation in 
a ribosome-independent fashion. These proteins also contain three necessary domains: the 
adenylation domain (A) which selects the appropriate amino acid, the condensation domain (C) 
which catalyzes peptide bond formation, and a peptidyl carrier protein (PCP) that shuttles the 
growing chain from module to module (Figure 1.3).19-20 These systems have a variety of optional 
domains as well, that can act upon the growing chain in a non-iterative fashion. An epimerization 
domain can take the L-amino acids, manufactured during primary metabolism, and invert the 
stereochemistry to produce the much rarer, D variant (6).  N-methylation is another optional 
domain that is accomplished through a s-adenysyl methionine (SAM) methyl transferase (7) and 
 
 
 
Figure 1.3 Schematic of a generic NRPS mechanism. The catalytic cycle begins when the A domain 
selects an appropriate amino acid and loads it to the cognate PCP. Peptide bond formation is then 
catalyzed by the C domain to produce substrate 1. Optional domains present in the modules include the 
Ep domain, responsible for epimerization of the a stereocenter (6), the MT domain which catalyzes N-
methylation (7), and the Cy domain that cyclizes nucleophilic sidechains to form the corresponding 
oxazole/thiazole rings (8). 
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lastly, cyclization of amino acids containing nucleophile sidechains (serine, threonine and 
cysteines) to form oxazoline and thiazoline rings (8). These rings can also undergo redox reactions 
to change their unsaturation state. Although many of these natural products are exclusively 
biosynthesized by PKS or NRPS systems, hybrid biosynthetic systems that combine both PKS and 
NRPS modules also exist and formulate molecules containing both polyketide portions and peptide 
portions, exponentially increasing the possible diversity that nature is able to make with these 
systems.  
The final step in the biosynthesis of macrocyclic PK and NRP natural products is offloading 
which, in the case of macrocycles, is catalyzed by a thioesterase that is appended to the terminal 
module of these biosynthetic systems. These enzymes are broadly classified as serine hydrolases 
and utilize a serine, histidine, aspartic acid catalytic triad to either hydrolyze off the growing linear 
chain or facilitate intramolecular cyclization to form the core macrocycle.   
1.2.3 Tailoring Enzymes in PKS and NRPS Systems  
 Polyketide/Non-ribosomal peptide cores are often modified by late stage tailoring 
enzymes, which can further increase the diversity seen in these systems. The common post-PKS 
and NRPS modifications seen are produced by a plethora of different enzymes, including 
oxidoreductases, group transferases, halogenases, cyclases, and deoxysugar biosynthetic 
casettes.21-22 Often these enzymes are responsible for the production of functional groups that are 
imperative for biological function. The very nature of macrolide (macrolactone glycoside)23 
antibiotics relies upon glycotransferases that append a variety of sugars to hydroxyls on 
macrocycles, whose cores are not active without this moiety. These hydroxyls can come from PKS 
KRs or from oxygenases, specifically P450s or flaven dependent oxygenases, that are able to 
install hydroxyl, aldehyde, and/or epoxide groups to often otherwise unactivated C-H bonds.  
 
1.3 Strategies for Synthesis of Natural Products  
Since the modern era of natural product total synthesis began, it has continued to expand 
exponentially, making complex scaffolds such as ciguatoxin CTX3C, a polyether containing 12 
rings and 30 stereogenic centers, synthetically tractable.24 The continued development of 
organometallics,25 chiral auxiliary chemistry, and asymmetric aldol reactions26 have been 
instrumental in natural product drug discovery as they facilitate access to analogues that are 
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unattainable by other methods including semi-synthesis and fermentation.27 Despite the 
formulation of these molecules usually being constrained to academic endeavors, complex total 
synthesis has also found practicality in industrial settings when low isolation yields cause 
“bottlenecks” that hinder development. This is best exemplified by Halaven (Eribulin mesylate), 
a drug approved in 2010 for the treatment of metastatic breast cancer.28-29 This molecule is 
considered the most structurally complex therapeutic formulated by total synthesis for clinical use. 
This molecule is a truncated, synthetic version of the halichondirn B isolated from a marine 
sponge. Low isolation yields, and the unculturable nature of sponges made access to this molecule 
for clinical development a major hurdle.30 The complexity seen, with its 19 stereocenters, would 
frequently make it out of reach for industrial scale total synthesis however, a herculean effort to 
formulate convergent synthesis led to a 62 step route, with the longest linear sequence being 30 
steps. The critical discovery, that changed the fate of this molecule in the clinic was the crystallinity 
of multiple late stage fragments, which facilitated easy access, with minimal chromatography, to 
the appropriate diastereomer needed to formulate this complicated scaffold.30-33  
Supply issues and medicinal chemistry efforts towards natural products are not limited to 
synthetic chemistry, but are also solved through fermentation, precursor directed biosynthesis 
(Figure 1.4), and/or semi synthesis.34 This is especially prevalent in antibiotic discovery. 
Erythromycin, the first clinically used antibiotic, has a single published total synthesis which 
requires 77 steps,35-37 illustrating the need for alternative methods. Fermentation has largely 
overcome this hurdle by providing rapid access to kilograms of this macrolide. The ease at which 
this can be produced allowed for further medicinal chemistry efforts to this scaffold which have 
identified second, third and even fourth generation antibiotics.38 These relatives are made by semi-
synthesis from the fermented erythromycin scaffold and include Azithromycin (Zithromax) one of 
the highest grossing drugs on the market today, which is synthesized through a Beckman 
rearrangement ring expansion. Other clinical natural products, like the anticancer agent taxol, are 
formulated for clinical use through semi-synthesis as well. In this case, isolation of the natural 
product faced insurmountable challenges as it is only produced in the bark of the pacific yew tree. 
In order to obtain it for clinical trials, the bark of a single tree had to be striped (effectively killing 
it) for each dose.39 Despite this, the clinical success of this drug later led to the discovery of a taxol 
precursor, 10-deacetyl-baccatin III made by the needles of the pacific yew tree, that could be 
extracted and synthetically converted to the anticancer agent without killing old growth trees. 
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Taking advantage of the efficiency and selectivity of the biosynthetic machinery in these 
organisms to formulate the full natural product or advanced intermediates cuts production time 
and costs significantly, lending credence to the effectiveness of this strategy.  
Although both methods are viable and have their advantages, each has their disadvantages: 
synthetic chemistry is able to produce almost unlimited structural variations, however the cost and 
time necessary is often debilitating, whereas fermentation and semi-synthesis is frequently more 
time and cost effective, but it is constrained by activated functional groups for manipulation, and 
low isolation yields. The ability to merge these two fields and explore chemoenzymatic syntheses 
could bridge the current gaps left by both disciplines and provide rapid access to previously 
inaccessible compound analogues. Despite the notable enzymatic transformations that are widely 
used in synthetic chemistry (esterases, lipases),40 the use of multienzyme systems such as PKS and 
NRPS modules has yet to gain widespread interest, presumably due to the specificity seen in these 
systems and the expertise necessary to overcome these hurdles. Continued research in this area is 
required to gain a more detailed understanding of the catalytic systems used by these enzymes as 
well as their selectivity profiles in order to reach our ultimate goal of engineering broad scope 
catalysts capable of processing large libraries of “unnatural” natural products with the same 
enzyme variant.  
 
1.4 Combinatorial Biosynthesis in Drug Discovery  
Utilizing PKS and NRPS systems to formulate natural product libraries has met with great 
enthusiasm in academics over the past two decades due to the almost limitless structural variation 
that could be imparted to scaffolds of interest. These systems have the capability to produce 
hundreds of millions of compounds by exploiting substrate promiscuity through protein and 
pathway engineering. Diversity can be introduced in these systems in three main ways: precursor 
directed biosynthesis, modification of discrete enzymes within a pathway, and recombinant 
pathway construction (Figure 1.4: 1, 2, and 3).41-44 Feeding of alternate precursors has been used 
extensively to modify natural products as it takes advantage of inherent flexibility in the 
biosynthetic systems to incorporate new extender units without the need for genetic engineering 
(Figure 1.4: 1).45-50 This is exemplified by the polyether antibiotic monensin, which contains a 
leaky AT and has been shown to accept synthetic propargyl malonyl when cultures are 
supplemented with it.51 Augmenting with larger synthetic intermediates has also shown some  
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success as in the 6-deoxyerythronolide B (DEBS) system. In this study, synthetic diketides were 
fed to E. coli containing plasmids encoding the remaining PKS modules as well as the enzymes 
responsible for glycosylation/oxidation. This system was effectively able process these substrates 
into novel macrolides.52 
 
 
Figure 1.4 Schematic of the strategies used in combinatorial biosynthesis: 1 Precursor Directed 
Biosynthesis which takes advantage of the inherent flexibility of the system and synthetic precursors 
to formulate unnatural analogues, 2 Module level modifications which include moving parts of one 
module into a homologous one termed “domain swapping”, as well as site-directed mutagenesis and 
directed evolution which take advantage of mutations throughout the biosynthetic cluster to produce 
new molecules, and finally 3 Pathway recombination which takes entire genes from multiple pathways 
to formulate chimeric ones. 
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The second two facets of combinatorial biosynthesis rely heavily on genetic engineering to 
produce structural variations. Modifications to discrete enzymes within a pathway frequently 
focuses on swapping of domains within modules. Diversity can be introduced in a number of ways 
by changing the selectivity and optional processing of an overall module including choice of 
malonyl or amino acid extender units (selected for by the AT or A domains), degree of unsaturation 
in both products (controlled by optional domains in PKS and NRPS systems), as well as altered 
stereochemistry.53-54 This strategy has led to impressive libraries in the both the DEBS pathway 
and the NRPS derived daptomycin pathway. Both of these studies swapped analogous domains in 
related systems to form novel molecules with the same scaffold, but altered redox states and side 
chain incorporation.55-58 Other methods of modifying discrete enzymes within a pathway take 
advantage of site directed mutagenesis or directed evolution to increase promiscuity for non-native 
extender units,59-62 fluorine atom incorporation,63 and redox state changes.64 Lastly, pathway level 
changes can produce hybrid molecules through the formulation of chimeric biosynthetic systems. 
This has met with success especially in the case of sugar containing natural products. The ability 
to append non-cognate sugars to macrolactones using genetic systems has produced altered 
biological activities, including modulating toxicity and potency.65-71  
Despite the successful examples discussed above, this strategy often meets with failure as 
alterations to biosynthetic enzymes frequently causes abysmal isolation yields, when products can 
be detected with many more expected products being elusive. Unraveling the molecular 
mechanism responsible for this diminished activity has garnered minimal traction as many of these 
manipulations have targeted early genes, making it impossible to determine what portions of the 
downstream modules are incompatible with the desired structural modifications. More detailed 
investigations into discrete enzymes within these systems will shed light on the selectivity of each 
step in the biosynthesis and can guide rational engineering endeavors in the future.  
 
1.5 Thesis overview 
 My doctoral research has focused on two projects aimed at merging synthetic chemistry 
with in vitro biocatalysis in order to leverage chemoenzymatic platforms for the discovery of 
“unnatural” natural products of biological significance. Combining this biochemical information 
with current and future structural endeavors will hopefully continue to shed light on the complex 
processes used by biosynthetic enzymes to effect synthetic transformations. This will enable us 
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to achieve our ultimate goal of engineering more general biocatalysts for medicinal chemistry 
exploration.  
 The first of the two projects focused on the use of discrete biosynthetic enzymes in the 
cryptophycin anticancer agent’s biosynthetic pathway to produce heterocyclic analogues for 
medicinal chemistry exploration. This work had four main themes, the first of which focused on 
the development of a scalable synthesis of seco cryptophycin chain elongation intermediates as 
the N-acetyl cysteamine (SNAC) thioesters, that could be diversified at a late stage. The second 
utilized these intermediates to interrogate the cryptophycin thioesterase (CrpTE) to effect 
macrocyclization. The in vitro evaluation produced all the desired macrocycles which could be 
isolated and tested for activity in HCT-116 human colorectal cancer cells. This strategy 
facilitated the discovery of one of the most potent analogues of this family seen to date with 
single digit picomolar IC50 values. In addition, this analogue does not contain a b epoxy 
functionality that had previously been thought necessary for maximum potency, as all other 
analogues lacking it show activities in the low nM range. 
 The second facet of the cryptophycin project, described in Chapter 3 has focused on 
gaining structural information on the CrpTE. Over the past decade countless crystal trays have 
been set in the hopes of identifying conditions that would promote crystal growth. With the 
continued failures our efforts turned to designing new constructs and taking advantage of a 
strategy like Surface Entropy Reduction (SER) in hopes of engineering better crystal packing 
interfaces. We in collaboration with Dr. John Lutz at Eli Lilly designed and formulated a number 
of constructs that hoped to eliminate some of the potential issues identified in a more thorough 
examination of the primary structure.  
 Although these efforts have yet to produce any significant breakthroughs in crystal 
formation, they have identified constructs that are predominantly monomeric allowing us to 
consider alternative structural pursuits. In collaboration with Dr. Vivekanandan Subramanian in 
biophysics, we screened the CrpTE for potential NMR characterization. Finding that it had ideal 
folding and tumbling properties, structural characterization utilizing multiple labeling strategies 
and triple resonance NMR experiments are possible. We are currently completing the 
assignments of each residue in the NMR spectra and will be moving forward with three-
dimensional analysis shortly.  
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 The last subset of my doctoral thesis, focuses on a second system, the pikromycin family 
of macrolide antibiotics. Previous efforts in our lab have focused on reconstituting the last two 
modules of the biosynthetic system for use in the production of the pikromycin macrocyclic core. 
From here these can be glycosylated and oxidized to form the fully functionalized macrolide 
antibiotics. Utilizing this platform, we hoped to explore the ability of these enzymes to accept 
unnatural chain elongation intermediates. It has been hypothesized that the TE may be the most 
selective enzyme in these pathways and may hold the key to successful processing of unnatural 
substrates. Although this work is ongoing, it has indicated that the TE does play a large role in 
selectivity of substrates, but that it has some flexibility. We have been able to formulate 
macrolactones on milligram scale that contain unnatural ester, amide, and di desmethyl 
functional groups, the details of which can be found in Chapter 4. It has also shown that the KS 
in these systems may also play a large role in selecting substrates and that it is sensitive to larger 
groups closer to the site of transthioesterification. 
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Chapter 2 
Chemoenzymatic Synthesis of Cryptophycin Anti-Cancer Agents 
 
2.1 Introduction to the Cryptophycin Family of Natural Products  
2.1.1 Cryptophycin Discovery 
The cryptophycins are a family of macrocyclic natural products produced by a lichen 
symbiotic cyanobacteria of the genus Nostoc sp ATCC 53789. These compounds were originally 
isolated in 1990 by researchers at Merck as a part of their algae screening program.1 The main 
isolate, later termed cryptophycin 1 (Figure 2.1), was determined to have exceptionally potent 
antifungal properties, specifically against its namesake Cryptococcus fungi, but was not pursued 
as a potential lead due to systemic toxicity seen in mice. In 1992, cryptophycin 1 was rediscovered 
in a related cyanobacteria Nostoc sp GSV 224 by Moore et al. as a potent antiproliferative agent .2 
A close analogue of cryptophycin 1, arenastatin A (later renamed cryptophycin 24) was also 
discovered in the same year from an Okinowan marine sponge Dysidea arenaria and is proposed 
to be biosynthesized by a cyanobacterial symbiont.3 Over the next 10 years, over 25 naturally 
occurring analogues of cryptophycin were isolated from GSV 224 including different chlorination 
 
 
Figure 2.1: Select cryptophycin analogues produced by the Lichen symbiont Nostoc.  
  19 
events, altered amino acids, as well as some variability in the PKS produced a/b unsaturated 
amide.4-6 All naturally occurring cryptophycins are described by subdividing them into 4 units that 
form the 16-membered core macrolactone; unit A a hydroxy-phenyloctenoic acid moiety, unit B 
a 3-chloro-O-methyl tyrosine, unit C a methyl-b-alanine, and unit D a leucic acid seen in Figure 
2.1.  
 
2.1. Introduction to the Cryptophycin Family of Natural Products  
2.1.2 Mechanism of Action for Cryptophycin Anticancer Agents   
Many of the isolated cryptophycins display potent antiproliferative activity with the major 
isolate, cryptophycin 1 containing low picomolar activity. More exciting was the marked potency 
seen against drug resistant cancers including p-glycoprotein (PGP) and multiple drug resistant 
protein (MRP) expressing cell lines.6-7 More in-depth studies into the mechanism of action of the 
cryptophycin has shown that it is an antimitotic, which specifically bind b tubulin leading to 
apoptosis and cell death. Tubulin is a hetero-dimeric protein comprised of 2 subunits, a and b 
(Figure 2.2, B), which associate and polymerize to formulate microtubules.8 The majority of anti-
mitotic agents bind to the b subunit of tubulin including the taxanes, vinca alkaloids, colchecine, 
and epothilone anticancer agents (Figure 2.2, A).9 The vinca alkalods and colchicine bind in 
distinctive sites named after these specific agents (the vinca site and the colchicine site shown in 
green and purple in Figure 2.2 C)10-11 and prevent the polymerization of tubulin. The taxanes and 
epothilone natural products also bind distinct site on b tubulin (the taxane site, shown in blue and 
yellow, Figure 2.2 C)12-13 and are known to operate by the opposite mechanism, promoting 
microtubule polymerization and further stabilizing them.14 Ultimately both modes of action cause 
altered microtubule dynamics which results in an inability to undergo effective mitosis and 
ultimately cell death.  
Despite the interest in cryptophycins as antimitotic, there are no crystal structures of b 
tubulin with cryptophycin bound leaving the exact site and mode of binding unclear. Biochemical 
assays along with computational methods have shed light on both the likely binding site as well as 
the orientation. Cryptophycins were determined to bind b tubulin and have a similar mechanism 
of action as the vinca alkaloids and colchicine in that they destabilize microtubules.15-17 
Competition assays with the afore mentioned microtubule binding agents taxol, colchicine, and 
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vinblastine show non-competitive inhibition with only vinblastine indicating the binding site 
overlaps with the vinca site.18-21 This is further supported by molecular dynamics and molecular 
docking experiments that identified a common binding site of multiple known depsipeptides 
natural products including the cryptophycins, termed the “peptide site”.22 Early hypotheses on the 
mode of binding included a covalent linkage through the epoxide group seen on unit A. A 
combination of synthetic analogues and biochemical assays have mostly disproven this theory. 
Cryptophycins containing other acceptor functionalities including enones, ynones and allylic 
electrophiles were all not active.23 Additionally, biochemical work that shows intact cryptophycin 
could be recovered from its tubulin complex upon denaturation.24All of these experiments indicate 
that most likely, the epoxide does not undergo a covalent modification upon binding to b tubulin 
and is likely a mixture of hydrophobic and electrostatic interactions.  
2.1.3 Structure Activity Relationship of Cryptophycin Anticancer Agents  
Aside from the many natural analogues of cryptophycin that were isolated, hundreds of 
synthetic analogues have been reported the majority of which were synthesized by Eli Lilly.25-43 
 
 
Figure 2.2 Common microtubule binding agents: (A) subdivided by mechanism of action. B Cartoon 
of tubulin assembly by the association of the a/b tubulin dimers. C The binding sites of A on b tubulin 
(C). The binding sites of Taxol and Epothilone somewhat overlap and stabilize microtubules whereas 
Vinblastine and Colchicine bind distinct sites and act by the opposite mechanism, destabilizing the 
microtubules.  
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These analogues have given a distinct understanding of the functional groups that are important 
for biological activity, a summary of which can be seen in Figure 2.3.  The unit A aryl group 
tolerates methyl group substituents as well as some larger amine containing groups in the para 
position, although substituting the benzene ring with a thiophene or a furan ring showed a 1000-
fold decrease in potency.14, 44 The R,R configuration of the unit A epoxide group is far superior to 
that of the S,S as well as the styrene, again showing 1000 fold decrease in potency.45-46 Replacing 
the epoxide with a chlorhydrin, cryptophycin 55 (Figure 2.1) was equally as potent as the native 
b epoxide as it spontaneously reforms this moiety in water. Many substitution patterns have been 
investigated in unit B, however without exception all caused a decrease in potency, including the 
necessity for the uncommon D-tyrosine stereochemistry.6, 45, 47 The b amino acid seen in unit C 
was necessary for the active conformation and larger substitutions off either the a or b position of 
this unit were detrimental to activity.30-31 A geminal dimethyl group introduced at the a position 
was tolerated fairly well and was later termed cryptophycin 52 (Figure 2.1), and used for the 
subsequent clinical trials. This small change imparted more stability to the ester bond between 
unit’s C and D as well as removed a stereocenter that was costly to generate synthetically. Unit D, 
which has some flexibility within the biosynthesis, tolerates changes to sec-butyl and n-propyl 
groups from the isobutyl without deleterious effects to potency.6 Interestingly, the stereochemistry 
may not be important in this region as an analogue with the inverted (R) stereochemistry appears 
to be equipotent as its (S) counterpart.41 
 
 
 
Figure 2.3 Generalized schematic of Cryptophycin SAR.  
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Out of all the synthetic analogues generated, one that contained a geminal dimethyl in unit C 
(cryptophycin 52, LY355703) was determined to be the best candidate for clinical trials by Eli 
Lilly.30 This modification protected the ester bond between unit’s C and D from degradation as 
well as simplified the synthesis. Cryptophycin 52 (LY355703) entered into clinical trials for non-
small cell lung cancer as well as platinum resistant ovarian cancer, but failed out of phase 2 due to 
reversible dose limiting peripheral neuropathy as well as only modest in vivo efficacy with the 
dosing schedule utilized.48-50 Despite these failures, both studies indicated that alternative 
analogues or dosing schedules could greatly affect the outcomes and should be further investigated 
especially for difficult to treat, resistant cancers. 
2.1.4 Cryptophycins as Antibody Drug Conjugate Warheads 
 Recently, the incredible potency of cryptophycins has generated interest in them as 
antibody drug conjugate (ADC) warheads. Sanofi was the first to investigate these using both 
cleavable and non-cleavable linkers to connect the benzyl amine containing cryptophycin with an 
hu2H11 antibody.51-52 Genentech has also utilized a similar strategy to conjugate cryptophycin to 
their antibody that targets HER2 and CD22 receptors.53 These have shown some promise for target 
antigen expressing cells.  
2.1.5 Biosynthetic Assembly of Cryptophycins  
The continued interest in cryptophycins as well as the complexity of this molecule and the 
difficulties formulating it, led to investigations into its biosynthesis, and potentially the use of 
discrete enzymes as biocatalysts for the production of novel analogues. The cryptophycins are 
biosynthesized by a mixed PKS/NRPS system (Figure 2.4). Unit A is believed to be initiated by 
an unusual NRPS loading domain that incorporates a phenylalanine which is then deaminated to 
produce a cinnamyl group.54 Feeding experiments previously reported by Magarvey et al. indicate 
that this is not the starter unit picked up by the first PKS module in the cryptophycin pathway, as 
there is a lack of deuterium present when the organism is supplemented with [2H8]phenylalanine.55 
It likely undergoes a single carbon truncation to give the phenyl acetyl group, which is then loaded 
and processed by the rest of the cryptophycin biosynthetic pathway.54 From here the full length 
unit A is extended via the condensation of three malonyl extender units by the Crp A and B PKS 
modules,55 with an s-adenosyl methionine (SAM) dependent methylation at C6,54 completing the 
unit A biosynthesis.  
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Once the PKS intermediate is formulated, it is passed off to the NRPS portion of the 
biosynthetic pathway, CrpC and CrpD. CrpC is a monomodular NRPS domain that contains an O-
methyl transferase which is capable of methylating the tyrosine residue. This tyrosine residue is 
further modified by CrpH, a Flavin dependent halogenase, that is responsible for the chlorination 
event, however it is unclear if this enzyme acts on the full length substrate or the tyrosine prior to 
incorporation. Next it is passed to the bimodular CrpD which first incorporates a methyl-b-alanine, 
derived from aspartate. Finally, CrpD module 2 incorporates an a-hydroxyisocaprioic acid moiety 
derived from leucine to produce the full length chain elongation intermediate. This is then passed 
to the third portion of CrpD, the thioesterase which is responsible for the formulation of the 
macrocyclic core by facilitating intramolecular attack of the unit A hydroxyl.55 This is further 
tailored by the CrpE, a heme containing P450 responsible for the installation of the b epoxy group 
on unit A from molecular oxygen.56 Each of the above modules has been shown to contain some 
inherent flexibility for unnatural substrates as is evident by the large size of this family (over 25 
members). This feature presents a unique opportunity to leverage some of the enzymes within this 
 
 
Figure 2.4 Biosynthetic Pathway of the mixed PKS/NRPS natural product cryptophycin.  
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pathway for use in a biocatalytic syntheses of not only the native molecules, but structural 
analogues that could combat some of the shortcomings seen in clinical trials.  
Thioesterases contain a serine, histidine, and aspartic acid catalytic triad that are able to 
accept upstream intermediates and effect macrocyclization. The linear chain elongation 
intermediate is passed from the upstream PKS or NRPS module via the peptidyl or acyl carrier 
protein by a prosthetic group known as the phosphopantatheine (Ppant) arm (Figure 2.5).57 
Nucleophilic attach by the serine hydroxyl on substrate bound Ppant arm, creates a tetrahedral 
intermediate stabilized by the area of the TE known as the oxanion hole. Loss of the Ppant arm 
then generates the acyl-TE intermediate and a free carrier protein. Within the TE active site the 
intramolecular hydroxyl is folded back in towards the ester bond, and nucleophilic attack causes 
macrocyclic offloading of the product (Figure 2.5).58 
In a previous study, we demonstrated that excised CrpTE is able to catalyze facile 
cyclization of native and modified substrates to formulate cryptophycin 3, 51 (Figure 2.1) and an 
unnatural cryptophycin containing a terminal olefin in unit A, originally synthesized as LY404291 
at Eli Lilly.59 This work indicated that the CrpTE’s inherent flexibility may render it an effective 
biocatalyst for the production of novel cryptophycin analogues. This was further supported by 
investigations into the Crp D-M2 NRPS module which further showed the ability of the CrpTE to 
accept unnatural amino acids for unit D, an unusual result as often the site of ring closure is very 
sensitive to amino acid changes.60  In order to continue to interrogate the CrpTE as well as explore 
some under-represented areas of cryptophycin SAR, we embarked on an effort to synthesize a 
series of novel cryptophycin chain elongation intermediates. Heterocyclic unit A analogues were 
designed to probe the CrpTE substrate tolerance, as well as produce analogues that may address 
 
 
Figure 2.5 Generalized schematic of a Thioesterase mechanism. The upstream carrier protein (CP) 
delivers the growing chain to the active site serine of the thioesterase. A deprotonation event, 
facilitated by the histidine and aspartic acid (catalytic triad) allows for nucleophilic transfer of the 
chain elongation intermediate. The histidine is then responsible for coordinating the intramolecular 
hydroxyl and facilitating cyclization 
  25 
some of major shortcomings identified in clinical trials, including dose limiting peripheral 
neuropathy and broad in vivo efficacy.48, 50  
 
2.2 Synthesis of seco cryptophycin analogues  
In order to test the flexibility of the CrpTE towards unnatural unit A aryl groups, we needed 
to devise a scalable synthesis of the seco cryptophycin intermediate containing an N-acetyl 
cysteamine (NAc) on unit D that is used as a recognition element by the TE. A synthesis of the 
native chain and the unit C gem dimethyl chain elongation intermediates had been reported 
previously59 as well as a diversifiable unit A synthesis61 that took advantage of crotylation 
chemistry to set the stereocenters seen in unit A. Initial analogues made use of this strategy 
unfortunately, low yields and scalability issues prompted us to investigate alternative strategies 
that would be more amenable to the larger scale formulation.  
Retrosynthetically, the linear chain elongation intermediate can be disconnected through 
the ester and amide bonds present between units A, B, C, and D as well as through the double bond 
of the a/b unsaturated amide present in unit A. In order to avoid peptide coupling between unit A 
and unit B that has been plagued with difficulties, analogues were synthesized using two key 
intermediates, a boronic ester containing unit AB and unit CD-NAc (Figure 2.6). Further 
disjoining units AB can be accomplished with a Horner Wadsworth Emmons olefination (HWE) 
olefination between the modified tyrosine (unit B) and a boronic ester containing unit A in order 
to take advantage of a late stage Suzuki coupling strategy reported by Bolduc et al.61 to diversify 
the aryl group. Unit A can be further disconnected by a single aldol reaction which set the (2R, 3S) 
 
 
Figure 2.6 Retrosynthetic analysis of seco cryptophycin chain elongation intermediate. This 
highlights the main disconnections including final peptide coupling between Units AB and Units CD, 
Suzuki coupling for aryl ring diversification, HWE for formulation of Unit AB, and an aldol 
responsible for setting the C6 and C7 stereocenters. 
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stereochemistry seen. Units’ CD-NAc can be formulated via peptide coupling of commercially 
available starting materials (Figure 2.5).   
2.2.1 Synthesis of Cryptophycin Unit AB Fragment 
Towards that end, unit A was synthesized using an Evans asymmetric aldol with N-
crotonyl oxazolidinone 2.1 and aldehyde 2.2, which proceeded in excellent yields with a high dr 
(>20:1) to afford the desired (2R, 3S) adduct 2.3. Subsequent silation with TBS 
trifluoromethanesulfonate and reductive cleavage of the chiral auxiliary afforded alcohol 2.4.39 
Tosylation and consecutive reductive deoxygenation was next investigated. Reduction of the 
corresponding tosylate proved difficult, however a screen of reducing reagents saw the best results 
with lithium triethylborohydride which produced the desired intermediate 2.6 in 85% yield.62 At 
this stage a pinacol boronic ester (2.7) was introduced via Hoveyda-Grubbs cross metathesis for 
use as a Suzuki handle for later diversification.61 Removal of the PMB protecting group of 2.8 
with DDQ and subsequent Des Martin Periodinane (DMP) oxidation to 2.9 furnished the unit A 
aldehyde fragment necessary for the HWE olefination (Scheme 2.1).63  
The phosphonate partner 2.12 (Scheme 2.2) was synthesized via Boc deprotection of 
previously described 2.10 with 4 M HCl/Dioxane and subsequent coupling with 
diethylphosphonoacetic acid (2.11) and EDC. From here conditions for the HWE olefination were 
explored. The best results were seen with sodium hydride in THF, which yielded diversifiable unit 
 
 
Scheme 2.1 Synthesis of unit A. Formation of unit A 18 from crotonyl alkylated Evans auxiliary 9, 
incorporating the use of a pinacol boronic ester for use as a Suzuki handle in late stage diversification.  
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AB fragment 2.13 in a 63% yield of the correct isomer (80% overall yield, with ~ 5:1 E:Z product 
dispersion).  
2.2.2 Formulation of Unit CD Fragment  
Unit CD-NAc was readily synthesized from commercially available leucic acid 2.15 and 
methyl-b-alanine 2.17 (Dimethyl unit C 2.18, see section 2.3.3, Scheme 2.3). Initial benzyl 
protection of leucic acid and subsequent coupling with b-amino acids 15 or 16 produced the 
desired ester, which could be readily deprotected via hydrogenolysis to furnish the desired acids 
2.21 or 2.22.64 These were coupled with NAc to yield Units CD.  
2.2.3 Assembly of Seco-Cryptophycin Chain Elongation Intermediate and Suzuki Diversification 
 
 
Scheme 2.2 Synthesis of unit AB. Formation of diversifiable units AB 22 from unit A (18) and unit B 
phosphonate adduct (21) mediated by a Horner Wadsworth Emmons (HWE) reaction. Successive 
Suzuki coupling produced the desired unit AB analogues 2.14 a-m.  
 
 
 
Scheme 2.3 Synthesis of unit CD. Formation of native unit CD fragment and dimethyl version from 
leucic acid and either b-homo-alanine or the dimethyl variant 2.18 
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With diversifiable substrates 2.13 in hand, coupling with 2.23 and successive Suzuki 
diversification were investigated. A screen of palladium catalysts as well as bases and solvents 
yielded no conditions that successfully produced cross coupling in moderate to high yields without 
racemization or degradation of the NAc thioester. With these results, Suzuki coupling prior to the 
final peptide coupling was investigated. Another screen of palladium catalysts and solvents yielded 
Pd2(dba)3 with K3PO4 in dimethyoxy ethane and water at reflux as the highest yielding, however 
racemization was still observed. By running this at room temperature for 12 hours, racemization 
was completely abolished and we were able to produce a suite of novel unit AB cryptophycin 
analogues 2.14 a-m (Scheme 2.2), in moderate to excellent yields (45 – 92%). Successive 
saponification of the methyl ester to produce 2.25 a-m (Scheme 2.4) also proved to be susceptible 
to racemization and a screen of different hydrolysis procedures yielded trimethyl tin hydroxide 
that provided the desired acids in good yield with no detectable racemization. Subsequent peptide 
coupling on ice produced the TBS protected intermediates with an 8:1 dr (Scheme 2.4).65-66 
Diastereomers were resolved using reverse phase HPLC in order to obtain CrpTE data for the 
native diastereomer only. Finally, deprotection of the silyl group using aqueous HF furnished the 
desired seco cryptophycin NAc analogues (Scheme 2.4, 2.28 a-m).  
 
 
 
Scheme 2.4 Assembly of the seco cryptophycin analogues. unit AB fragments (2.14 a-m) and unit CD 
fragment (2.23 or 2.24) fragments were simultaneously deprotected and carried through to EDC 
coupling without purification. Diastereomers were separated by reverse phase HPLC prior to 
deprotection with HF.  
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2.3 Optimization and Evaluation of seco cryptophycin analogues with CrpTE biocatalyst  
2.3.1 Analytical Scale Evaluation of the CrpTE with Seco Analogues  
With a diversifiable synthesis in hand we began exploring the flexibility of CrpTE against 
the heterocyclic unit A chain elongation intermediates (Scheme 2.4, 2.28 a-m). Initially, 
enzymatic conditions were optimized using the native, benzyl containing intermediate. Initial 
screens utilized the standard 5% DMSO to look at different concentrations of substrate and using 
an arbitrary 0.5 uM of CrpTE catalyst. Screening conditions from 10 uM to 500 uM substrate 
concentration at 3 different temperatures showed that these enzymes are much more efficient at 
elevated temperatures (30 °C or 37 °C) and need to be at lower concentrations. This is likely 
because of the inherent insolubility of the substrates in the reaction media, leading to enzyme 
inaccessibility. In order to keep reaction volumes to the minimum, and to minimize the variability 
seen in the 37 °C reactions, 30 °C and 50 uM was chosen as the optimal substrate concentration 
for analysis (Figure 2.7).  
The initial set of CrpTE analogues contained six membered ring heterocycles in place of 
the native benzene ring (Figure 2.8, 2.28 b-g) were run using the previously optimized conditions. 
Initial analytical scale reactions revealed remarkable turnover to product compared to the native 
benzyl substrate (Figure 2.7, a).  The 2-, 3-, 4-pyridyl and pyrazine (2.28 b, c, e, g) substrates 
 
 
Figure 2.7 Analysis of substrate concentration on % conversion. Conditions include  5% DMSO and 
0.5 uM CrpTE. 
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showed complete turnover of starting material and nearly undetectable levels of hydrolytic bi-
products (Figure 2.8) in contrast to 2.28a, which shows incomplete consumption of starting 
material for an overall conversion of ~ 68%. This is reflected in the % conversion as well as 
cyclization to hydrolysis ratios (Table 2.1), all of which are significantly greater (91 – 96% 
conversion, >10:1 cyclization:hydrolysis ratio) when compared to the native substrate (68% 
conversion, 9:1 cyclization: hydrolysis). It is unclear if this is due to more favorable interactions 
in the binding pocket of the CrpTE, reflecting more productive catalysis or if these heterocyclic 
groups impart improved solubility in the reaction medium making these substrates more accessible 
to the enzyme.  
 
 
Figure 2.8 QTOF-LCMS analysis of seco cryptophycin analogues with the CrpTE, product peaks are 
denoted in blue color and hydrolysis peaks in green.  
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The set of unnatural unit A analogues was expanded to include five membered ring 
aromatic heterocycles with varying alkyl chains. 2-, 3-, and 4-methyl pyrazole (2.28 h-j) were 
formulated and tested in the same analytical assay as previously discussed, utilizing the benzyl 
substrate as standard. The 2-methyl pyrazole (2.28 h) and 3-methyl pyrazole (2.28 i) groups 
showed slightly lower % conversion than the previous six membered rings at 85% and 84% (Table 
2.1). This decrease in conversion was not attributed to nonproductive catalysis (as the hydrolysis 
to cyclization ratios are still above those of the native substrate), but to a lack in substrate 
consumption. Despite these substrates being processed less efficiently than the six membered ring 
 
 
Table 2.1 Comparison of cryptophycin analogues 2.29 a-m percent conversion, isolation yields, and 
cyclization to hydrolysis ratio.  
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analogues, they retain % conversion to product comparable to native substrate reaction catalyzed 
by wild type CrpTE. Interestingly, the 4-methyl pyrazole (2.28 j) showed nearly complete 
conversion to product with essentially no remaining starting material and no hydrolytic 
byproducts. 
  Testing a larger alkyl chain, the 4-isopropyl pyrazole (2.28 l) provided important insight 
into potential size restrictions of the CrpTE binding pocket. Although there is again a very high 
cyclization:hydrolysis ratio (40:1), starting material remained after conclusion of the reaction 
(83% conversion), indicating possible steric constraints within the enzyme. Finally, a dimethyl 
isoxazole substrate was investigated. This substrate showed similar % conversion in comparison 
with the native substrate (Figure 2.8) with a significant amount of starting material remaining.  
2.3.2 Semi-Preparative Scale Enzymatic Reactions, Isolation, and Subsequent Biological 
Evaluation   
All reactions were conducted on semi-preparative scale (using the same conditions as the 
analytical reactions) of 10 mg in order to obtain isolated yields, full structural characterization, 
and biological evaluation. These results corresponded closely with percent conversions observed 
in the analytical reactions. The six membered heterocycles 2.29 b, c, e, and f were isolated in good 
yields from 62 – 66% (Table 1). The five membered rings 2.29 h - 12j, 12i and 12m were also 
isolated in yields that span from 55% for the isoxazole analogue to 69% for the 4-methyl pyrazole 
analogue (Table 1). All novel cryptophycin analogues generated from these chemoenzymatic 
reactions were confirmed by HRMS, 1HNMR, and 13CNMR and subsequently tested for biological 
activity.  
Each of the cryptophycin analogs were assessed for IC50 in HCT-116 human colorectal 
cancer cell line. Previous studies on synthetic cryptophycin analogues containing a thiophene and 
a furan in place of the benzyl ring on unit A showed a marked decrease in activity.67 Our results 
(Table 2) showed significant differences in activities depending on the heterocyclic ring present. 
For the six membered rings, the IC50 values spanned a wide range even within the pyridyl set of 
analogues, varying by three orders of magnitude from the 2.29 c and 2.29 e (0.860 nM and 0.51 
nM, Table 2) to the 2.29 b (102 nM, Table 2). The five membered rings show even larger 
differences in IC50 values spanning almost six orders of magnitude. The inclusion of an isoxazole 
ring (2.29 m) greatly diminished activity, however, the introduction of a 4-methyl pyrazole ring 
  33 
(2.29 j) provided a low pico-molar IC50, making it one of the most potent cryptophycin analogues 
observed to date. The potency observed in the 4-methyl pyrazole cryptophycin derivative has only 
been observed in previously described b-epoxy cryptophycin analogues, which had previously 
demonstrated the requirement of the epoxide functionality to achieve maximum activity. Here, we 
have shown that a similar single digit picomolar potency is achievable in the absence of the b-
epoxy group. This could have crucial effects on the neurotoxicity observed with these compounds 
during clinical trials as this moiety has been considered the likely cause of this side-effect.  
2.3.3 Formulation of Geminal Dimethyl Unit C variants of Unit A Analogues 
Utilizing the above data to guide our design of analogues to test with the CrpTE biocatalyst, 
the geminal dimethyl unit C analogues were synthesized utilizing the same chemistry as above for 
our top three analogues, the 3- and 4- pyridyl as well as the 4-methyl pyrazole, substituting the 
dimethyl unit C (2.18). The ester linkage between units C and D is thought to be somewhat 
metabolically labile and addition of a second methyl group adjacent to this labile position is known 
to improve drug half-lives as well as remove a stereocenter which simplifies the synthesis.6, 68 In 
our previous work we showed an increase in hydrolytic byproducts (6:1 cyclization to hydrolysis 
versus 10:1) when including the gem dimethyl in the benzyl containing unit A.59  Our new 
 
 
Table 2.2 IC50 values for unit A heterocyclic analogues in HCT 116 cells.  
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analogues (2.28 d, f, and k) were first tested on an analytical scale for a direct comparison of 
hydrolysis to cyclization ratios as well as % conversion to their monomethyl counterparts. All 
three showed an increase in hydrolytic activity when incubated with CrpTE (Table 2.1 and Figure 
2.8) as well as a higher percentage of unreacted starting material, consistent with our previous 
findings. Despite the lower overall processing to macrocycle, the corresponding chain elongation 
intermediates were processed with almost the same efficiency as the native substrate, further 
demonstrating the remarkable flexibility of CrpTE against substrates containing non-native 
functional groups in both the PKS and NRPS derived portions of the molecule.  
 
2.4 Evaluation of Cryptophycin P450 with Unit A Analogues 
2.4.1 Cytochrome P450 Background  
Cytochromes P450 have been used extensively in the pharmaceutical industry for the 
production of drug molecules as they are capable of regio- and stereo-selectively installing 
oxidative functionality often replacing otherwise inactivated C-H bonds. P450s are iron-heme 
containing enzymes capable of utilizing molecular oxygen to formulate the oxygenated organic 
compound and water via a two electron transfer mechanism mediated by NAD(P)H. The catalytic 
mechanism, which has been reviewed extensively,69-70 starts with ferrous iron (FeII), generated by 
a single electron transfer, and the binding of O2. A second electron transfer event generates the 
peroxo intermediate which can then be protonated to generate compound 0 (Figure 2.9). 
Compound 0 then rapidly undergoes heterolytic cleavage to produce compound 1, water, and an 
FeIV radical species known as compound 1. This is then able to abstract a hydrogen atom from the 
correctly oriented substrate, leading to a radical rebound that produces the hydroxylated species 
(Figure 2.9). In this catalytic process, there are three separate possible shunt pathways including 
autoxidation shunt, the peroxide shunt, and the oxidase shunt pathway all of which cause 
ineffective catalysis.  
The cryptophycin pathway contains a late stage P450 that is responsible for the installation 
of the b epoxy functionality that imparts 100 to 1000 times greater potency to the styrene 
counterparts. Historically, this has been incredibly difficult to install both regio- and stereo-
selectively as only a couple of catalytic systems exist to execute this transformation, many of which 
having only modest selectivity for the b epoxide over the a. Initial synthetic methods utilized m-
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Chloroperoxybenzoic acid however the yields were only moderate as the selectivity seen with this 
method was at most 2.5:1 b:a isomer.71 Other strategies have utilized dimethyldioxirane 
(DMDO)46 however these usually didn’t increase the diastereomeric ratio or Shi conditions72 
which only produced a 17% conversion due to low solubility in the aqueous reaction conditions. 
Diol epoxidations have also been utilized and took advantage of a modified sharpless epoxidation 
strategy that gave the desired b epoxide from the diol in 3 steps with a 38% overall yield.73 Despite 
some success installing this functionality, the use of a P450 to facilitate this process could have 
profound implications for the formulation of the most active compounds.  
Previously, Dr. Yousong Ding cloned and expressed the MBP fusion of CrpE as soluble protein. 
As the native redox partners for this protein was unknown, spinach ferredoxin (Fdx) and ferredoxin 
NADP+ reductase (Fdr) along with the glucose-6-phosphate NADPH regeneration system were 
utilized to recapitulate the P450 activity and show ~45% conversion of cryptophycin 3 to 
cryptophycin 1. This was further extended to show that the P450 was tolerant of structural 
 
 
Figure 2.9 P450 catalytic cycle; O2 is utilized along with a two electron transfer, mediated by 
NAD(P)H to produce the desired hydroxylated species.  
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variations on unit B and C indicating this P450 could be used as a biocatalyst for the production 
of epoxidized cryptophycin analogues.56   
2.4.2 Evaluation of P450 with unit A heterocyclic analogues 
With successful implementation of the CrpTE as a biocatalyst for the production of novel 
cryptophycin analogues, we turned to investigating the use of the CrpE P450 to generate fully 
functionalized, b epoxy cryptophycins. With the help of Dr. Yogan Khatri, the CrpE was re-cloned 
into His tag containing pET-17b as the MBP fusion was not ideal due to its large size. This was 
then expressed in TB media, with extensive oxygenation. Purification yielded bright red protein 
which, when combined with the Fdx/Fdr NADPH system, again showed ~45% turnover of styrene 
 
 
Figure 2.10 Analysis of CrpE P450 with styrene cryptophycin analogues. Epoxidized products 
observed by mass are in blue.  
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cryptophycin 3 to epoxidated cryptophycin 1 (Figure 2.10). Interestingly, experimentation with 
another redox partner commonly used in the lab, RhFRED produced no turnover to product 
indicating the importance of an appropriate redox partner. With the CrpE activity reconfirmed, the 
newly generated, unit A analogues were assayed with the CrpE.   
 Initial analytical tests were run and analyzed by TOF-MS, showing varying results. 
Turnover to a product that corresponds to the epoxidized mass is observed with the 3-pyridyl, 4 
pyridyl, pyrazine, and 2 methyl pyrazole cryptophycins (Figure 2.10, peaks corresponding to 
product by MS in blue). The most potent analogue from the previous section, the 4 methyl pyrazole 
shows a mass indicative of the dihydroxylated species which has been seen before with extremely 
electron withdrawing aryl substituents. The rest of the analogues produced no detectable product 
formation. Although the initial results are not as exciting as with the CrpTE, seeing turnover to 
epoxidized products on these was surprising, as aryl ring modifications are conjugated into the 
double bond, causing the electronics of it to change significantly from analogue to analogue, likely 
causing the decrease or lack of product production.  
 In order to utilize this enzyme along with our CrpTE for the effective production of 
epoxidized cryptophycins, continued optimization and exploration of reaction conditions needs to 
be examined. The native substrate only shows ~45% turnover to product which isn’t optimal. It is 
currently unclear if this is caused by instability in the protein or another factor. This protein begins 
to precipitate out of the reaction mixture within a few hours which may not be enough time to 
effect total turnover of substrate indicating dosing schedules should be investigated for better 
consumption of starting material. Another potential problem is that spinach ferredoxin is being 
used as a surrogate redox partner, because the native one is currently unknown. This system may 
not be as adept at electron transfer as the native partners would be causing decreases in turnover. 
Continued exploration of surrogate redox partners or a screening campaign of the seven potential 
redox partners found within the producing organism’s genome may lead to better turnover and 
more effective production of products.  
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Chapter 3 
Structural Studies and Mechanistic Insights into the Cryptophycin 
Thioesterase 
 
3.1 Background on Thioesterase Structure and Function 
3.1.1 Overall Structural Features of Thioesterases   
The promising data from our in vitro biochemical assays prompted us to investigate the 
structural and mechanistic features that impart the broad scope flexibility seen with the CrpTE. 
Type 1 thioesterases belong to a larger family of a/b hydrolases, which also includes proteases, 
esterases, and lipases.1 Unlike other PKS or NRPS domains, thioesterases generally contain very 
low sequence identity within the family(<30%), making it difficult to predict the type of chemistry 
these will catalyze. All known structures show that TEs contain a similar  b-a-b motif that displays 
a central b sheet (with either seven or eight strands with seven being more common for Type 1 
thioesterases while eight is more frequently seen in other hydrolases, Figure 3.1). The active site 
serine is located between the fifth b strand and N terminus of a helix 3 as a part of a characteristic 
Gly-xx-Ser-xx-Gly motief, known as the “nucleophilic elbow”. Currently, there are a handful of 
known macrocyclizing PKS and NRPS TEs which have shed light on the innate differences in 
 
 
Figure 3.1 General thioesterase structure diagrams. (A) General topology schematic of a Type 1 TE 
highlighting the active site catalytic triad residues as well as the oxanion participants shown in black 
circles (B) 3D representation of the aflatoxin TE (pdb 3ILS) highlighting active site residues, the 
central b sheet, and the lid region.  
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structure between the two.2-15 Sequence alignments have previously shown that the most structural 
diversity in TEs lies within two a helices (although three are not uncommon) in the region between 
b6 and b7 known as the lid region (Figure 3.1, A). This usually consists of two a helices that can 
range from 25 to 80 amino acids in length has been hypothesized to play a major role in 
selectivity.16 The cryptophycins are made by a mixed PKS/NRPS system with the thioesterase 
being appended to the terminal NRPS domain. Despite some rather detailed studies on both PKS 
and NRPS TEs, there have yet to be any on macrocyclizing TE’s from mixed systems begging the 
question, will this display structural features more similar to PKS TEs, NRPS TEs or will it contain 
some of both?  
3.1.2 Structural Insights into PKS Derived TEs 
Studies on the PKS TEs in the erythromycin (DEBS) and pikromycin (Pik) pathways 
revealed unusual features seen in this subtype of hydrolases that are not present in other members 
of this family.  There are two N terminal dimerization helices as well as a surprisingly large and 
wide active site, shaped as a channel that spans the entire protein. This channel is lined with a 
mixture of conserved hydrophobic residues as well as a few non-conserved hydrophilic ones, that 
differ between these proteins and likely play a vital role in the catalytic mechanism.15  A mixture 
of docking studies on the DEBS TE as well as crystal structures with a substrate mimic affinity 
probes show a complex interplay of a few distinct hydrogen bonding interactions as well as 
significant hydrophobic packing and likely inherent substrate structural features necessary for 
productive cyclization.11-12, 15 This has been corroborated through a mixture of synthetic substrates 
and docking studies that have shed light on some of the necessary structural features as well as 
demonstrated the proteins tolerance for non-essential elements with the formulation of new 
macrocyclic products.15, 17 
3.1.3 Structural Insights into NRPS Derived TEs 
NRPS TE’s have also benefited from structural and biochemical characterization. In the 
NRPS derived tyrocidine and daptomycin TE systems, solid phase peptide synthesis was utilized 
to formulate a suite of unnatural chain elongation intermediates that furnished novel macrocyclic 
analogues with varying biological activities.18-20  The substrate tolerance seen in these TEs has 
been attributed to a hydrogen bond network that enables substrate preorganization. Thus, the TE 
in this case, was hypothesized to exert minimal influence except on the amino acid being employed 
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as the intramolecular nucleophile, which appears to be critical for productive catalysis.21 This is 
further supported by structural studies on the NRPS TEs from the surfactin and fengycin 
biosynthetic pathways. These TE’s possesses a large, bowl shaped active site, in contrast to the 
tunnel seen in PKS TEs. The bowl is lined with predominantly nonpolar and aromatic amino acids, 
with specific interactions occurring primarily at the hydroxyl containing C-terminus of the linear 
NRPS substrate.10, 14 These compelling studies continue to shed light on the complex mechanism 
employed in these different systems. Further investigations into PKS, NRPS, and PKS/NRPS 
hybrid TEs are necessary to expand our understanding of the factors that govern macrocyclization 
on a broad scale.   
Extensive screening in the Sherman/Smith labs over the past 10 years have demonstrated 
the CrpTE is resistant to crystal packing and has yet to garner any traction, fostering the need for 
design and formulation of alternate constructs with potentially better crystal packing interfaces. In 
conjunction with Dr. John Luz at Eli Lilly, we pursued a two-pronged approach to obtain crystals. 
The first focuses on the identification, cloning, and expression of the initial set of enzyme mutants 
to help promote crystal packing. The second involved a strategy of trapping native substrates in 
the active site, which will hopefully facilitate protein ordering, as well as provide important 
insights regarding substrate binding and orientation. 
 
3.2 Optimization of the CrpTE for Structural Characterization  
3.2.1 Rational Construct Design of variant CrpTEs 
In accordance with our first approach and in collaboration with Dr. John Luz (Eli Lilly), 
we identified a series of potential regions for protein engineering. Utilizing the Surface Entropy 
Reduction prediction (SERp) server developed by the University of California at Los Angeles two 
surface cysteines, as well as six predicted surface residues were identified as problematic. This 
server predicts tertiary structure from primary sequence data and utilizes that to identify regions 
of charged or hydrophilic amino acids that may be interfering with packing, and ultimately crystal 
formation. Utilizing this knowledge, three separate expression constructs were designed: the first 
included mutations of the two surface cysteines (C145S and C226S, Table 3.1 DHS7150) to 
serines, the second contained the two surface cysteine residue mutations plus the first four 
mutations of charged residues less polar ones that were found adjacent to one another (E61G, 
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K66S, E70A, and K77A, Table 3.1 DHS7151), and the third containing mutations to all six of the 
problematic residues (K195G and K219A, Table 3.1 DHS7152).  
The cryptophycin thioesterase is natively attached to an upstream peptidyl charrier protein 
on the terminal NRPS module by a linker region. Analysis of the protein sequence using BLAST 
and AntiSMASH (a secondary metabolite analysis and prediction server) as well as the Phyre2 
secondary structure server revealed disordered region at the N-terminus of the originally cloned 
CrpTE, which was excised in the middle of the initial linker. In hopes of developing a construct 
with better crystallization properties, variants that included the entire linker region, half the linker 
region, and none of the linker region were designed. All three constructs were made by quick 
change mutagenesis and consisted of a seven amino acid addition (Table 3.1 DHS 7153) to the 
amino terminus of the original clone, a five amino acid truncation (Table 3.1, DHS 7154), and a 
ten amino acid truncation (Table 3.1, DHS 7155). The addition is predicted to add secondary 
structure lending credence to this variant and the truncations would remove the disordered regions 
in two portions in case of deleterious effects. Combining some of these mutations produced four 
other constructs that could be utilized as well.  
3.2.2 Variant CrpTE Protein Expression and Purification 
 
 
Table 3.1 Schematic and table of mutant constructs of Crp TE generated. Corresponding expression 
yields are also denoted.  
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With the new constructs in hand, we investigated expression and purification of these 
protein that would be amenable to crystallization screens. Proteins were initially screened on 3 mL 
cultures for overexpression and solubility. Luckily, all of the constructs had significant 
overexpression bands seen in supernatant with minimal aggregates in the pellet. All six initial 
constructs (DHS7151 – 7155) were then grown on large scale, 3L batches in TB. Purification of 
1L the mutant proteins in HEPES buffer without glycerol (glycerol is known to cause active site 
acylation with this protein) and with varying concentrations of imidazole proved effective. The 
first chromatographic step included nickel affinity chromatography which produced between 70 
and 105 mg of protein for each of the constructs (Table 1). Following purification, cleavage with 
TEV protease and subsequent size exclusion chromatography led to sufficiently pure protein for 
initial crystallization screening. All the CrpTE variants were tested for activity prior to crystal 
screen and each showed minimal difference in turnover of substrates.  
With these proteins in hand, we in collaboration with Dr. Janet Smith’s Lab at the 
University of Michigan began crystallization screens. Size exclusion chromatography (SEC) of 
some of the mutant proteins used for setting trays revealed significant differences in monomeric 
and dimeric protein populations, with the original construct being 3:1 monomer to dimer. PKS 
TE’s are known to be dimers (as their entire modules are dimers) however, NRPS’s are thought to 
 
 
Figure 3.2 Gel of initial expression tests for mutant CrpTEs. These were run on 3 mL volumes and 
show over expression in the soluble fraction and minimal insoluble protein in the pellet.  
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be monomers. Previous biochemical and structural work has briefly touched on the subject with 
slightly differing results. In the lipopeptide forming surfactin TE, dimerization was seen through 
the b sheet in the crystal structure, however this was not observed via SEC, causing them to 
conclude this was an artifact of crystallization.14 In contrast, the fengycin TE structure showed 
only monomers, however the SEC showed some tendency for dimerization.10 Our results have 
shown that different constructs lengths show different propensities for dimerization. The 
constructs containing shorter lengths at the amino terminus show interesting results, with the both 
constructs (DHS7154 – 7155) having significantly higher ratios of monomer to dimer than the 
initial one (greater than 10:1 vs 3:1). All the SEM mutant constructs as well as the plus 7 amino 
acid (DHS7150 – 7153) show similar dispersion of monomer and dimer (around 3:1) as the original 
construct (Figure 3.3). These were all separated via SEC and incubated overnight at 4 °C to 
determine if either the monomers or dimers would re-equilibrate to their original dispersion. 
Reinjection of all the monomeric forms as well as the three dimeric forms produced in higher 
quantity showed that neither the monomer or dimer fractions of any of the constructs showed re-
equilibration, and that they were stable in their initially adopted state.  
 
 
Figure 3.3 Size exclusion results for the different CrpTE constructs. These show that the minus 5 
amino acid and minus 10 amino acid variants have a lower propensity for dimerization. 
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With the different constructs expressed and separated into their monomer and dimer 
constituents, initial screening trays were set at high concentration (greater than 30 mg/mL) using 
Qiagen classics I and II kits. These initial screens produced 2 small crystal hits from two different 
mutant TEs, DHS 7156 and 7158 (minus 5aa) with the underlying factor in each hit being that they 
are the monomer population and the addition of magnesium chloride. With these promising initial 
results, countless refinement screens were run, however to date none have produced viable crystals 
for x-ray diffraction.  
3.2.3 Engineering the CrpTE from a Hydrolase to an Acyl Transferase 
Our second approach focused on trapping substrates in the CrpTE active site. This 
approached served two purposes, first often proteins are too flexible to crystalize unless substrate 
is present as it can help effectively lock the protein into its catalytic conformation and second 
obtaining a crystal structure with the full length chain elongation intermediate has not been 
accomplished to date and would provide a wealth of information about the selectivity and catalytic 
mechanism employed by these proteins. In order to accomplish this, we utilized a strategy 
previously reported for FAS that effectively changing the enzymes function from a hydrolase to 
an acyltransferase via two active site mutations.22 The first mutation was to the active site serine 
to cysteine (S94C, DHS 7160), which would serves as a more effective nucleophile for acylation. 
The second is to remove the active site histidine (H265) which is responsible for coordination of 
both the intramolecular hydroxyl group as well as water, which is necessary to abrogate hydrolytic 
or intramolecular offloading. The S94C as well as two separate histidine 265 mutants (H265N and 
H265Q) were constructed via quick change mutagenesis, in the hopes that one would be stable 
(Table 3.1, DHS 7161 – 7162) as often active site mutations are deleterious to protein folding. 
Upon expression and purification of these two variants using the same procedure as the previous 
constructs produced highly soluble, stable protein much to our surprise as this has not been the 
case with active site mutations in PKS TEs.  
With both double mutant CrpTE proteins in hand, they were assessed for substrate 
occupancy via QTOF-MS with the N-acetyl cysteamine substrate described previously (Scheme 
2.4, 2.28a). Initial screens aimed at identifying conditions for effective acylation. High pH buffers 
(tris pH9/10) were investigated along with temperatures ranging from 4 °C to 37 °C, and substrate 
to protein ratios from 2:1 to 20:1. Each of these were checked initially at three time points, by flash 
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freezing prior to assessment on the TOF. These initial screens produced no detectable acylation of 
the active site for either protein. After exhausting possible buffer and temperature conditions, we 
decided to investigate a more active substrate, bearing a thiophenol in place of the N-acetyl 
cysteamine (Scheme 3.1). This was generated utilizing a similar synthetic scheme as described in 
Chapter 2. Unit AB was formulated in an analogous manner to the SNAc containing substrate.  
Thiophenol containing unit CD was formulated by the benzyl deprotection of 2.19 with H2/Pd 
followed by thiophenylation using tributyl phosphine and diphenyl disulfide. This was then Boc 
deprotected, coupled to unit AB, and desilate as described in Chapter 2 to produce substrate 3.2. 
With this new, more active substrate, buffer, temperature, and times were again assayed in 
order to determine the optimal acylation procedure. Results indicated that higher temperatures (30 
or 37 °C), high pH buffer (Tris pH = 9) for short times (30 min to 1 hour) were optimal, however 
slow hydrolysis was still seen upon overnight incubation at 4 °C. Continued screening of 
temperatures and buffer conditions, indicated it was the higher pH buffers necessary for acylation 
that was responsible for the aberrant hydrolysis. Quenching of the reactions using a 10% formic 
acid solution, produced an acylated protein that was stable for 24 hours upon 4 °C storage. In hopes 
of eliminating the formic acid quench, a quick acylation time (30 min to 1 hour) in pH 9 Tris buffer 
at 37 °C followed by subsequent buffer exchange back to pH 7 HEPES and storage at 4 °C, 
produced a substrate bound enzyme that was again stable for more than 24 hours. Subsequent size 
exclusion chromatography produced protein for crystal screening. Again, the Qiagen classics I and 
II screening kits were utilized, but did not produce any significant crystals. 
 
 
Scheme 3.1 Synthesis of thiophenol containing substrate.  
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3.3 Evaluation of the Cryptophycin Thioesterase as a Candidate for Solution Phase Structure 
3.3.1 Background Information on Solution Phase (NMR) Structural Determination  
With the discovery of mostly monomeric CrpTE as well as the knowledge that it does not 
re-equilibrate to dimer, and the lack of crystallization hits in the crystal screens, we began to look 
for alternative methods for structural characterization. With the advent of super conducting, high 
field strength magnets, user friendly control software, and multi-frequency detection channels 
nuclear magnetic resonance (NMR) can be utilized to structurally characterize a wide range of 
 
 
Figure 3.4 General schematic of the workflow involved in assigning carbon and hydrogen signals 
using standard triple resonance NMR experiments, CBCA(CO)NNH and CBCANNH. 
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biological entitles. This method has the advantage of being able to detect protein structural changes 
in response to experimental conditions, giving us the ability to titrate in substrates and effectively 
monitor discrete amino acid shifts as the protein undergoes its catalytic cycle, giving us vital 
information about the dynamics of TE’s. 
Smaller proteins (<10 kDa) often lend themselves to assignment based on homonuclear 
two-dimensional experiments like TOCSY and NOESY, however larger sized proteins are 
accompanied by exponentially more signals, resulting in crowding that can’t be resolved.23 Further 
three-dimensional heteronuclear triple-resonance NMR experiments are necessary in these cases 
to assign the backbone and sidechain shifts. Standard resonance assignments are made through 
CBCANNH and CBCA(CO)NNH,24-26 which gives correlations for each NH group to both the 
corresponding Ca and Cb as well as the preceding Ca and Cb. which allows you to determine 
adjacent amino acid resonances (Figure 3.4). Utilizing knowledge of characteristic amino acid 
frequencies (Alanine, Serine, Threonine, and Glycine contain characteristic resonances) allow you 
to generate a general sequence idea (ex: Ala-xx-Thr-xx-xx-Ala) and compare that to your known 
sequence. From here you can identify the portions of the sequence using these known amino acids 
allowing the assignment of each atom of the polypeptide backbone to a shift in the spectra. In order 
 
 
Figure 3.5 Magnetization transfer pathways seen in three-dimensional NMR experiments necessary 
for the assignment of large proteins: CBCANNH, CBCA(CO)NNH, HNCA, HNCO, HNCACO, and 
HNCOCA 
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to assign the CrpTE, a 35 kDa protein, and ultimately build a structure it is necessary to not only 
run the previous two experiments, but others to confirm the assignments as well as resolve 
ambiguous signals. A standard set of three dimensional experiments which allow for the 
assignment of large proteins may include HNCA, HNCO, HNCACO, HNCOCA (Figure 3.5) all 
of which require different labeling patterns including 13C, 15N, and 2H.27 Once the backbone is 
assigned and the Ca and Cb of each sidechain has been assigned from those initial experiments 
(Figure 3.4) for flowchart on how you can utilize experiments to walk down peptide chain), an 
HCCH-TOCSY experiment can give the rest of the sidechain assignments, with the help of a 
separate experiment, HCCONH if these can’t be completely resolved. From here J values collected 
can be used to compute the structure based on the Karplus angles of each atom in the backbone. 
Sidechain position is assigned in an analogous manner once the backbone has been determined. 
3.3.2 Formulation of CrpTE Protein for NMR Experiments  
Utilizing the results from the construct optimization, DHS 7154 (minus 5aa) was chosen 
for structural characterization as it was predominantly monomeric and proved most stable to NMR 
buffer conditions (sodium phosphate buffer, pH = 6.5). The initial NMR experiment to check for 
protein folding and stability was a 1H/15N HSQC, which required 15N labeled protein. The protein 
was grown by first inoculating a 5 mL starter culture in LB using freshly transformed Bl21 (DE3) 
E. coli. This was grown to a high OD600 (~6 – 8 hours) and was used to inoculate overnight cultures 
in M9 media (see SI for recipe) augmented with 15NH4Cl and kanamycin (50 ug/mL). The 
overnight culture was then used to inoculate 1 liter cultures of the M9 (1:100 innoculum) media 
supplemented with kanamycin (50 ug/mL). This was grown to OD600 of 0.5 at 37 °C, cooled to 20 
°C and induced with 100 uM IPTG. This was expressed for 18 hours, spun down at 6,000 rpm for 
30 min and stored at -78 °C for purification. Frozen cells were purified using Phosphate buffer 
with varying amounts of imidazole over NiNTA resin, prior to cleavage with TEV protease, and 
size exclusion chromatography. Buffer exchanging into a pH 6 phosphate buffer yielded protein 
ready for NMR experiments. 
In collaboration with Dr. Vivekanandan Subramanian in UM Biophysics, initial 1H/15N 
HSCQ showed excellent resolution (Figure 3.6) and 250 NHs of the 296 total were resolved. In 
order to start putting together the backbone of the CrpTE, 13C, 15N, and 2H CrpTE was generated 
using the same procedure as above, substituting globally 13C labeled glucose and growing in 70% 
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D2O. Upon purification and TEV cleavage, this produced 19 mg/L of pure protein which was 
immediately concentrated to 500 uM and used to run HNCACB, CBCACONH, HNCA, and 
HNCACO experiments. Utilizing these experiments as well as NMR processing software 
SPARKY, each of the NHs present in the initial 1H/15N HSCQ have been correlated with their 
respective Ca and Cb. We are currently building the assignments off these correlations which will 
be used in the future structural characterization.  
 
 
 
 
 
 
 
 
 
 
Figure 3.6 15N/2H HSQC spectrum of CrpTE as observed in SPARKY NMR program.  
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Chapter 4 
Molecular Interrogation of Polyketide Synthase Modules in the 
Pikromycin System Using Unnatural Pentaketides  
 
4.1 Background on the Macrolide Antibiotic Pikromycin 
4.1.1 Macrolides as Antibiotics  
Polyketide antibiotics were originally discovered in 1950 with the isolation of pikromycin, 
followed closely by the isolation of a second macrolide antibiotic erythromycin, which is still used 
clinically today.1-2 The mechanism of action of these molecules was later determined to be through 
disruption of protein synthesis by binding to the 50S subunit of the bacterial ribosome.3 More 
recent work has shown that these likely bind to the peptidyl (P) site and disrupt the peptidyl transfer 
activity, which joins incoming t-RNA attached amino acids with the growing amino acid chain, 
ultimately stalling protein synthesis.4-6 It is also thought that these can act as a physical barrier by 
sitting in the nascent peptide exit channel (NPET).7 Although erythromycin was widely successful, 
its inherent instability causes breakdown products that produce undesirable gastric side effects. 
This combined with the continued emergence of resistant bacterial strains has led to extensive SAR 
campaigns for analogues with better biological properties and to combat continually emerging 
resistance. 
Erythromycin is considered a first generation antibiotic and is produced industrially from 
enhanced strains of Saccharopolyspora erythraea. Second generation analogues (Figure 4.1)8 
were developed by semi synthesis from erythromycin in order to combat the pharmacokinetic and 
pharmacodynamics shortcomings seen in the clinic, which lead to the discovery of the widely used 
Azithromycin (Z-pac). Third and fourth generation antibiotics have more recently been 
investigated to help combat one of the major forms of resistance seen in bacteria; macrolide, 
lincosamides, streptogramin B (MLSB) resistance. Macrolide antibiotics bind to the 23S RNA 
portion of the 50S subunuit.9 Resistance is conferred by either mono or demethylation of the 23S 
ribosomal RNA by the ERM (erythromycin resistance methylase) family of methyl transferases.10-
11 In the presence of erythromycin (specifically the cladinose sugar appended to C3), the previously 
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inaccessible ErmC ribosomal binding site is uncovered and translated, producing the methyl 
transferase protein that confers resistance. The requirement for the cladinose sugar for this process 
has led to third generation macrolides known as ketolide antibiotics, which remove the cladinose 
sugar and oxidize the remaining alcohol to a ketone, inhibiting resistance mechanisms.10  Addition 
of the alkyl-aryl side chain at positions 11 and 12 on the Erythromycin core, confers a second 
binding site on the ribosome and also helps modulate susceptibility in the macrolide resistant 
strains. 
4.1.2 Biosynthesis of Pikromycin  
In an effort to facilitate medicinal chemistry efforts necessary for the production of novel 
antibiotics, the Sherman lab has pursued a detailed understanding of the modular PKS biosynthetic 
systems responsible for the production of macrolide antibiotics, including pikromycin.12-16 
Pikromycin, the original member of this family is a natural ketolide antibiotic. Although it is not 
as potent as the Erythromycin series of antibiotics, its ability to induce MLS  
 
 
Figure 4.1 Antibiotic generations and their binding site on the ribosome. The MLS inducing cladinose 
sugar and the alkyl-aryl side chain that confers a second binding region are highlighted in pink and 
navy.  
  59 
 
resistance is greatly diminished. Analogues formulated from this scaffold in efforts to make this 
macrolide more potent have produced solithromycin which is currently in clinical trials. 
Pikromycin contains a unique PKS biosynthetic system that it is capable of producing both a 12 
membered ring, the methymycin family of natural products as well as the 14 membered 
pikromycin ring structures (Figure 4.2). These can both be glycosylated and oxidized by 
cytochromes P450 to produce the full macrolide antibiotic (Figure 4.2). The inherent flexibility 
seen within this system makes it uniquely suited for exploration into the use of intact modules for 
 
 
Figure 4.2 Pikromycin biosythetic pathway for the formation of aglycones 10-Deoxymethynolide (10-
DML) and Narbonolide. Further tailoring enzymes for glycosylation and P450 transformations 
formulate the full macrolide antibiotics. 
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a biocatalytic syntheses of novel macrolide antibiotics.  Utilizing the biosynthetic machinery of 
macrolide antibiotics to introduce new functionality and alter the core pharmacophore could 
provide rapid access too novel structures with better pharmacological properties. Bioengineering 
efforts toward this end have focused on the introduction of non-native and unnatural malonyl 
derivatives, modification of module domain architecture in vivo to produce altered oxidation states, 
as well as swapping of entire modules with native modules from other systems to produce 
significant structural modifications.17 This has met with some success, however generally only 
trace products are detectable by mass spectrometry and in general this strategy meets with more 
failure than it does success. In order to further engineer polyketide synthases, a detailed 
understanding of the key factors involved in producing these must be understood. 
4.1.3 Structural Investigations of Polyketide Synthases 
Recent structural work on pikromycin modules has provided new insights into the overall 
architecture of PKS modules and their catalytic mechanism. Historically, crystal structures of 
excised domains have given us a wealth of information and served as a surrogate for full length 
module crystals, as to date they have remained elusive. Crystal structures of excised KS-AT from 
the Curacin and DEBS pathway, initially showed an elongated structure, similar to that of FAS 
 
 
Figure 4.3 Cryo-EM reconstruction of PikAIII. (C) showing the single active site chamber in 
comparison to the curacin excised module (B) which shows a similar linear structure to FAS (A). 
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leading to the structural model that has predominated.18-19 A breakthrough in intact PKS structural 
work came in 2015 with the publication of two Cryo-electron microscopy (Cryo-EM) papers that 
described a previously unseen architecture in PKSs.20-21 The reconstruction of the PikAIII module 
(Figure 4.3) showed an overall arc shape with a single active site chamber, not the extended 
structure that had long been hypothesized.22 The second surprising finding from these studies 
showed the incredibly mobility of the ACP, especially when substrate bound. The ACP appears to 
be able to shuttle its substrate around the arc shaped chamber, sampling separate domain active 
sites and effecting catalytic transformations. These studies had a profound impact on the current 
state of PKS catalytic mechanism knowledge and continued studies like this with different modules 
as well as different substrates could help indicate where catalysis stalls, giving us a selectivity 
profile, and guide engineering efforts to overcome this.   
4.1.4 Biochemical Characterization of PikAIII-TE and PikAIII/AIV 
To combat the current PKS selectivity deficit, work in the Sherman lab has been moving 
towards using synthetic chain elongation intermediates to interrogate the ultimate (PikAIV) and 
pent-ultimate (PikAIII) modules ability to produce unnatural macrolactones. A previous graduate 
student Dr. Douglas Hansen, was able to reconstitute the final two modules of the Pik biosynthetic 
system in vitro using a synthetically formulated pentaketide to produce both 10-Deoxymethynolide 
(10 DML) and narbonolide.13 In order to formulate these two different sized rings, he utilized both 
the native PikAIII/AIV system seen in the biosynthesis, as well as a non-native fusion protein of 
 
 
Figure 4.4 Reconstitution of PikAIII-TE and PikAIII/AIV modules. This facilitated the production of 
the 12 and 14 membered aglycones 10 DML and Narbonolide with successive biotransformation to their 
respective macrolide antibiotics. 
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AIIITE which were both heterologously expressed and, when combined with the synthetic 
pentaketides, methyl malonyl and an NADP recycling system, were able to formulate the two 
aglycones. This was further expanded to produce the active antimicrobial macrolides through 
biotransformations with engineered strains of Streptomycese venezuele (which natively produce 
pikromycin) that have had the pikromycin PKS cluster knocked out but are capable of 
glycosylating and oxidizing macrolactone rings.23-24  
In order to probe the selectivity and specificity of these enzymes, unnatural chain 
elongation intermediates with altered carbon sidechains and stereochemistry on the right half of 
the pentaketides were formulated in order to interrogate PikAIII-TE.12 Utilizing this fusion protein 
alone would hopefully help further narrow down the cause of any processing deficiencies. The 
results of the altered carbon chains show a clear trend towards less efficient turnover as the 
modifications become more drastic. The C10 desmethyl (4.5 to 4.12) shows almost wildtype 
turnover (56%) to its 12 membered macrolactone counterpart however, when you remove the C9 
 
 
Figure 4.5 Initial right half pentaketides analogues assayed with PikAIII-TE. The different desmethyl 
analogues show different propensities for extension and cyclization while the epimers showed no 
turnover to macrolactones.  
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ethyl group (4.8 to 4.15) you see a significant decrease in macrolactone recovery (9%). Attempts 
to process substrates with altered stereochemistry at the C8 and C9 position (4.9 – 4.11) produced 
no macrolactone products, however extended products were isolated and characterized as extended 
shunt products that included a decarboxylation and a hemiketalization. This suggested that the 
module was able to process all these substrates to some extent, but that it was the TE that precluded 
effective production of macrocyclic products. This was further supported through the generation 
of the Pik hexaketide containing altered stereochemistry and attempts at biocatalytic conversion 
through the stand alone TE. This produced exclusively hydrolyzed starting material, further 
demonstrating the profound role the TE plays in macrocycle production. 
In an accompanying publication by Dr. Aaron A. Koch, the previous results were further 
explained and the TE was engineered to partially overcome this effect.14 Molecular dynamics 
simulations that showed the PikTE could accommodate the epimerized substrates but that intrinsic 
substrate organization precluded cyclization. With this knowledge an active site mutation, S148C 
was made which altered the catalytic mechanism, which was capable of effectively cyclizing the 
epimerized hexaketide. This was then reincorporated into the PikAIII module and the epimerized 
pentaketides was again tested. This time, the module was able to formulate 2 corresponding 
macrolactones, the expected 11-epi-10 DML (4.16, 12% isolated yield) as well as a second ring in 
which the native KR in PikAIII didn’t act on the substrate producing a similar 3-keto-11 epi-10 
DML (12% isolated yield). These studies indicate that the modules are capable of processing at 
least distal chain modifications and continues to highlight that the TE is likely the underlying cause 
for unproductive formation of macrocyclic products.  
 
4.2 Synthesis of Alternate Pentaketides Chain Elongation Intermediates  
In order to continue to probe the flexibility of the terminal PikAIII-TE as well as the 
PikAIII/PikAIV biosynthetic pathway, a second suite of unnatural pikromycin pentaketides were 
designed to contain functionality that would not otherwise be present in polyketide synthase 
products, including heteroatoms in place of carbons, altered side chains, as well as various lengths 
of the backbone ketide units (Figure 4.6). With these substrates in hand we hoped to assay the 
ability of our PKS proteins to accept and process them to their corresponding macrolides, or other 
biproducts and help shed light on the complex factors associated with accepting, extending, and 
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cyclizing polyketide macrolactones, as well as guide structural studies, and ultimate engineering 
efforts.  
4.2.1 Synthesis of Ester and Amide Containing Pentaketides  
The first analogues formulated contained an a/b unsaturated ester (4.27) and amide (4.28) 
in place of the a/b unsaturated ketone. These were formulated by taking advantage of a peptide 
coupling strategy. The left portion of both the ester and the amide analogues were synthesized by 
protecting group manipulation of commercially available (S) – Roche ester 4.19 and (S)-Boc-β2-
HomoAla-OH 4.21 followed by thiophenylation of the acid with tributyl phosphine and diphenyl 
disulfide. The right half was formulated via cross metathesis of 2-pentenoic acid with 4.26 whose 
synthesis was reported previously.13 Subsequent deprotection of the two discrete left halves to 
produce 4.22  and 4.23 and coupling between these and 4.26 using either HATU or DCC/DMAP 
produced the desired TBS protected pentaketides. Deprotection with aq. HF produced the desired 
ester and amide containing pentaketides 4.27 and 4.28. 
4.2.2 Synthesis of Pentaketides containing Varied Alkyl Substituents  
Next we focused on the desmethyl, dimethyl, cyclohexyl, and ether analogues (4.37 – 4.40) 
as we envisioned utilizing a cyclic anhydride ring opening strategy for the formation of all four. 
 
 
Figure 4.6 Potential unnatural pentaketide analogues. These were designed to contain heteroatoms, 
unnatural side chains, and altered ketide length 
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Using glutaric anhydride 4.29 as the test platform, conditions for ring opening were investigated. 
Unfortunately, attempts to open the glutaric anhydride test platform with vinyl magnesium 
bromide produced either Michael addition polymerization or double addition products (Scheme 
4.2, A). Although our initial attempts were not successful, the ring opening strategy was still an 
attractive option for formulating these four analogues, leading us to investigate Weinreb amides. 
Opening of the anhydride could first be accomplished using N,O-dimethylhydroxylamine 
hydrochloride (4.31) in pyridine and DCM to form the Weinreb amide 4.32. Attempts to displace 
 
 
Scheme 4.1 Synthesis of ester and amide containing pentaketides.  
 
 
Scheme 4.2 Vinyl magnesium bromide ring opening strategy for analogue formation. First (A), second 
(B), and (C) third iterations of the cyclic anhydride opening strategy used to formulate altered carbon 
chain analogues.  
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the Weinreb amide in the presence of the acid functionality was met with some success although 
the elevated temperatures necessary to displace the Weinreb again promoted Michael addition and 
low reaction yields (Scheme 4.2, B). In order to mitigate the instability, we hypothesized that 
protection of the acid as a methyl ester could be used as the Weinreb amide would coordinate the 
vinyl magnesium bromide well enough to produce predominantly the desired product. This 
reaction was successful and produced 4.34 in a 62%yield. Subsequent cross metathesis with 4.25 
proceeded smoothly, however saponification with LiOH was prone to Michael addition upon the 
presence of methanol or long reaction times. Thiophenylation and subsequent aq. HF deprotection 
produced the desired desmethyl pentaketides 4.37. This strategy was utilized in order to make both 
the dimethyl and the cyclohexyl (racemic) containing analogues. The dimethyl analogue showed 
exclusive opening to the less hindered site as expected however unfortunately attempts to utilize 
the same strategy with a diglycolic anhydride the ether containing Weinreb produced varying 
products including addition into the methyl ester. This is likely due to the presence of a second 
five membered ring coordination network that can occur with the ether oxygen into the methyl 
ester.  
 
 
Scheme 4.3 Synthesis of desmethyl, dimethyl and cyclohexyl pentaketide analogues. Desmethyl 
pentaketides 4.37 as well as the dimethyl pentaketides 4.38 and cyclohexyl pentaketide 4.39 were 
formulated utilizing the same chemistry. Utilizing the diglyclic anhydride to formulate the ether 
containing pentaketide 4.40 unfortunitley did not produce the corresponding a/b unsaturated ketone.   
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4.2.3 Synthesis of Extended Chain Pentaketides  
Next we focused our attention on the substrates with altered ketide chain lengths in order 
to investigate the ability of TEs to formulate odd membered ring sizes. The initial analogue 
contained a homologation site directly adjacent to the a/b unsaturated ketone. This was chosen as 
it was easily homologated from the alcohol state of the right half of the pentaketides. After 
cleavage of the Evans chiral auxiliary to the alcohol 4.41 as reported previously13, subsequent 
tosylation, and cyanide displacement produced 4.42 which was reduced to the aldehyde and 
subjected to Wittig olefination conditions to produce 4.43. This was then cross metathesized with 
4.4413 to produce the homologated acid product. This was then thiophenylated and deprotected 
unfortunately, intramolecular Michael addition upon deprotection of the cyclizing alcohol 
precluded us from testing this substrate directly with our enzymes. Future attempts will be made 
to add a photocleavable protecting group to this in order to facilitate a single pot deprotection, 
biocatalytic reaction strategy that has been employed for other unstable substrates.25 Other 
homologation positions throughout the chain, including closer to the head group as well as prior 
to the a/b-unsaturated ketone will also be investigated.  
 
4.3 Biochemical Evaluation of Synthesized Pentaketides  
With the first set of substrate analogues in hand, analytical enzymatic reactions with the 
monomodule fusion protein PikAIII-TE, responsible for the production of 12 membered rings as 
well as the terminal two modules PikAIII/AIV responsible for the production of 14 membered 
rings were explored. Our previous results with the PikAIII-TE and the PikTE stand-alone proteins 
 
 
 
Scheme 4.4 Synthetic scheme for the formulation of homologated pentaketides.  
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show that the TE is usually the bottleneck to forming unnatural macrolactones, however the effects 
of this on the 14 membered rings have not been explored.  
4.3.1 Evaluation of Pentaketide Analogues with PikAIII-TE 
With five new pentaketides analogues in hand we began to assay the PikAIII-TE for its 
ability to produce new 12 membered rings. PikAIII accepts methyl malonyl as an extender unit 
which has been synthesized as the SNAc variant. It also contains a KR domain which requires 
NADPH to complete its reduction. With the high cost of NADPH it is not feasible to use 
 
 
Figure 4.7 Analytical reaction traces with new pentaketides utilizing the PikAIII-TE fusion protein. The 
no enzyme controls for each being in black and the different enzymatic reactions being denoted in the 
various colors. [*SM indicates starting material] 
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stoichiometric equivalents, instead a NADP recycling system which employs glucose-6-phosphate 
(G6P) and glucose-6-phosphate dehydrogenase (G6PDH) was used.  
Analytical reactions on a 50 uL scale were run along with a no enzyme controls to help 
discern what are enzymatic products versus reactions condition degradation products. 
Interestingly, the starting materials show different propensities for degradation as is evident when 
comparing starting material in just buffer versus starting material with the reaction components 
(see Chapter 7 for experimental traces). The ester, amide, and desmethyl products appear to show 
a distinctive [M+H] that is +9 from the starting material mass. It is still unclear what these products 
are however in the presence of enzyme, they seem to be produced in minimal quantities.  
Analysis of the reactions with the PikAIII-TE were initially disappointing (Figure 4.7) The 
native pikromycin pentaketides (green) shows a distinctive product peak (whose retention time 
was verified with an authentic standard), however the five analogues showed no peaks containing 
either the expected [M+H], [M+Na], or [M-18] peak that are often present when macrolactones 
are produced. The disappearance of starting material, however indicates that some enzymatic 
transformation is occurring. Further analysis of the reaction masses led to identification of peak 
masses that corresponding to an AIII extension, but hydrolysis instead of cyclization in the ester, 
amide, and desmethyl pentaketides ([M+H] = 303, 302, 287, Figure 4.8). Water mediated 
hydrolysis off of the thioesterase is a well-known competing process when it is incapable of 
cyclization, lending credence to the hypothesis that the thioesterase is often the “bottleneck” for 
 
 
Figure 4.8 Mechanism of hydrolytic byproduct production in PikAIII-TE. Extension of the pentaketides 
by PikAIII and subsequent TE mediated hydrolysis gives the masses seen in the box for each of the 
unnatural substrates which correspond to those seen in Figure 4.7. 
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production of novel macrolactones. Analysis of the reactions with the dimethyl and cyclohexyl 
substituents show minimal, if any consumption of starting material, indicating that the PikAIII is 
unable to accept these larger substituents. This begins to shed light on the selectivity of PikAIII, 
which appears to rely heavily on the substituents proximal to the trans-thioesterification site. 
4.3.2 Evaluation of Pentaketide Analogues with PikAIII/AIV 
 Despite to inability of PikAIII-TE to produce macrolactone products, the realization that 
PikAIII could accept the Ester, Amide, and Desmethyl pentaketides lend us to test them with the 
PikAIII/AIV system. This would give us insight into whether or not PikAIV would be capable of 
 
 
Figure 4.9 Analytical reaction traces with new pentaketides utilizing the PikAIII/AIV coupled system 
with the no enzyme controls for each being in black and the different enzymatic reactions being 
denoted in the various colors. [*SM indicates starting material] 
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accepting and processing them as well as the TE’s ability to cyclize 12 versus 14 membered rings. 
The cyclohexyl and dimethyl analogues were tested as well, with the assumption that they would 
not be accepted even in the presence of PikAIV. The proteins were expressed and purified as 
described previously and the fidelity of them was tested using the pikromycin pentaketide. The 
results were as expected and showed a large peak that was verified to be narbonolide with an 
authentic standard (Figure 4.9, Green).  
Analysis of the PikAIII/AIV reactions with the Ester, Amide, and Desmethyl pentaketides 
proved significantly different from those in the PikAIII-TE reactions. In this case, two peaks with 
the potential product mass were identified along with some extended, hydrolytic byproduct peaks 
for. Again, the dimethyl and cyclohexyl showed minimal consumption of starting material. 
In order to determine if either of the two peaks corresponding to the product masses were 
in fact the desired macrolactones, the reactions were run on a 10 mg scale and the products isolated 
for complete characterization. In each case, the later of the two isobaric peaks was the desired 
macrolactone isolated in 32% yield, 25% yield and 12% yield for ester, amide, and desmethyl 
narbonolide derivatives (Figure 4.10). Unfortunately, the byproducts were not isolated in large 
enough quantities for full characterization however ongoing efforts to elucidate their structure are 
underway. Analysis of potential products based on chemical formula derived from the mass, 
indicates these could be one of a few possibilities. First, although polyketides are usually fairly 
specific for the stereoisomer they produce, it is possible that with unnatural analogues that alternate 
ones could be produced. Other potential products that would have the same mass are doubly 
 
 
Figure 4.10 Semi-preparative Pik AIII/AIV scale ups of select pentaketides. Utilizing reaction 
conditions described and 3 uM of each protein, the corresponding isolation yields were obtained. 
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extended (PikAIII, PikAIV) hydrolytic products that have either hemiketalized or cyclized off 
another hydroxyl to produce a six membered macrolactone (Figure 4.11). Further characterization 
will hopefully shed light on these alternate products giving us more insight into the product 
dispersion.   
4.3.3 Evaluation of Pentaketide Analogues with PikAIII-TE S148C Mutant 
With our previous publication showing the effectiveness of the PikAIII-TE serine to 
cysteine mutant for the production of unnatural macrolactones we were cautiously optimistic that 
this variant may produce better results with the ester, amide, and desmethyl pentaketides. The 
fidelity of the PikAIII-TE S148C was tested using the pikromycin pentaketides, which shows a 
similar conversion to the desired product as the native PikAIII-TE (Figure 4.11, Green). 
Unfortunately, with these newly generated analogues, there was still no detection of masses 
consistent with potential products. What was observed was full conversion to of starting material 
to a variety of masses which are currently under investigation. For the ester containing pentaketide, 
the PikAIII-TE showed single extension and hydrolysis peak corresponding to an [M+H] of 319, 
however in the PikAIII-TE S148C mutant we see conversion to three separate products with 
[M+H] = 404, 356, and 298 (Figure 4.11, Blue), all of which can not be reconciled by any known 
or proposed byproducts of PKS reactions including dimerization of substrates, hemiketalization, 6 
 
 
Figure 4.11 Potential isoberic macrolactone products produced by the Pik AIII/AIV system. 
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membered ring formation, and decarboxylation of hydrolyzed starting materials. The amide 
reaction showed production of a single discernable peak with a [M+H] = 403 (Figure 4.11, 
Purple), which likely corresponds to the same transformation seen in the analogous mass from the 
ester reaction. Lastly, the desmethyl reaction shows three new peaks however the actual [M+H] 
mass is not readily identifiable as there are multiple fragmentation patterns in each peak. The 
dimethyl and cyclohexyl pentaketides were not run with these mutant proteins, as we have already 
established that the PikAIII can not accept these substrates making any consumption of starting 
material likely a TE mediated hydrolytic byproducts that are known to occur with this cysteine 
containing variant.  
 
 
Figure 4.12 Comparison of analytical reactions with Ester, Amide, and Desmethyl Pentaketides 
against wildtype Pik AIIITE and Pik AIII-TE S148C. Black denoting the no enzyme control for each 
with the corresponding traces labeled.  
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Chapter 5 
Summary, Discussion, and Future Directions  
 
Polyketides and non-ribosomal peptide synthases natural products are structurally diverse 
compounds that display a wealth of pharmacological activates. My graduate work has been 
focused on combining synthetic chemistry and biosynthetic enzymes in order to probe the ability 
to utilize these enzymes for the chemoenzymatic production of natural products and natural 
product analogues. The full scope of this work hopes to combine biochemical data on selectivity 
of biosynthetic enzymes for unnatural substrates with high resolution structural characterization. 
With a detailed understanding of the selectivity and reaction mechanisms of these enzymes, we 
can design more general biocatalysts for the production of large libraries of natural products, aiding 
in not only the drug discovery process, but hopefully the production scale use of chemoenzymatic 
methods as well. This chapter will summarize the findings of the three projects I worked on for 
my dissertation as well as discuss continuing and future work towards our ultimate goal of 
understanding these complex systems well enough to engineer broad scope biocatalysts.  
 
5.1 Biocatalytic Synthesis of Cryptophycin Anticancer Agents  
5.1.1 Summary and Discussion of Work Completed  
 The implementation of a biocatalytic synthesis for the production of cryptophycin 
anticancer agents has led to two important discoveries including previously unknown structural 
features that retain pico molar activity and may help modulate toxicity and efficacy as well as 
important insights into the continued characterization of biosynthetic enzymes. Despite the 
extensive SAR that was completed for these molecules prior to clinical trials in 2002, a distinct 
lack of heterocyclic functionality was investigated in unit A, presumably due to the deleterious 
effects seen with replacing the benzyl group with either a thiophene or furan ring. Despite these 
failures we saw this as a unique opportunity to not only fill a gap in the SAR of these molecules, 
but to continue the exploration of a biosynthetic enzyme of interest, the CrpTE. This enzyme has 
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previously been shown to be flexible to changes in the amino acid portion, however it showed a 
complete change in selectivity, from productive cyclization to non-productive hydrolysis with the 
removal of the aryl group.1 At the time, it remained unclear how alternative starter units would 
affect the downstream ability of the thioesterase to process these substrates.  
 Development of a diversifiable synthesis that was amenable to large scale formulation (tens 
of grams) of the cryptophycin chain elongation intermediate facilitated the production of a library 
of nine initial heterocyclic unit A analogues. These were assayed with the CrpTE on analytical 
scale with incredibly promising initial results. All the analogues showed comparable or grater 
turnover to product. This trend was confirmed upon semi-preparative scale up to 10 mg and 
isolation of the corresponding macrocycles which proceeded in 49 - 69% in comparison to that of 
the natural analogues at 49%. The initial hypothesis derived from these observations centered on 
solubility of the substrate. It is evident form the retention times on the TOF-MS analysis that many 
of these were more soluble than their benzyl counterpart, however this does not appear to explain 
all the data presented as a deeper investigation into the concentration dependence on turnover 
indicated that even well below the solubility threshold, the native substrate never produced 
turnover numbers higher than 80%. It is currently unclear what factors may produce this interesting 
result however, utilizing current and future structural studies, described in Chapter 3 we hope to 
shed light on this phenomenon.  
 With our initial nine cryptophycin analogues in hand, we in collaboration with Dr. Frederik 
Valeriote at the Henry Ford Health Center, investigated the effects on IC50 in HCT 116 human 
colorectal cancer cells. These results produced three interesting leads with one, the 4-methyl 
pyrazole being far superior to rest. This compound showed an IC50 of 10 pM in this cell line. In 
order to do a head to head comparison, cryptophycin 52 (the one used by Eli Lilly for clinical 
trials) showed an IC50 value of 3.3 pM, indicating our analogue is equipotent. The most interesting 
discovery with this compound is that it achieves this potency as the styrene derivative. The b epoxy 
functionality found on all the most potent derivatives previously described indicate that this is 
necessary for maximum potency, showing between a 100 and 1000-fold difference in potency. 
This discovery could have important implications for this molecule in the clinic as the epoxide has 
long been speculated to be partially responsible for the excessive neurotoxicity seen with these 
compounds. Although this is by far the most interesting compound, the 3-methylpyrazole and the 
4-methyl pyrazole also shown picomolar IC50 values, making them also more potent than the 
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majority of styrene analogues. These all have basic nitrogen’s likely placed in similar orientations 
in chemical space indicating these may be forming a previously unknown interaction upon binding 
to b tubulin. Further structural work and/or docking studies would be necessary to confirm this.   
 With the exciting results from the analogues generated by the CrpTE we wanted to expand 
our chemoenzymatic synthesis to utilizing the CrpE, the P450 responsible for the installation of 
the b epoxide. Although it was exciting to identify a new analogue with low picomolar activity 
lacking this group, the majority of the analogues still of interest as warheads for antibody drug 
conjugates, contain this epoxide functionality, which is notoriously difficult to install. Having an 
active biocatalyst that can work on a variety of substrates could be of great use in formulating 
some of these analogues currently. With that we set out to gain active protein and test it for activity 
with our current analogues. Although these results are not as exciting, with the P450 being able to 
formulate presumed products for only a few of the analogues, it gives us some information on the 
current scope of this catalyst. Likely, as the aryl rings are conjugated to the double bond being 
epoxidized, electronics plays a huge factor in whether or not this can act upon a substrate.  
5.1.2 Future Directions 
 With the discovery of this new, equipotent, styrene analogue continued investigations 
into its viability as a clinical candidate need to be explored. We are currently working with Dr. 
Valeriote at the Henry Ford Health Center to run maximum tolerated dose (MTD) studies in 
order to run a future PK examination of this analogue. It should also be screened more 
extensively for IC50 values in a variety of cancer cell lines, including a more thorough 
examination of resistant cell lines as that may be where this holds the most promise.  
 Cryptophycins are currently being extensively analyzed as antibody drug conjugates 
(ADCs) which could also be an interesting avenue of exploration for this analogue. The methyl 
pyrazole aryl ring contains a methyl amine functionality which could be replaced or utilized as 
an alternative linking region for these molecules. Currently, as the cryptophycins don’t contain 
any readily linkable functional groups, a benzyl amine is utilized to facilitate this without 
deleterious effects. Although many of these ADCs have been made and patented, they have yet 
to show up in the clinic indicating that they have not been as effective as previously hoped, 
potentially due to issues with warhead efficacy. Utilizing our analogue, without the epoxide, may 
show better efficacy and facilitate the continued development of these treatments.  
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5.2 Structural and Mechanistic Insights into the CrpTE  
5.2.1 Summary and Discussion of Work Completed  
 With the exciting results from Chapter 2, our interest in the structural and mechanistic 
features of the CrpTE led to a collaboration with both Dr. John Lutz at Eli Lilly and Dr. Janet 
Smith’s lab at the University of Michigan in hopes of solving a crystal structure of this fascinating 
enzyme. After numerous attempts over the past decade, we knew undertaking this again was going 
to require significant efforts. Utilizing numerous servers and prediction software, we identified a 
number of regions that could be problematic for crystal packing. Utilizing this knowledge, we 
designed and constructed numerous mutant CrpTE plasmids. These were all expressed, purified 
and screened for crystallization. Despite two initial hits, with two separate constructs, numerous 
counter screens to date, have not produced any viable crystals for x-ray diffraction. Despite this 
failure, a crucial discovery came during the purification of these mutant proteins which indicated 
two of the constructs were almost exclusively monomeric, whereas the others showed different 
dispersions of monomer and dimer as high as 2:1. This discovery facilitated a new collaboration 
with Dr. Vivekanandan Subramanian in biophysics, with the hopes of being able to utilize NMR 
to gain a solution phase structure of the CrpTE. Initial experiments looking at the stability, 
solubility, and tumbling of the CrpTE proved that it was an excellent candidate for further 
characterization. As this protein is large for the capabilities of NMR, at 35 KD, multiple three-
dimensional experiments, containing different 15N, 13C, and 2H labeling patterns is required in 
order to gather enough data to unambiguously assign each atom in this protein with its 
corresponding NMR signal. These proteins have been formulated and the experiments run, with 
excellent resolution. Although this work has not been complete, the data has been collected and it 
is a matter of fitting the pieces together in order to complete the assignments.  
5.2.2 Future Directions  
 Once the assignments for the protein have been made, we must utilize the J values acquired 
from these experiments to build a three-dimensional model of the CrpTE in order to gain a 
structure. Once this has been completed we will have the unique opportunity to explore the 
dynamics of this protein using our synthesized substrates. Despite a number of crystal structures 
to date of type I TEs, there are no NMR structures and none of the crystal structures contain full 
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length substrate. A few utilized a substrate mimic affinity probes as well as docking/modeling 
studies in order to gain insight into the binding orientation, however these are only able to speculate 
about the mechanism of cyclization. Using the NMR we are able to titrate in substrate and visualize 
the changes in both the protein backbone and sidechains (depending on the labeling pattern). Using 
these shift perturbations, we should be able to build a model of the changes in pose of this enzyme 
as it facilitates macrocyclization. 
 
5.2 Molecular Interrogation of Polyketide Synthase Modules in the Pikromycin Biosynthetic 
Pathway   
5.2.1 Summary and Discussion of Work Completed  
 Engineering of polyketide synthase modules has the ability to produce almost limitless 
structural modifications, however studies toward this goal have shown that a detailed 
understanding of these systems and their selectivity will be required to accomplish this. With the 
successful reconstitution of the PikAIII-TE and PikAIII/AIV modules, we began to focus on 
formulating “unnatural” pentaketides to interrogate these further and hopefully produce the 
corresponding macrocycles. In accordance with our goals, five new pentaketides were synthesized 
and tested with these proteins as well as the PikAIII-TE S148C variant that has previously been 
shown to facilitate macrolactone production where the wild type failed.  
 Initial examination of the ester, amide, and desmethyl pentaketides (4.27, 4.28, and 4.37) 
with the PikAIII-TE construct indicated that the PikAIII could accept and process these, 
formulating the extended product, however the TE was not able to cyclize them to macrolactones 
and only produced hydrolytic byproducts. Running the same assay with the dimethyl and 
cyclohexyl pentaketides showed no meaningful conversion of starting material by enzymatic 
conversion indicating these larger groups are unable to be accepted by the PikAIII.  
 Despite not producing macrolactones, we continued examining these analogues with 
PikAIII/AIV in order to gain insight into the ability of PikAIV to produce products. The ester, 
amide, and desmethyl pentaketides again showed consumption of starting material, however with 
this system, two peaks with the product mass were observed. Scale up reactions of 10 mg were run 
in hopes of isolating both products, however only the later of the two peaks in all cases (produced 
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in significantly greater yield) contained significant product for full characterization. These were 
determined to be 14 membered macrolactones although we only assume the stereochemistry is the 
as expected. Further analysis of these will need to be done in order to confirm the relative 
stereochemistry is as expected. The other peak corresponding to product mass has not been fully 
characterized for any of the three products however analysis of mass and hydrogen spectra indicate 
it may be a six membered macrolactone. Without full characterization this is only speculation and 
there are other structures that could potentially produce the same mass, however six membered 
macrolactones do have some precedence. Although it is unknown if this byproduct is TE catalyzed 
or spontaneous, previous work with triketides have shown that formation of a six membered ring 
at a rate significantly above a spontaneous are produced in the presence of a TE indicating this is 
likely a protein mediated process. Testing of the dimethyl and cyclohexyl pentaketides again 
showed no meaningful consumption of starting material as expected again indicating these are too 
large for the PikAIII KS to load. 
 Finally, we tested the PikAIII-TE S148C variant that has previously been shown to 
facilitate macrolactone production. Analysis of these reactions did not produce peaks that 
contained a mass consistent with product production. There are a number of produced products, 
however none are reconcilable with known byproduct pathways. Interestingly both the ester and 
amide show a peak that corresponds to the same transformation, which is [+ 119] from the product. 
In the DEBS TE, dimerize substrate has been observed, which could account for the significantly 
higher mass present here, however no combination of two pentaketides produces this mass 
(cyclized, dimerized substrate has an [M+H] = 453). Further characterization will be necessary to 
determine what is being produced by this TE variant and may shed light on interesting potential 
byproducts.  
5.2.2 Future Directions  
 This work is still in the middle stages of completion and requires synthetic work and 
enzymatic follow up to complete the story and answer some of the questions that have been 
identified thus far. Full characterization of the products being produced for the ester, amide, and 
desmethyl substrates with all three proteins is needed to fully understand the limitations of these 
enzymes as well as continued work on the synthetic substrates that have not been realized in Figure 
4.6. These studies will continue to shed light on the selectivity of the KS for alternative head groups 
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as well as the TEs ability to formulate macrolactones with esters/amides in different positions in 
the ring. Formulation of homologated pentaketides for examination with the PikAIII-TE and 
PikAIII/AIV may indicate size constraints as well as show that odd membered rings are possible 
for bacterial TEs (previously these have only been seen in very limited numbers in fungal 
pathways).  
 All the newly formulated pentaketides can also be tested with a second reconstituted 
system, the JuvE5 and JuvE6 from the juvenimycin pathway.2 This system natively accepts a 
hexaktide and produces the core macrolactone (tylactone) of a well-known, vetrenary antibiotic 
tylosin. Recently, our lab has discovered that this system is capable of accepting and processing 
the pik pentaketide into a 14 membered ring analogous to narbonolide except this one contains for 
a C3 reduction. Substitution of the native TE with the TE from the DEBS system has shown 
exceptional turnover to product with isolation yields of 42% (unpublished data). Utilizing the same 
JuvE5 and JuvE6 fusion protein, we can assay our pentaketides analogues with this system to gain 
insight into its selectivity.  
 The next facet of this project will focus on taking the macrolactones produced by this 
substrate manipulation and utilizing our Streptomycese venezuelae biotransformation strains to 
hopefully construct the corresponding macrolide antibiotics. These can then be tested with a wide 
range of bacterial pathogens for activity, further establishing this means of antibiotic discovery.  
 
5.4 Contributions to the Understanding of PKS Pathways for use in Combinatorial 
Biosynthesis 
 With the continued interest in natural products as drug leads, alternative strategies that 
reconcile the continued desire for medicinal chemistry efforts with the difficulties in synthesizing 
these molecules would play a profound role in the drug discovery world. The idea of engineering 
biosynthetic pathways in a strategy termed combinatorial biosynthesis has long been postulated to 
be capable of producing almost unlimited structural modifications to natural product scaffolds, 
facilitating the inexpensive and rapid production of libraries of “unnatural” natural products that 
can shed light on SAR and impart better drug properties on molecules of interest. Despite some 
notable examples, this strategy has largely met with failure presumably because we currently only 
have a limited understanding of the complex factors that govern the selectivity and specificity of 
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each catalytic domain. In both the cryptophycin pathway and the pikromycin pathway summarized 
above, we have used a mixture of biochemical analysis with structural interrogation to shed light 
on different facets of the catalytic cycle that are likely hindering the ability to utilize genetic 
recombination to formulate new products. Utilizing this knowledge, we envision being able to use 
mutagenesis both rationally, gained from the structural investigations, and in the form of directed 
evolution to engineer these proteins to accept and process substrates that are currently out of reach. 
Once optimized proteins of interest have been identified these can be screened again in an in vitro 
setting as broader scope catalysts with synthetic precursors and/or be reincorporated into the full 
biosynthetic pathways, pushing the field closer to realizing the vast amounts of products that can 
potentially be accessed through genetic engineering. 
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Chapter 6 
Cryptophycin Experimentals 
 
6.1 Chemical Synthesis of Seco Cryptophycin Analogues  
6.1.1 Unit A Synthetic Procedures and Characterization   
 
2 was synthesized over two steps from commercially available S1, all spectra were in accordance 
with previous literature.1-2 
 
 
(R)-4-benzyl-3-((2R,3S)-3-hydroxy-5-((4-methoxybenzyl)oxy)-2-vinylpentanoyl)oxazolidin-
2-one (2.3).  To a flame dried three neck flask under N2 was added a stirred solution of imide 2.1 
(7.5 g, 30.58 mmol, 1 eq) in CH2Cl2 (305 mL, 0.1 M) and treated with dibutylboron 
trifluoromethanesulfonate (1M in DCM, 33.64 mL, 33.64 mmol, 1.1 eq) at -78 °C. After stirring 
for 5 min, the mixture was treated with Et3N (6.02 mL, 42.81 mmol, 1.4 eq), then kept for 1 h at -
78 °C, and 20 min at 0 °C. The reaction was re-cooled to -78 °C and treated with a solution of the 
aldehyde 2.2 (8.31 g, 42.81 mmol, 1.4 eq) in CH2Cl2 (25 mL). The reaction was kept for 1 h at -
78 °C, then warmed to 0 °C for 1 h. The reaction was quenched by addition of pH 7 buffer (30 
mL) followed by MeOH (30 mL), keeping temperature > 5 °C. After 5 min, 30% H2O2 (30 mL) 
was added and the mixture stirred for 1 h at 0 °C. Organics were removed under reduced pressure 
and the remaining aqueous layer was extracted with EtOAc (3 x 100 mL). The organic phase was 
washed with 1 N HCl, 5% aq NaHCO3, brine, dried over Na2SO4, and concentrated. The crude 
HO OH
NaH, PMBCl,
Bu4NI, THF
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product was purified by flash chromatography (33% EtOAc/Hexanes) to give 2.3 (11.98 g, 89% 
yield) as a clear and colorless oil: Rf = 0.2 (33% EtOAc/Hexanes); 1H NMR (600 MHz, CDCl3) δ 
7.31 (ddd, J = 7.4, 6.4, 1.3 Hz, 2H), 7.28 – 7.25 (m, 2H), 7.24 – 7.21 (m, 2H), 7.20 – 7.15 (m, 2H), 
6.04 (dddd, J = 17.6, 10.0, 9.0, 1.1 Hz, 1H), 5.39 – 5.36 (m, 1H), 5.36 – 5.34 (m, 1H), 4.68 (ddt, J 
= 11.4, 6.3, 3.0 Hz, 1H), 4.58 – 4.51 (m, 1H), 4.42 (s, 2H), 4.25 – 4.19 (m, 1H), 4.18 – 4.11 (m, 
2H), 3.78 (d, J = 1.1 Hz, 3H), 3.69 – 3.64 (m, 1H), 3.64 – 3.56 (m, 1H), 3.28 – 3.17 (m, 1H), 2.74 
(dd, J = 13.4, 9.5 Hz, 1H), 1.93 – 1.78 (m, 1H), 1.74 (dt, J = 14.5, 7.0 Hz, 1H), 1.55 (s, 2H); 13C 
NMR (150 MHz, CDCl3) δ 173.46, 159.19, 152.90, 135.04, 131.67, 130.14, 129.42, 129.30, 
128.91, 127.35, 121.00, 113.78, 72.87, 70.54, 67.74, 65.95, 55.25, 55.17, 52.53, 37.58, 33.87; 
HRMS (ESI) clcd for C25H29NO6 [M+Na] 462.1887, found 462.1885. 
 
 
(R)-4-benzyl-3-((2R,3S)-3-((tert-butyldimethylsilyl)oxy)-5-((4-methoxybenzyl)oxy)-2-
vinylpentanoyl)oxazolidin-2-one (S 2.3).  To a solution of 3 (17.56 g, 39.9 mmol, 1 eq) and 2,6-
lutidine (46.28 mL, 79.9 mmol, 2 eq) in CH2Cl2 (135 mL, 0.3 M) was added tert-
butylsilyltrifluoromethane sulfonate (11.6 mL, 59.9 mmol, 1.5 eq) and the solution was stirred at 
rt for 18h. The mixture was quenched with H2O (100 mL), stirred for 30 min, and the extracted 
with CH2Cl2 (3 x 100 mL). The organic phase was washed with 1 N HCl, sat. aq NaHCO3, brine, 
dried over Na2SO4, and concentrated. The crude product was purified by flash chromatography 
(20% EtOAC/Hexane) to give S 2.3 (17.22 g, 78% yield) as a pale yellow oil: Rf = 0.6 (33% 
EtOAc/Hexanes);1H NMR (400 MHz, CDCl3) δ 7.33 – 7.26 (m, 3H), 7.25 (d, J = 8.8 Hz, 2H), 
7.18 (d, J = 6.9 Hz, 2H), 6.85 (d, J = 8.6 Hz, 2H), 6.00 (ddd, J = 9, 9.3,  18.2 Hz, 1H), 5.27 (d, J = 
10.2 Hz, 1H), 5.26 (d, J = 18.1 Hz, 1H), 4.58 (dd, J = 6.6 Hz, 8.8 Hz, 1H), 4.56 – 4.52 (m, 1H), 
4.41 (d, J = 11.4 Hz, 1H), 4.36 (d, J = 11.5 Hz, 1H), 4.21 (td, J = 5.2 Hz, 6.4 Hz, 1H), 4.05 (dd, J 
= 2 Hz, 9.2 Hz, 1H), 3.86 (t, J = 8.2 Hz, 1H), 3.78 (s, 3H), 3.59 (td, J = 6.5, 9.2 Hz, 1H), 3.48 (dt, 
J = 6.2, 9.4 Hz, 1H), 3.23 (dd, J = 3.0, 13.4 Hz, 1H), 2.70 (dd, J = 9.7, 13.4 Hz, 1H), 1.95 – 1.85 
(m, 2H), 0.86 (s, 9H), 0.02 (s, 3H), 0.01 (s, 3H);13C NMR (100 MHz, CDCl3) δ 172.62, 159.24, 
153.02, 135.58, 134.24, 130.86, 129.68, 129.49, 129.10, 127.48, 127.48, 119.70, 113.86, 72.77, 
O N
O
Bn
O
OPMB
OH
TBSOTf, 2,6-Lutidine, DCM
O N
O
Bn
O
OPMB
OTBS
2.3 S 2.3
  87 
71.29, 66.03, 65.94, 55.66, 55.48, 53.39, 37.73, 35.47, 26.02, 18.22, -4.23, -4.38; HRMS calcd for 
C31H43NO6Si [M+Na] 576.2752, found 576.2767 
 
 
(2S,3S)-3-((tert-butyldimethylsilyl)oxy)-5-((4-methoxybenzyl)oxy)-2-vinylpentan-1-ol (2.4). 
To a stirred solution of S2.3 (17.22 g, 31.14 mmol, 1 eq) in THF (625 mL, 0.05M) was added a 
solution of NaBH4 (5.89 g, 155.7 mmol, 5 eq) in H2O (240 mL) at 0 °C. The reaction mixture was 
stirred at 0 °C for 5 min, warmed to rt, and stirred for 5 h. The reaction was quenched by the 
addition of sat. aq NH4Cl solution (200 mL) and the mixture stirred at rt for 1 h. The THF was 
removed under reduced pressure and the aqueous layer was extracted with EtOAc (3 x 75 mL), 
organics combined, washed with brine, dried over Na2SO4, and concentrated. The crude product 
was purified by flash chromatography (18% EtOAc/Hexanes) to afford 2.4 (10.04 g, 85% yield) 
as a colorless oil; Rf = 0.25 (20% EtOAc/Hexanes); 1H NMR (400 MHz, CDCl3) δ 7.25 (d, J = 
8.5 Hz, 2H), 6.88 (d, J = 8.6 Hz, 2H), 5.71 (ddd, J = 17.3, 10.4, 8.6 Hz, 1H), 5.18 (dd, J = 10.5, 
2.0 Hz, 1H), 5.10 (d, J = 17.4 Hz, 1H), 4.43 (d, J = 11.5 Hz, 1H), 4.38 (d, J = 11.5 Hz, 1H), 3.99 
(dd, J = 12.7, 3.0 Hz, 0H), 3.80 (s, 3H), 3.75 (dt, J = 10.8, 6.6 Hz, 1H), 3.61 (ddd, J = 11.0, 7.0, 
5.0 Hz, 1H), 3.46 (t, J = 6.5 Hz, 2H), 2.50 – 2.35 (m, 1H), 2.15 (t, J = 5.7 Hz, 1H), 1.88 – 1.70 (m, 
2H), 0.88 (s, 9H), 0.09 (s, 3H), 0.06 (s, 3H);13C NMR (100 MHz, CDCl3) δ 159.28, 135.60, 130.61, 
129.41, 118.67, 113.89, 72.72, 71.06, 66.63, 63.67, 55.43, 51.34, 34.11, 25.98, 18.14, -4 
 
 
(5S,6S)-5-(2-((4-methoxybenzyl)oxy)ethyl)-2,2,3,3,9,9,10,10-octamethyl-6-vinyl-4,8-dioxa-
3,9-disilaundecane (2.5).3-4 To a stirred solution of alcohol (9.81 g, 25.78 mmol, 1 eq) in dry 
pyridine (250 mL, 0.1 M) was added p-toluenesulfonyl chloride (7.37 g, 38.66 mmol, 1.5 eq) at 0 
°C. The mixture was warmed to rt and stirred for 4 h prior to re-cooling to 0 °C. The reaction was 
quenched by the slow addition of 0.5 N HCl (300 mL). The aqueous layer was extracted with 
diethyl ether (3 x 200 mL), organics combined, washed with 1 M HCl, brine, dried over Na2SO4, 
and concentrated. The residue was purified using a silica plug (18% EtOAc/Hexanes) to afford 2.5 
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(11.67 g, 84.6% yield) as a colorless oil: Rf = 0.4 (20% EtOAc/Hexanes); 1H NMR (400 MHz, 
CDCl3) δ 7.75 (d, J = 8.4 Hz, 2H), 7.30 (d, J = 8.4 Hz, 2H), 7.21 (d, J = 8.4 Hz, 2H), 6.86 (d, J = 
8.4 Hz, 2H), 5.58 (ddd, J = 8.7, 10.3, 17.3 Hz, 1H), 5.12 (dd, J = 1.2, 9.2 Hz, 1H), 5.04 (d, J = 17.2 
Hz, 1H), 4.39 (d, J = 11.6 Hz, 1H), 4.33 (d, J = 11.6 Hz, 1H), 4.08 (dd, J = 6.6, 9.4 Hz, 1H), 3.94 
(dd, J = 7.4, 9.4 Hz, 1H), 3.93 – 3.89 (m, 1H), 3.79 (s, 3H), 3.35 (t, J = 6.4 Hz, 2H), 2.46 – 2.42 
(m, 1H), 2.42 (s, 3H), 1.74 – 1.57 (m, 2H), 0.78 (s, 9H), -0.01 (s, 3H), -0.05 (s, 3H); 13C NMR 
(100 MHz, CDCl3) δ 159.30, 144.80, 133.44, 133.15, 130.53, 129.91, 129.39, 128.14, 119.79, 
113.92, 72.73, 70.54, 68.83, 66.36, 55.43, 48.61, 34.64, 25.91, 21.77, 18.11, -4.25, -4.69; HRMS 
(ESI) calcd for C28H42O6SSi [M+H] 534.2471, found 534.269. 
 
 
tert-butyl(((3S,4R)-1-((4-methoxybenzyl)oxy)-4-methylhex-5-en-3-yl)oxy)dimethylsilane 
(2.6).5  To a flame dried round bottom flask under N2 was added tosylate 2.5 (3.72 g, 6.96 mmol, 
1 eq) in dry THF (70 mL, 0.1 M). The mixture was cooled to 0 ºC and treated with lithium 
triethylborohydride (1M in THF, 17.39 mL, 17.39 mmol, 2.5 eq). The reaction was stirred at rt for 
2 h, cooled to 0 °C, quenched with water (15 mL), 3 N NaOH (15 mL), 30% H2O2 (15 mL), and 
stirred for 30 min. The organics were removed under reduced pressure and the aqueous layer was 
extracted with EtOAc (3 x 50 mL), the organics were combined, washed with brine, dried over 
Na2SO4, and concentrated. The crude product was purified by flash chromatography (10% 
EtOAc/Hexanes) to afford 2.6 (1.87 g, 74% yield) as a clear and colorless oil: Rf = 0.5 (10% 
EtOAc/Hexanes); 1H NMR (600 MHz, CDCl3) δ 7.25 (d, J = 9.0 Hz, 2H), 6.87 (d, J = 8.2 Hz, 
2H), 5.85 – 5.66 (m, 1H), 4.43 (d, J = 11.5 Hz, 1H), 4.38 (d, J = 11.5 Hz, 1H), 3.80 (s, 3H), 3.76 
(dt, J = 8.0, 4.2 Hz, 1H), 3.52 – 3.43 (m, 2H), 2.29 (td, J = 7.1, 3.9 Hz, 1H), 1.75 – 1.60 (m, 3H), 
0.99 (d, J = 6.9 Hz, 3H), 0.88 (s, 9H), 0.05 (s, 3H), 0.03 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 
159.23, 140.84, 130.85, 129.39, 114.67, 113.87, 72.68, 72.65, 67.24, 55.43, 43.58, 33.36, 26.05, 
18.27, 14.68, -4.26, -4.39; HRMS (ESI) calcd for C21H36O3Si [M+H] 364.2434, found 364.2439. 
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(tert-butyl(((3S,4R,E)-1-((4-methoxybenzyl)oxy)-4-methyl-6-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)hex-5-en-3-yl)oxy)dimethylsilane (2.8).6 A solution of Hoveyda Grubbs II 
(0.10 g, 0.16 mmol, 0.05 eq) catalyst in dry CH2Cl2 (15 mL, 0.2 M)) was added to a flame dried 
two neck flask fitted with reflux condenser under N2. Olefin 2.6 (1.15 g, 3.15 mmol, 1 eq) was 
then added to the mixture, followed by vinylboronic acid pinacol ester  2.7 (1.07 mL, 6.31 mmol, 
3 eq, passed through silica plug with 10% EtOAc/Hex to remove stabilizer immediately prior to 
use), and the reaction was heated to reflux for 18 h. The crude reaction was concentrated and 
purified by flash chromatography (5% EtOAc/Hexanes) to afford 2.8 (1.10 g, 74% yield) as a pale 
yellow oil: Rf = 0.35 (5% EtOAc/Hexanes); 1H NMR (400 MHz, CDCl3) δ 7.25 (d, J = 8.1 Hz, 
2H), 6.87 (d, J = 8.0 Hz, 2H), 6.56 (dd, J = 18.1, 6.6 Hz, 1H), 5.43 (d, J = 18.1 Hz, 1H), 4.41 (d, 
J = 18.0 Hz, 1H), 4.38 (d, J = 17.9 Hz, 1H), 3.87 – 3.75 (m, 1H), 3.80 (d, J = 0.8 Hz, 3H), 3.55 – 
3.38 (m, 2H), 2.40 (q, J = 6.2 Hz, 1H), 1.66 (q, J = 6.7 Hz, 2H), 1.26 (s, 12H), 1.00 (d, J = 6.9 Hz, 
3H), 0.87 (d, J = 0.8 Hz, 9H), 0.03 (s, 3H), 0.02 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 159.31, 
156.21, 130.88, 129.52, 123.53 113.96, 83.26, 72.77, 72.45, 67.42, 55.50, 45.53, 32.93, 26.12, 
25.06, 24.96, 18.32, 13.32, -4.20, -4.42; HRMS (ESI) calcd for C27H47BO5Si [M+H] 491.3359, 
found 491.3350.  
 
 
(3S,4R,E)-3-((tert-butyldimethylsilyl)oxy)-4-methyl-6-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)hex-5-en-1-ol (S 2.4). To a solution of 2.8 (1.90 g, 3.87 mmol, 1 eq) in CH2Cl2 
(25 mL, 0.15 M) and water (1.49 mL) at rt was added DDQ (1.32 g, 5.81 mmol, 1.5 eq) and the 
mixture was stirred for 1 h. The reaction was quenched with sat. NaHCO3 and diluted with water. 
The aqueous layer was extracted with CH2Cl2, the organics were combined, dried over Na2SO4, 
and concentrated. The crude product was purified by flash chromatography (12% EtOAc/Hexanes) 
to afford 2.8 (1.21 g, 83 % yield) as a colorless oil: Rf = 0.15 (10% EtOAc/Hexanes); 1H NMR 
(600 MHz, CDCl3) δ 6.54 (dd, J = 18.1, 6.6 Hz, 1H), 5.46 (dd, J = 18.1, 1.5 Hz, 1H), 3.87 (ddd, J 
= 7.9, 5.0, 3.8 Hz, 1H), 3.77 – 3.67 (m, 2H), 2.49 (pdd, J = 6.8, 5.0, 1.5 Hz, 1H), 2.03 (t, J = 5.4 
Hz, 1H), 1.71 – 1.63 (m, 2H), 1.26 (d, J = 1.7 Hz, 12H), 1.01 (d, J = 6.8 Hz, 3H), 0.89 (s, 9H), 
0.08 (s, 3H), 0.07 (s, 3H);13C NMR (150 MHz, CDCl3) δ 155.72, 123.53, 83.07, 74.24, 60.63, 
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44.92, 34.15, 25.84, 24.80, 24.71, 17.98, 12.81, -4.41, -4.69; HRMS (ESI) calcd for C19H39BO4Si 
[M+H] 371.2783, found 371.2778. 
 
(3S,4R,E)-3-((tert-butyldimethylsilyl)oxy)-4-methyl-6-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)hex-5-enal (2.9). To an open round bottom flask was added alcohol S 2.4 (1.00 
g, 4.09 mmol, 1 eq) in CH2Cl2 (41 mL, 0.1 M) and treated with NaHCO3 (1.72 g, 20.45 mmol, 5 
eq) and desmartin periodinane (2.082 g, 4.91 mmol, 1.2 eq). The reaction was stirred at rt for 1 hr, 
quenched with 10% Na2S2O3 solution, and stirred until both layers were clear. The mixture was 
separated and the aqueous layer extracted with CH2Cl2 (3 x 100 mL). The organics were combined, 
washed with brine, dried over sodium sulfate and concentrated. The crude product was purified by 
flash chromatography (10% EtOAc/Hexanes) to afford 2.9 (0.768 g, 77% yield) as a colorless oil: 
Rf = 0.5 (10% EtOAc/Hexanes); 1H NMR (400 MHz, CDCl3) δ 9.75 (dd, J = 2.1, 1.1 Hz, 1H), 
6.50 (dd, J = 18.1, 6.6 Hz, 1H), 5.46 (d, J = 18.0 Hz, 1H), 4.22 (dt, J = 8.1, 4.2 Hz, 1H), 2.54 – 
2.42 (m, 2H), 2.41 – 2.33 (m, 1H), 1.25 (s, 12H), 1.01 (dd, J = 6.9, 0.9 Hz, 3H), 0.85 (d, J = 0.8 
Hz, 9H), 0.05 (s, 3H), 0.02 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 202.47, 154.68, 123.53, 83.36, 
70.89, 47.17, 45.54, 29.86, 25.92, 24.98, 24.88, 18.16, 13.03, -4.33, -4.56; HRMS (ESI) calcd for 
C19H37BO4Si [M+H] 368.2554, found 368.250. 
6.1.2 Unit AB Synthetic Procedures and Characterization  
 
2.10 was synthesized in three steps as previously reported and all spectra were in accordance.7 
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methyl (R)-3-(3-chloro-4-methoxyphenyl)-2-(2-(diethoxyphosphoryl)acetamido)propanoate 
(2.12). To an open flask was added 2.10 (1.10 g, 3.20 mmol, 1 eq) and 4 M HCl/Dioxane (20 mL). 
This was stirred for 30 min at rt prior to acid and organics being removed under reduced pressure. 
The resulting white solid product was used directly. 
The above, deprotected product was added to a flask under N2 and suspended in DMF (32 mL, 0.1 
M). To this was added 2-(diethoxyphosphoryl)acetic acid 2.11 (0.69 g, 3.52 mmol, 1.1 eq) 
EDC·HCl (0.73 g, 3.84 mmol, 1.2 eq), HOBt hydrate (0.59 g, 3.84 mmol, 1.2 eq), and DIPEA 
(1.03 g, 1.40 mL, 8.00 mmol, 2.5 eq) and stirred at rt overnight. The reaction was quenched with 
half sat. aq NH4Cl, extracted 3 x 30 mL of DCM, organics combined, washed 2 x 100 mL of sat. 
aq. NH4Cl, dried over sodium sulfate, and concentrated. The crude product was purified by flash 
purification (1-7% MeOH/DCM) to afford 2.12 (0.90 mg, 66.6% yield) as a clear and colorless 
oil: Rf = 0.2 (2.5% MeOH/DCM); 1H NMR (600 MHz, CDCl3) δ 7.16 (d, J = 2.2 Hz, 1H), 7.09 
(bd, J = 7.5 Hz, 1H), 7.04 (dd, J = 8.4, 2.2 Hz, 1H), 6.84 (d, J = 8.4 Hz, 1H), 4.78 (td, J = 7.1, 5.4 
Hz, 1H), 4.13 (dt, J = 14.9, 7.2 Hz, 1H), 4.06 (dq, J = 8.2, 7.1 Hz, 2H), 3.85 (s, 3H), 3.70 (s, 3H), 
3.08 (dd, J = 14.2, 5.4 Hz, 1H), 2.97 (dd, J = 14.2, 6.8 Hz, 1H), 2.85 (d, J = 10.7 Hz, 1H), 2.81 (d, 
J = 10.5 Hz, 1H), 1.31 (t, J = 7.1 Hz, 3H), 1.27 (t, J = 7.1 Hz, 3H); 13C NMR (150 MHz, CDCl3) 
δ 171.45, 163.95, 163.93, 154.24, 131.09, 129.15, 128.72, 122.48, 112.22, 77.37, 77.16, 76.95, 
62.95 (d, J = 15.3 Hz), 62.91 (d, J = 15.3), 56.25, 53.94, 52.52, 36.88, 35.70, 34.83, 16.48, 16.43, 
16.39; HRMS (ESI) calcd for C17H25ClNO7P [M+H] 421.1057, found 421.1053.  
 
 
methyl (R)-2-((2E,5S,6R,7E)-5-((tert-butyldimethylsilyl)oxy)-6-methyl-8-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)octa-2,7-dienamido)-3-(3-chloro-4-methoxyphenyl)propanoate (2.13). To a flame 
dried flask under N2 was added unit B phosphonate 2.12 (0.63 g, 1.49 mmol, 1 eq) suspended in 
dry THF (15 mL, 0.1 M). The solution was cooled to 0 °C and NaH (60% suspension in oil, 0.055 
g, 1.64 mmol, 1.1 eq) was added slowly. The reaction was stirred for 20 min prior to the dropwise 
addition of aldehyde 2.9 (0.55g, 1.49 mmol, 1 eq) in THF (5 mL). The reaction was allowed to stir 
at 0 °C for 1 h and quenched with half sat. NH4Cl (10 mL). The THF was removed under reduced 
pressure and the remaining aqueous layer was extracted with DCM (3 x 50 mL), organics 
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combined, washed with brine, dried over sodium sulfate, and concentrated. The crude product was 
purified by flash chromatography (6-45% EtOAc/Hexanes) to afford 2.13 (0.545 g, 57.4% yield) 
as a clear and colorless oil: Rf = 0.25 (25% EtOAc/Hexanes); 1H NMR : (400 MHz, CD3OD) δ 
7.21 (d, J = 2.2 Hz, 1H), 7.10 (dd, J = 8.5, 2.2 Hz, 1H), 6.97 (d, J = 8.4 Hz, 1H), 6.75 (dt, J = 15.2, 
7.5 Hz, 1H), 6.57 (dd, J = 18.0, 7.7 Hz, 1H), 5.96 (d, J = 15.3 Hz, 1H), 5.38 (d, J = 18.3 Hz, 1H), 
4.68 (dd, J = 8.9, 5.5 Hz, 1H), 3.84 (s, 3H), 3.73 (q, J = 5.4 Hz, 1H), 3.70 (s, 3H), 3.11 (dd, J = 
14.0, 5.6 Hz, 1H), 2.90 (dd, J = 14.0, 9.0 Hz, 1H), 2.41 – 2.25 (m, 3H), 1.26 (s, 12H), 1.01 (d, J = 
6.8 Hz, 3H), 0.89 (s, 9H), 0.06 (s, 3H), 0.03 (s, 3H); 13C NMR: (100 MHz, CD3OD) δ 171.84, 
166.53, 155.89, 153.97, 141.84, 130.37, 129.89, 128.26, 124.84, 123.53, 121.75, 111.90, 82.97, 
74.64, 55.10, 53.75, 51.28, 45.03, 36.94, 35.85, 25.03, 23.70, 23.65, 17.56, 14.36, -5.44, -5.74. 
; HRMS (ESI) calcd for C32H51BClNO7Si [M+H] 635.3216, found 635.3215. 
6.1.3 Heterocyclic Unit AB Analogues  
 
General suzuki coupling procedure: To a long tube was added 2.13 (1 eq), K3PO4 (2.5 eq), aryl 
iodide (2 eq), and Pd2(dba)3 (0.05 eq) prior to evacuation and N2 refill. This was suspended in a 
mixture 1,2 dichloroethane and water (4:1, 0.1 M) and the reaction was stirred vigorously until 
reaction completion as assessed by TLC (2 – 12 hours). The reaction was diluted with 0.5 M HCl 
and CH2Cl2, the aqueous layer was extracted with CH2Cl2 (3 x 20 mL). The organics were 
combined, dried over Na2SO4 and purified by flash chromatography system as indicated below.  
 
 
methyl (R)-2-((2E,5S,6R,7E)-5-((tert-butyldimethylsilyl)oxy) 
-6-methyl-8-phenylocta-2,7-dienamido)-3-(3-chloro-4-
methoxyphenyl)propanoate (2.14a). Reaction was run as per 
general Suzuki procedure, and purified by flash chromatography system (20 – 50% 
EtOAc/Hexanes) to afford 23a (0.086 g, 93% yield) as a pale yellow oil: Rf = 0.35 (25% 
EtOAc/Hexanes); 1H NMR (400 MHz, CD3OD) δ 7.33 (d, J = 7.5 Hz, 2H), 7.27 (t, J = 7.6 Hz, 
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2H), 7.21 (d, J = 2.2 Hz, 1H), 7.18 (t, J = 7.2 Hz, 1H), 7.10 (dd, J = 8.4, 2.2 Hz, 1H), 6.96 (d, J = 
8.4 Hz, 1H), 6.78 (dt, J = 15.2, 7.5 Hz, 1H), 6.38 (d, J = 16.0 Hz, 1H), 6.19 (dd, J = 16.0, 8.2 Hz, 
1H), 5.96 (d, J = 15.4 Hz, 1H), 4.69 (dd, J = 8.9, 5.6 Hz, 1H), 3.83 (s, 3H), 3.80 (q, 1H), 3.70 (s, 
3H), 3.11 (dd, J = 14.0, 5.6 Hz, 1H), 2.90 (dd, J = 14.0, 9.0 Hz, 1H), 2.44 (q, J = 6.5 Hz, 1H), 2.37 
(t, J = 6.9 Hz, 2H), 1.11 (d, J = 6.9 Hz, 3H), 0.90 (s, 8H), 0.06 (s, 3H), 0.05 (s, 3H); 13C NMR 
(100 MHz, CD3OD) 173.28, 168.03, 155.41, 143.50, 139.03, 133.10, 131.82, 131.73, 131.33, 
129.67, 129.50, 128.04, 127.06, 126.17, 123.18, 113.33, 76.54, 56.53, 55.15, 52.72, 44.11, 38.62, 
37.27, 26.44, 18.98, 16.80, -4.01, -4.32.; HRMS (ESI) calcd for C32H44ClNO5Si [M+H] 586.2750 
found 586.2754.  
methyl (R)-2-((2E,5S,6R,7E)-5-((tert-butyldimethylsilyl)oxy) 
-6-methyl-8-(pyridin-2-yl)octa-2,7-dienamido)-3-(3-chloro-
4-methoxyphenyl)propanoate (2.14b). Reaction was run as per 
general Suzuki procedure, and purified by flash chromatography 
system (Amine Silica, 20 – 50% EtOAc/Hexanes) to afford 2.14b (0.078 g, 45% yield) as a pale 
yellow oil: Rf = 0.35 (Amine column, 16-60% EtOAc/Hexanes);1H NMR (400 MHz, CD3OD) δ 
8.44 (d, J = 4.0 Hz, 1H), 7.76 (td, J = 7.8, 1.8 Hz, 1H), 7.46 (d, J = 8.0 Hz, 1H), 7.28 – 7.18 (m, 
1H), 7.21 (d, J = 2.1 Hz, 1H), 7.10 (dd, J = 8.5, 2.2 Hz, 1H), 6.96 (d, J = 8.3 Hz, 1H), 6.77 (dt, J 
= 15.3, 7.4 Hz, 1H), 6.64 (dd, J = 16.0, 8.2 Hz, 1H), 6.49 (d, J = 16.0 Hz, 1H), 5.98 (d, J = 15.4 
Hz, 1H), 4.70 (dd, J = 9.0, 5.5 Hz, 1H), 3.83 (m, 4H), 3.70 (s, 3H), 3.11 (dd, J = 14.0, 5.5 Hz, 1H), 
2.90 (dd, J = 14.0, 9.0 Hz, 1H), 2.51 (h, J = 6.8 Hz, 1H), 2.38 (t, J = 6.8 Hz, 2H), 1.14 (d, J = 6.8 
Hz, 3H), 0.90 (s, 10H).13C NMR (100 MHz, CD3OD) δ 173.27, 167.95, 157.17, 155.41, 149.74, 
143.24, 139.05, 138.66, 131.83, 131.34, 131.12, 129.70, 126.38, 123.38, 123.17, 122.34, 113.34, 
76.26, 56.53, 55.15, 52.73, 44.06, 38.62, 37.31, 26.43, 18.97, 16.47, -4.04, -4.34. HRMS (ESI) 
calcd for C31H43ClN2O5Si [M+H] 587.2703, found 587.2705.  
 
methyl (R)-2-((2E,5S,6R,7E)-5-((tert-butyldimethylsilyl) 
oxy)-6-methyl-8-(pyridin-3-yl)octa-2,7-dienamido)-3-(3-
chloro-4-methoxyphenyl)propanoate (2.14c,d). Reaction was 
run as per general Suzuki procedure, and purified by flash 
chromatography system (Amine silica, 16-60% EtOAc/Hexanes) to afford 2.14c,d (0.049 g, 72% 
yield) as a pale yellow oil: Rf = 0.15 (50% EtOAc/Hexanes); 1H NMR (600 MHz, CD3OD) δ 8.49 
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(d, J = 2.1 Hz, 1H), 8.35 (dd, J = 4.9, 1.5 Hz, 1H), 7.85 (d, J = 8.0 Hz, 1H), 7.37 (dd, J = 8.0, 4.8 
Hz, 1H), 7.21 (d, J = 2.1 Hz, 1H), 7.10 (dd, J = 8.4, 2.2 Hz, 1H), 6.96 (d, J = 8.5 Hz, 1H), 6.78 (dt, 
J = 15.2, 7.5 Hz, 1H), 6.43 (d, J = 16.1 Hz, 1H), 6.36 (dd, J = 16.1, 7.9 Hz, 1H), 5.97 (dt, J = 15.3, 
1.4 Hz, 1H), 4.70 (dd, J = 8.9, 5.6 Hz, 1H), 3.83 (s, 4H), 3.70 (s, 3H), 3.11 (dd, J = 14.0, 5.6 Hz, 
1H), 2.91 (dd, J = 14.0, 9.0 Hz, 1H), 2.49 (td, J = 7.2, 4.7 Hz, 1H), 2.38 (ddd, J = 7.4, 5.8, 1.4 Hz, 
2H), 1.13 (d, J = 6.9 Hz, 3H), 0.90 (s, 9H), 0.06 (s, 3H), 0.05 (s, 3H); 13C NMR (150 MHz, 
CD3OD) δ 173.27, 167.97, 155.43, 148.28, 148.13, 143.21, 136.88, 135.48, 134.71, 131.82, 
131.35, 129.68, 127.66, 126.31, 125.28, 123.20, 113.39, 76.32, 56.56, 55.15, 52.72, 44.24, 38.69, 
37.29, 26.42, 18.96, 16.65, -4.00, -4.34; HRMS (ESI) C31H43ClN2O5Si [M+H] 587.2703, found 
587.2702. 
 
methyl (R)-2-((2E,5S,6R,7E)-5-((tert-butyldimethylsilyl)oxy)-
6-methyl-8-(pyridin-4-yl)octa-2,7-dienamido)-3-(3-chloro-4-
methoxyphenyl)propanoate (2.14e,f). Reaction was run as per 
general Suzuki procedure, and purified by flash chromatography System (Amine Silica, 15 - 55% 
EtOAc/Hexanes) to afford 2.14e,f (0.062 g, 71% yield) as a pale yellow oil: Rf = 0.25 (50% 
EtOAc/Hexanes); 1H NMR (400 MHz, CD3OD) δ 8.49 (d, J = 2.2 Hz, 1H), 8.36 (dd, J = 4.9, 1.5 
Hz, 1H), 7.85 (dd, J = 8.0, 2.0 Hz, 1H), 7.37 (dd, J = 7.8, 4.8 Hz, 1H), 7.21 (d, J = 2.2 Hz, 1H), 
7.10 (dd, J = 8.4, 2.2 Hz, 1H), 6.96 (d, J = 8.4 Hz, 1H), 6.78 (dt, J = 15.2, 7.5 Hz, 1H), 6.44 (d, J 
= 16.2 Hz, 1H), 6.36 (dd, J = 16.1, 7.6 Hz, 1H), 5.97 (d, J = 15.3 Hz, 1H), 4.69 (dd, J = 8.9, 5.6 
Hz, 1H), 3.87 – 3.77 (m, 1H), 3.82 (s, 3H), 3.70 (s, 3H), 3.11 (dd, J = 14.0, 5.5 Hz, 1H), 2.90 (dd, 
J = 14.0, 9.0 Hz, 1H), 2.56 – 2.44 (m, 1H), 2.38 (t, J = 6.6 Hz, 2H), 1.13 (d, J = 6.8 Hz, 3H), 0.90 
(s, 8H), 0.06 (s, 3H), 0.05 (s, 3H); 13C NMR (150 MHz, CD3OD) 13C NMR (151 MHz, cd3od) δ 
173.28, 167.96, 155.44, 150.23, 147.68, 143.05, 139.96, 131.83, 131.36, 129.67, 129.19, 126.37, 
123.20, 122.32, 113.40, 76.19, 56.56, 55.14, 52.73, 44.24, 38.75, 37.28, 26.41, 18.96, 16.56, -4.02, 
-4.36; HRMS C31H43ClN2O5Si [M+H] 587.2703, found 587.2699. 
 
methyl (R)-2-((2E,5S,6R,7E)-5-((tert-butyldimethylsilyl) 
oxy)-6-methyl-8-(pyrazin-2-yl)octa-2,7-dienamido)-3-(3-
chloro-4-methoxyphenyl)propanoate (2.14g). Reaction was 
run as per general Suzuki procedure, and purified by flash 
OMe
OH
N
OMe
Cl
OOTBSN
OMe
OH
N
OMe
Cl
OOTBS
N
N
  95 
chromatography system (Amine Silica, 20 – 55% EtOAc/Hexanes) to afford 2.14g (0.115 g, 65% 
yield) as a pale yellow oil: Rf = 0.2 (50% EtOAc/Hexanes); 1H NMR (600 MHz, CD3OD) δ 8.57 
(d, J = 1.5 Hz, 1H), 8.51 (s, 1H), 8.39 (d, J = 2.6 Hz, 1H), 7.21 (d, J = 2.2 Hz, 1H), 7.10 (dd, J = 
8.4, 2.2 Hz, 1H), 6.96 (d, J = 8.5 Hz, 1H), 6.90 (dd, J = 15.9, 8.3 Hz, 1H), 6.78 (dt, J = 15.2, 7.5 
Hz, 1H), 6.54 (d, J = 16.0 Hz, 1H), 5.98 (d, J = 15.4 Hz, 1H), 4.70 (dd, J = 8.9, 5.5 Hz, 1H), 3.86 
– 3.84 (m, 1H), 3.83 (s, 3H), 3.70 (s, 3H), 3.11 (dd, J = 14.0, 5.6 Hz, 1H), 2.91 (dd, J = 14.0, 9.0 
Hz, 1H), 2.55 (q, J = 6.9 Hz, 1H), 2.41 – 2.33 (m, 2H), 1.15 (d, J = 6.8 Hz, 3H), 0.89 (s, 9H), 0.06 
(s, 3H), 0.05 (s, 3H); 13C NMR (150 MHz, CD3OD) δ 173.27, 167.93, 155.42, 152.99, 145.49, 
143.89, 143.49, 143.07, 141.77, 131.82, 131.34, 129.69, 127.88, 126.41, 123.19, 113.38, 76.20, 
56.56, 55.15, 52.73, 44.13, 38.74, 37.30, 26.42, 18.97, 16.46, -4.01, -4.36; HRMS (ESI) calcd for 
C30H42ClN3O5Si [M+H] 588.2655, found 588.2659.  
 
methyl (R)-2-((2E,5S,6R,7E)-5-((tert-butyldimethylsilyl) 
oxy)-6-methyl-8-(1-methyl-1H-pyrazol-5-yl)octa-2,7-
dienamido)-3-(3-chloro-4-methoxyphenyl)propanoate 
(2.14h). Reaction was run as per general Suzuki procedure, and 
purified by flash chromatography system (Amine silica, 20 – 70% EtOAc/Hexanes) to afford 2.14h 
(0.044 g, 63% yield) as a pale yellow oil: Rf = 0.1 (50% EtOAc/Hexanes); 1H NMR (600 MHz, 
CD3OD) δ 7.32 (d, J = 2.0 Hz, 1H), 7.19 (d, J = 2.2 Hz, 1H), 7.08 (dd, J = 8.4, 2.2 Hz, 1H), 6.95 
(d, J = 8.4 Hz, 1H), 6.76 (dt, J = 15.2, 7.5 Hz, 1H), 6.37 (d, J = 15.9 Hz, 1H), 6.32 (d, J = 2.1 Hz, 
1H), 6.19 (dd, J = 15.9, 8.3 Hz, 1H), 5.96 (dt, J = 15.4, 1.3 Hz, 1H), 4.68 (dd, J = 8.9, 5.6 Hz, 1H), 
3.82 (s, 3H), 3.80 (s, 1H), 3.78 (s, 3H), 3.68 (s, 3H), 3.10 (dd, J = 14.0, 5.6 Hz, 1H), 2.89 (dd, J = 
14.0, 8.9 Hz, 1H), 2.46 (s, 1H), 2.36 (t, J = 6.5 Hz, 2H), 1.10 (d, J = 6.9 Hz, 3H), 0.88 (s, 9H).13C 
NMR (150 MHz, CD3OD) δ 173.28, 167.98, 155.44, 143.09, 142.83, 139.14, 138.52, 131.81, 
131.36, 129.67, 126.33, 123.21, 118.11, 113.41, 103.42, 76.23, 56.57, 55.17, 52.72, 44.20, 38.79, 
37.28, 36.45, 26.42, 25.03, 18.97, 16.77, -3.99, -4.36; HRMS (ESI) calcd for C30H44ClN3O5Si 
[M+H] 590.2812, found 590.2811.  
 
methyl (R)-2-((2E,5S,6R,7E)-5-((tert-butyldimethylsilyl)oxy)-
6-methyl-8-(1-methyl-1H-pyrazol-3-yl)octa-2,7-dienamido)-
3-(3-chloro-4-methoxyphenyl)propanoate (2.14i). Reaction 
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was run as per general Suzuki procedure, and purified by flash chromatography (Amine column, 
16 - 55% EtOAc/Hexanes) to afford 2.14i (0.065 g, 70.6% yield) as a pale yellow oil: Rf = 0.25 
(50% EtOAc/Hexanes); 1H NMR (600 MHz, CD3OD) δ 7.46 (d, J = 2.3 Hz, 1H), 7.21 (d, J = 2.2 
Hz, 1H), 7.10 (dd, J = 8.5, 2.2 Hz, 1H), 6.96 (d, J = 8.4 Hz, 1H), 6.75 (dt, J = 15.2, 7.5 Hz, 1H), 
6.30 (d, J = 2.3 Hz, 1H), 6.17 (dd, J = 16.2, 8.1 Hz, 1H), 5.96 (d, J = 15.4 Hz, 1H), 4.69 (dd, J = 
9.0, 5.6 Hz, 1H), 3.84 (s, 3H), 3.83 (s, 3H), 3.78 (q, J = 5.6 Hz, 1H), 3.70 (s, 3H), 3.11 (dd, J = 
14.1, 5.6 Hz, 1H), 2.91 (dd, J = 14.0, 9.0 Hz, 1H), 2.42 (p, J = 6.7 Hz, 1H), 2.38 – 2.30 (m, 2H), 
1.09 (d, J = 6.8 Hz, 3H), 0.90 (s, 9H), 0.06 (s, 3H), 0.04 (s, 3H); 13C NMR (150 MHz, CD3OD) δ 
173.29, 167.99, 155.43, 152.12, 143.43, 134.95, 133.03, 131.82, 131.37, 129.71, 126.28, 123.29, 
123.22, 113.38, 103.22, 76.44, 56.55, 55.16, 52.71, 43.95, 38.60, 38.52, 37.33, 26.44, 18.98, 16.48, 
-4.04, -4.32; HRMS (ESI) calcd for C30H44ClN3O5Si [M+H] 590.2812, found 590.2809. 
 
methyl (R)-2-((2E,5S,6R,7E)-5-((tert-butyldimethylsilyl) 
oxy)-6-methyl-8-(1-methyl-1H-pyrazol-4-yl)octa-2,7-
dienamido)-3-(3-chloro-4-methoxyphenyl)propanoate 
(2.14j,k). Reaction was run as per general Suzuki procedure, and purified by flash chromatography 
(Amine column, 16 – 60% EtOAc/Hexanes) to afford 2.14j,k (0.085 g, 92% yield) as a pale yellow 
oil: Rf = 0.2 (50% EtOAc/Hexanes); 1H NMR (400 MHz, CD3OD) δ 7.61 (s, 1H), 7.48 (s, 1H), 
7.21 (d, J = 2.2 Hz, 1H), 7.10 (dd, J = 8.4, 2.2 Hz, 1H), 6.96 (d, J = 8.4 Hz, 1H), 6.77 (dt, J = 15.2, 
7.5 Hz, 1H), 6.20 (d, J = 16.0 Hz, 1H), 5.95 (d, J = 15.5 Hz, 1H), 5.90 (dd, J = 16.1, 8.1 Hz, 1H), 
4.69 (dd, J = 8.9, 5.6 Hz, 1H), 4.46 (p, J = 6.7 Hz, 1H), 3.83 (s, 3H), 3.75 (q, J = 5.5 Hz, 1H), 3.70 
(s, 3H), 3.11 (dd, J = 14.0, 5.6 Hz, 1H), 2.91 (dd, J = 14.0, 8.8 Hz, 1H), 2.34 (qt, J = 13.5, 7.1 Hz, 
3H), 1.46 (d, J = 6.7 Hz, 6H), 1.07 (d, J = 6.8 Hz, 3H), 0.90 (s, 9H), 0.06 (s, 3H), 0.03 (s, 3H); 13C 
NMR (100 MHz, CD3OD) δ 173.29, 168.04, 155.42, 143.72, 137.18, 131.83, 131.35, 129.68, 
126.09, 126.03, 123.19, 121.88, 121.43, 113.36, 76.65, 56.55, 55.16, 54.99, 52.72, 44.16, 38.27, 
37.28, 26.44, 23.07, 18.99, 16.38, -4.04, -4.32; HRMS (ESI) calcd for C30H44ClN3O5Si [M+H] 
590.2812, found 590.2813.  
 
methyl (R)-2-((2E,5S,6R,7E)-5-((tert-butyldimethylsilyl) 
oxy)-8-(1-isopropyl-1H-pyrazol-4-yl)-6-methylocta-2,7-
dienamido)-3-(3-chloro-4-methoxyphenyl)propanoate 
(2.14l). Reaction was run as per general Suzuki procedure, 
OMe
OH
N
OMe
Cl
OOTBS
N
N
OMe
OH
N
OMe
Cl
OOTBS
N
N
  97 
and purified by flash chromatography system (Amine silica, 20 – 50% EtOAc/Hexanes) to afford 
2.14l (0.056 g, 83% yield) as a pale yellow oil: Rf = 0.35 (50% EtOAc/Hexanes); 1H NMR (600 
MHz, CD3OD) δ 7.53 (s, 1H), 7.47 (s, 1H), 7.21 (d, J = 2.2 Hz, 1H), 7.10 (dd, J = 8.4, 2.2 Hz, 1H), 
6.96 (d, J = 8.4 Hz, 1H), 6.77 (dt, J = 15.2, 7.5 Hz, 1H), 6.18 (d, J = 16.0 Hz, 1H), 5.95 (d, J = 
15.4 Hz, 1H), 5.89 (dd, J = 16.1, 8.1 Hz, 1H), 4.69 (dd, J = 9.0, 5.6 Hz, 1H), 3.84 (s, 3H), 3.83 (s, 
3H), 3.75 (q, J = 5.5 Hz, 1H), 3.70 (s, 3H), 3.11 (dd, J = 14.0, 5.6 Hz, 1H), 2.90 (dd, J = 14.0, 9.0 
Hz, 1H), 2.42 – 2.27 (m, 3H), 1.06 (d, J = 6.9 Hz, 3H), 0.89 (s, 9H), 0.05 (s, 3H), 0.03 (s, 3H). 13C 
NMR (150 MHz, CD3OD) δ 173.29, 168.03, 155.42, 143.67, 137.61, 131.83, 131.58, 131.36, 
129.68, 129.33, 126.10, 123.18, 122.45, 121.24, 113.36, 76.60, 56.55, 55.15, 52.72, 44.16, 38.72, 
38.32, 37.28, 26.44, 18.98, 16.45, -4.05, -4.31; HRMS (ESI) calcd for C32H48ClN3O5Si [M+H] 
618.3125, found 618.3129.  
 
methyl (R)-2-((2E,5S,6R,7E)-5-((tert-butyldimethylsilyl)oxy)-
8-(3,5-dimethylisoxazol-4-yl)-6-methylocta-2,7-dienamido)-
3-(3-chloro-4-methoxyphenyl)propanoate (2.14m). Reaction 
was run as per general Suzuki procedure, and purified by flash 
chromatography system (Amine silica, 10 – 50% EtOAc/Hexanes) to afford 2.14m (0.057 g, 85% 
yield) as a pale yellow oil: Rf = 0.35 (33% EtOAc/Hexanes); 1H NMR: (400 MHz, CD3OD) δ 
7.20 (d, J = 2.2 Hz, 1H), 7.10 (dd, J = 8.3, 2.2 Hz, 1H), 6.96 (d, J = 8.4 Hz, 1H), 6.76 (dt, J = 15.2, 
7.6 Hz, 1H), 6.11 (d, J = 16.3 Hz, 1H), 5.96 (d, J = 15.4 Hz, 1H), 5.90 (dd, J = 16.4, 8.5 Hz, 1H), 
4.68 (dd, J = 9.0, 5.5 Hz, 1H), 3.84 (s, 3H), 3.83 – 3.77 (m, 1H), 3.70 (s, 3H), 3.12 (dd, J = 14.0, 
5.5 Hz, 1H), 2.90 (dd, J = 14.0, 9.0 Hz, 1H), 2.48 – 2.32 (m, 5H), 2.26 (s, 3H), 1.11 (d, J = 6.9 Hz, 
3H), 0.90 (s, 9H), 0.07 (s, 3H), 0.06 (s, 3H).13C NMR: (100 MHz, CD3OD) δ 173.27, 167.98, 
166.46, 159.59, 155.42, 143.21, 135.80, 131.81, 131.33, 129.67, 126.21, 123.17, 119.01, 114.23, 
113.36, 76.35, 56.54, 55.17, 52.73, 44.65, 39.15, 37.26, 26.42, 18.97, 17.68, 11.50, 11.40, -3.95, -
4.38; HRMS (ESI) calcd for C31H45ClN2O6Si [M+H] 605.2808, found 605.2801.  
6.1.3 Synthesis of Units CD  
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2.19 and 2.20 were synthesized by a procedure from Ghosh et. Al.8 from leucic acid (2.15), all 
spectra were in accordance with published literature.8-9  
 
 
(S)-1-((2-acetamidoethyl)thio)-4-methyl-1-oxopentan-2-yl (R)-3-((tert-butoxycarbonyl) 
amino)-2-methylpropanoate (2.23) or (S)-1-((2-acetamidoethyl)thio)-4-methyl-1-oxopentan-
2-yl 3-((tert-butoxycarbonyl)amino)-2,2-dimethylpropanoate: (2.24): To a solution of 2.21 or 
2.22 in DMF (0.1M) was added EDC HCl (1.5 eq) and HOBt (1.2 eq) and the reaction was 
stirred for 30 min. NAc was added and stirred for 10 min prior to the addition of catalytic DMAP 
(0.05 eq). The reaction was stirred for 12 hours, diluted with water and EtOAc and the aqueous 
layer was extracted (2 x 40 mL), organics combined, washed with sat. NH4Cl (2 x 100 mL), and 
dried over sodium sulfate. The organics were removed under reduced pressure and the remaining 
residue was purified by flash chromatography system (1 – 10% MeOH/DCM) to afford 2.23 or 
2.24 as white solids. Spectra was in accord with published literature.10  
 
6.1.4 Synthesis of unit A seco chain elongation intermediates  
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O
R
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O
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O
R
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O
2.23 R = H 
2.24 R = CH3
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    DIPEA, DCM
2. aq. HF, ACN
OH
H
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2.14 a-m
2.23 R1 = H
2.24 R = CH3
2.26 R1 = H
2.27 R = CH3
2.25 a-m
2.28 a-c,e,g-j,l,m R1 = H
2.28 d,f,k R2 = CH3
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General Peptide Coupling Procedure: Unit A/B (1 eq) was suspended in 1,2 dichloroethane (0.2 
M), treated with trimethyl tin hydroxide (4 eq), and heat to 80 °C for 4 hours. The reaction was 
cooled in a -20 °C freezer for 1 hour, filtered through celite, and concentrated. The crude acid was 
used directly.  
 
Simultaneously Unit C/D (1.1 eq) was suspended in 4 M HCl/Dioxane (5 mL) and stirred for 1 h, 
concentrated and used directly. 
 
Unit A/B acid was suspended in DCM, cooled to 0 °C, and treated with HATU (1.1 eq). 
Simultaneously amine salt of units C/D were suspended in DCM and treated with DIPEA (2.5 eq), 
cooled to 0 °C and added to Unit A/B. The reaction was allowed to stir overnight, warming to rt. 
The reaction was diluted with half saturated sodium bicarbonate, the aqueous layer extracted with 
DCM (3 x 10 mL), organics combined, washed with brine, dried over Na2SO4, concentrated and 
purified as specified below.  
 
General Deprotection Procedure: The crude coupling product was suspended in acetonitrile (0.1 
M) in a polypropylene vial. This was treated with 33% aq. HF (2 eq) and aloud to stir until the 
reaction was complete, as monitored by TLC. The reaction was quenched by the slow addition of 
sat. NaHCO3 until the aqueous layer was basic. The aqueous layer was then extracted with DCM 
(3 x 10 mL), organics combined, washed with brine, dried over Na2SO4, concentrated, and purified 
as specified. 
 
  (S)-1-((2-acetamidoethyl)thio)-4-methyl-1-oxopentan-2-
yl (R)-3- ((R)-3-(3-chloro-4-methoxyphenyl)-2-
((2E,5S,6R,7E)-5-hydroxy-6-methyl-8-phenylocta-2,7-
dienamido)propanamido)-2-methylpropanoate (2.28a). 
Reaction was run as per general coupling procedure, general deprotection procedure, and purified 
by flash chromatography (1-10% MeOH/DCM) to afford 2.28a (0.051 g, 42% yield over 3 steps) 
as a clear and colorless oil: Rf = 0.65 (10% MeOH/DCM). This was then deprotected as per general 
deprotection procedure and purified by flash chromatography (2 – 15% MeOH/DCM) to afford 
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the final product xx (xx, xx% yield) as a clear and colorless oil: Rf = 0.25 (10% MeOH/DCM); 1H 
NMR: (600 MHz, CD3OD) δ δ 7.37 (d, J = 7.0 Hz, 2H), 7.27 (t, J = 7.9 Hz, 2H), 7.25 (d, J = 2.2 
Hz, 1H), 7.18 (t, J = 7.3 Hz, 1H), 7.14 (dd, J = 8.4, 2.2 Hz, 1H), 6.97 (d, J = 8.4 Hz, 1H), 6.81 (dt, 
J = 15.1, 7.3 Hz, 1H), 6.41 (d, J = 15.9 Hz, 1H), 6.23 (dd, J = 15.9, 8.5 Hz, 1H), 6.01 (d, J = 15.4 
Hz, 1H), 5.21 (dd, J = 9.6, 4.0 Hz, 1H), 4.58 (dd, J = 8.1, 7.0 Hz, 1H), 3.83 (s, 3H), 3.65 (dt, J = 
8.7, 4.6 Hz, 1H), 3.48 (dd, J = 13.5, 6.6 Hz, 1H), 3.34 – 3.27 (m, 2H), 3.19 (dd, J = 13.5, 7.0 Hz, 
1H), 3.06 – 2.97 (m, 3H), 2.85 (dd, J = 13.7, 8.1 Hz, 1H), 2.70 (q, J = 7.0 Hz, 1H), 2.44 – 2.35 (m, 
2H), 2.35 – 2.28 (m, 1H), 1.91 (s, 3H), 1.80 – 1.74 (m, 1H), 1.74 – 1.69 (m, 1H), 1.66 – 1.59 (m, 
1H), 1.15 (d, J = 6.9 Hz, 3H), 1.10 (d, J = 7.1 Hz, 3H), 0.94 (d, J = 6.5 Hz, 3H), 0.91 (d, J = 6.5 
Hz, 3H).13C NMR: (150 MHz, CD3OD) 200.34, 175.06, 173.49, 173.42, 168.07, 155.40, 143.51, 
139.05, 132.50, 132.09, 131.91, 131.50, 129.84, 129.48, 128.05, 127.14, 126.08, 123.20, 113.35, 
78.63, 75.34, 56.57, 56.24, 44.21, 42.73, 41.95, 40.57, 39.85, 38.82, 38.07, 28.58, 25.74, 23.48, 
22.54, 21.97, 17.53, 14.87; HRMS calcd for C39H52ClN3O8S [M+H] 758.3236, found 758.3238. 
 
(S)-1-((2-acetamidoethyl)thio)-4-methyl-1-oxopentan-2-yl 
(R)-3-((R)-3-(3-chloro-4-methoxyphenyl)-2-
((2E,5S,6R,7E)-5-hydroxy-6-methyl-8-(pyridin-2-yl)octa-
2,7-dienamido)propanamido)-2-methylpropanoate 
(2.28b). Reaction was run as per general coupling procedure, and purified by flash 
chromatography (1-10% MeOH/DCM) Rf = 0.65 (10% MeOH/DCM). This was then deprotected 
as per general deprotection procedure and purified by flash chromatography (2 – 15% 
MeOH/DCM) to afford the final product 2.28b (0.025 g, 38% yield over 3 steps) as a clear and 
colorless oil: Rf = 0.25 (10% MeOH/DCM); 1H NMR: (600 MHz, CD3OD) δ 8.44 (d, J = 4.1  Hz, 
1H), 7.76 (td, J = 7.7, 1.9 Hz, 1H), 7.51 (d, J = 8.1 Hz, 1H), 7.26 (d, J = 2.3 Hz, 1H), 7.25 – 7.22 
(m, 1H), 7.14 (dd, J = 8.4, 2.2 Hz, 1H), 6.97 (d, J = 8.4 Hz, 1H), 6.81 (dt, J = 15.0, 7.3 Hz, 1H), 
6.67 (dd, J = 16.0, 8.4 Hz, 1H), 6.52 (d, J = 16.0 Hz, 1H), 6.02 (d, J = 15.4 Hz, 1H), 5.21 (dd, J = 
9.5, 4.0 Hz, 1H), 4.58 (dd, J = 8.1, 6.9 Hz, 1H), 3.84 (s, 3H), 3.68 (dt, J = 8.7, 4.7 Hz, 1H), 3.48 
(dd, J = 13.5, 6.6 Hz, 1H), 3.33 – 3.30 (s, 2H), 3.21 (dd, J = 13.5, 7.0 Hz, 1H), 3.05 – 2.99 (m, 
3H), 2.85 (dd, J = 13.8, 8.1 Hz, 1H), 2.71 (q, J = 7.0 Hz, 1H), 2.51 – 2.44 (m, 1H), 2.44 – 2.37 (m, 
1H), 2.37 – 2.29 (m, 1H), 1.91 (s, 3H), 1.81 – 1.69 (m, 2H), 1.67 – 1.59 (m, 1H), 1.18 (d, J = 6.9 
Hz, 3H), 1.11 (d, J = 7.2 Hz, 3H), 0.95 (d, J = 6.5 Hz, 3H), 0.92 (d, J = 6.5 Hz, 3H).13C NMR 
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(150 MHz, CD3OD) δ 200.34, 175.09, 173.49, 173.42, 168.05, 157.30, 155.43, 149.71, 143.29, 
138.74, 138.61, 131.92, 131.56, 131.35, 129.85, 126.27, 123.36, 122.32, 113.42, 111.43, 78.67, 
75.12, 56.61, 56.25, 44.08, 42.75, 41.97, 40.60, 39.87, 38.75, 38.09, 28.61, 25.76, 23.46, 22.54, 
21.99, 17.10, 14.86; HRMS (ESI) calcd for C38H51ClN4O8S [M+H] 759.3189, found 759.3184. 
 
(S)-1-((2-acetamidoethyl)thio)-4-methyl-1-oxopentan-2-yl 
(R)-3-((R)-3-(3-chloro-4-methoxyphenyl)-2-
((2E,5S,6R,7E)-5-hydroxy-6-methyl-8-(pyridin-3-yl)octa-
2,7-dienamido)propanamido)-2-methylpropanoate 
(2.28c). Reaction was run as per general coupling procedure, and purified by flash chromatography 
(1-10% MeOH/DCM) Rf = 0.65 (10% MeOH/DCM). This was then deprotected as per general 
deprotection procedure and purified by flash chromatography (2 – 15% MeOH/DCM) to afford 
the final product 2.28c  (0.037, 51% yield over 3 steps) as a clear and colorless oil: Rf = 0.25 (10% 
MeOH/DCM);  1H NMR  (600 MHz, CD3OD) δ 8.52 (d, J = 2.2 Hz, 1H), 8.36 (dd, J = 4.9, 1.6 
Hz, 1H), 7.89 (dt, J = 8.1, 1.9 Hz, 1H), 7.37 (ddd, J = 8.0, 4.9, 0.9 Hz, 1H), 7.26 (d, J = 2.2 Hz, 
1H), 7.14 (dd, J = 8.4, 2.3 Hz, 1H), 6.97 (d, J = 8.5 Hz, 1H), 6.81 (dt, J = 15.2, 7.3 Hz, 1H), 6.46 
(d, J = 16.1 Hz, 1H), 6.41 (dd, J = 16.0, 7.9 Hz, 1H), 6.02 (d, J = 15.4 Hz, 1H), 5.21 (dd, J = 9.5, 
4.0 Hz, 1H), 4.59 (dd, J = 8.0, 6.8 Hz, 1H), 3.84 (s, 3H), 3.67 (dt, J = 8.0, 4.6 Hz, 1H), 3.48 (dd, J 
= 13.5, 6.6 Hz, 1H), 3.33 – 3.30 (m, 2H) 3.20 (dd, J = 13.5, 6.9 Hz, 1H), 3.03 (td, J = 6.6, 1.9 Hz, 
3H), 3.04 – 3.00 (m, 1H) 2.85 (dd, J = 13.7, 8.1 Hz, 1H) 2.70 (q, J = 7.0 Hz, 1H), 2.51 – 2.36 (m, 
2H), 2.36 – 2.28 (m, 1H), 1.91 (s, 3H), 1.83 – 1.68 (m, 2H), 1.65 – 1.61 (m, 1H), 1.17 (d, J = 6.9 
Hz, 3H), 1.10 (d, J = 7.1 Hz, 3H), 0.95 (d, J = 6.5 Hz, 3H), 0.92 (d, J = 6.5 Hz, 3H); 13C NMR 
(150 MHz, cd3od) δ 200.34, 175.08, 173.48, 173.42, 168.04, 155.42, 148.27, 148.22, 143.30, 
136.34, 135.52, 134.79, 131.91, 131.53, 129.85, 127.95, 126.19, 125.24, 123.23, 113.41, 78.66, 
75.16, 56.60, 56.24, 49.00, 44.33, 42.75, 41.97, 40.59, 39.86, 38.87, 38.08, 28.60, 25.76, 23.47, 
22.54, 21.99, 17.34, 14.86; HRMS (ESI) calcd for C38H51ClN4O8S [M+H] 759.3189, found 
759.3192. 
 
 (S)-1-((2-acetamidoethyl)thio)-4-methyl-1-oxopentan-2-yl 
3-((R)-3-(3-chloro-4-methoxyphenyl)-2-((2E,5S,6R,7E)-5-
hydroxy-6-methyl-8-(pyridin-3-yl)octa-2,7-
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dienamido)propanamido)-2,2-dimethylpropanoate (2.28d). Reaction was run as per general 
coupling procedure, and purified by flash chromatography (1-10% MeOH/DCM) Rf = 0.65 (10% 
MeOH/DCM). This was then deprotected as per general deprotection procedure and purified by 
flash chromatography (2 – 15% MeOH/DCM) to afford the final product 2.28d (0.19, 51% yield 
over 3 steps) as a clear and colorless oil: Rf = 0.25 (10% MeOH/DCM); 1H NMR (600MHz, 
CD3OD) δ 8.52 (d, J = 2.3 Hz, 1H), 8.35 (dd, J = 4.8, 1.6 Hz, 1H), 7.89 (dt, J = 8.0, 2.0 Hz, 1H), 
7.74 (t, J = 6.4 Hz, 1H), 7.37 (dd, J = 8.0, 4.9 Hz, 1H), 7.28 (d, J = 2.2 Hz, 1H), 7.15 (dd, J = 8.4, 
2.3 Hz, 1H), 6.96 (d, J = 8.5 Hz, 1H), 6.80 (dt, J = 15.0, 7.3 Hz, 1H), 6.46 (d, J = 16.1 Hz, 1H), 
6.40 (dd, J = 16.0, 7.9 Hz, 1H), 6.01 (d, J = 15.4 Hz, 1H), 5.20 (dd, J = 9.5, 3.8 Hz, 1H), 4.65 (dd, 
J = 8.5, 6.5 Hz, 1H), 3.92 (p, J = 6.2 Hz, 2H), 3.83 (s, 3H), 3.66 (dt, J = 8.7, 4.6 Hz, 1H), 3.44 – 
3.27 (m, 2H), 3.11 – 3.00 (m, 2H), 2.85 (dd, J = 13.9, 8.5 Hz, 1H), 2.44 (td, J = 7.2, 4.3 Hz, 1H), 
2.39 (dt, J = 13.0, 6.4 Hz, 1H), 2.32 (dt, J = 14.9, 7.6 Hz, 1H), 1.91 (s, 3H), 1.83 – 1.69 (m, 2H), 
1.64 (ddd, J = 13.4, 8.4, 3.9 Hz, 1H), 1.17 – 1.14 (m, 9H), 0.95 (d, J = 6.5 Hz, 3H), 0.92 (d, J = 
6.4 Hz, 3H). 13C NMR (150 MHz, CD3OD) δ 200.53, 176.86, 173.76, 173.42, 168.17, 155.38, 
148.26, 148.21, 143.36, 136.35, 135.52, 134.80, 131.89, 131.69, 129.82, 127.96, 126.16, 125.25, 
123.23, 113.41, 78.81, 75.15, 64.74, 56.61, 56.39, 47.89, 44.69, 44.31, 41.94, 39.86, 38.88, 37.86, 
28.73, 25.87, 25.26, 23.49, 23.26, 23.18, 22.59, 21.95, 17.35. HRMS (ESI) calcd for 
C39H53ClN4O8S  [M+H] 773.3345, found 773.3353. 
 
 
(S)-1-((2-acetamidoethyl)thio)-4-methyl-1-oxopentan-2-yl 
(R)-3-((R)-3-(3-chloro-4-methoxyphenyl)-2-((2E,5S,6R,7E)-
5-hydroxy-6-methyl-8-(pyridin-4-yl)octa-2,7-
dienamido)propanamido)-2-methylpropanoate (2.28e) Reaction was run as per general 
coupling procedure, and purified by flash chromatography (1-10% MeOH/DCM) Rf = 0.65 (10% 
MeOH/DCM). This was then deprotected as per general deprotection procedure and purified by 
flash chromatography (2 – 15% MeOH/DCM) to afford the final product 2.28e (0.048, 49% yield 
over 3 steps) as a clear and colorless oil: Rf = 0.25 (10% MeOH/DCM); 1H NMR (599 MHz, 
Methanol-d4) δ 8.42 (d, J = 6.3 Hz, 1H), 7.40 (d, J = 6.3 Hz, 1H), 7.25 (d, J = 2.2 Hz, 1H), 7.14 
(dd, J = 8.5, 2.2 Hz, 1H), 6.97 (d, J = 8.4 Hz, 1H), 6.80 (dt, J = 15.0, 7.3 Hz, 1H), 6.61 (dd, J = 
16.0, 8.5 Hz, 1H), 6.44 (d, J = 15.9 Hz, 1H), 6.01 (d, J = 15.4 Hz, 1H), 5.21 (dd, J = 9.5, 4.0 Hz, 
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1H), 4.58 (dd, J = 8.1, 6.9 Hz, 1H), 3.84 (s, 3H), 3.67 (dt, J = 7.9, 4.7 Hz, 1H), 3.48 (dd, J = 13.5, 
6.6 Hz, 1H), 3.20 (dd, J = 13.5, 7.0 Hz, 1H), 3.03 (td, J = 6.7, 1.9 Hz, 2H), 2.85 (dd, J = 13.8, 8.1 
Hz, 1H), 2.70 (q, J = 6.9 Hz, 1H), 2.51 – 2.42 (m, 1H), 2.42 – 2.25 (m, 2H), 1.91 (s, 3H), 1.82 – 
1.68 (m, 2H), 1.63 (ddd, J = 13.1, 8.1, 4.0 Hz, 1H), 1.17 (d, J = 6.8 Hz, 3H), 1.10 (d, J = 7.1 Hz, 
3H), 0.94 (d, J = 6.5 Hz, 3H), 0.92 (d, J = 6.5 Hz, 3H).13C NMR (150 MHz, CD3OD) δ 200.34, 
175.08, 173.48, 173.42, 168.02, 155.43, 150.20, 147.73, 143.18, 139.50, 131.92, 131.53, 129.84, 
129.42, 126.25, 123.24, 122.39, 113.42, 78.67, 75.03, 56.61, 56.23, 44.30, 42.75, 41.97, 40.60, 
39.87, 38.90, 38.09, 28.61, 25.76, 23.46, 22.54, 21.99, 17.19, 14.86.HRMS (ESI) calcd for 
C38H51ClN4O8S [M+H] 759.3189, found 759.3187. 
 
 
(S)-1-((2-acetamidoethyl)thio)-4-methyl-1-oxopentan-2-yl 
3-((R)-3-(3-chloro-4-methoxyphenyl)-2-((2E,5S,6R,7E)-5-
hydroxy-6-methyl-8-(pyridin-4-yl)octa-2,7-
dienamido)propanamido)-2,2-dimethylpropanoate (2.28f). 
Reaction was run as per general coupling procedure, and purified by flash chromatography (1-10% 
MeOH/DCM) Rf = 0.65 (10% MeOH/DCM). This was then deprotected as per general 
deprotection procedure and purified by flash chromatography (2 – 15% MeOH/DCM) to afford 
the final product 2.28f (0.039, 45% yield over 3 steps) as a clear and colorless oil: Rf = 0.25 (10% 
MeOH/DCM);1H NMR (600MHz, CD3OD) δ 8.41 (d, J = 6.1 Hz, 1H), 7.40 (d, J = 6.1 Hz, 1H), 
7.27 (d, J = 1.9 Hz, 1H), 7.15 (dd, J = 8.5, 2.2 Hz, 1H), 6.96 (dd, J = 8.5, 1.0 Hz, 1H), 6.79 (dt, J 
= 14.5, 7.1 Hz, 1H), 6.61 (dd, J = 16.0, 8.5 Hz, 1H), 6.43 (d, J = 16.0 Hz, 1H), 6.00 (d, J = 15.4 
Hz, 1H), 5.20 (dd, J = 9.5, 3.8 Hz, 1H), 4.65 (dd, J = 8.4, 6.6 Hz, 1H), 3.83 (s, 3H), 3.66 (dt, J = 
8.5, 4.4 Hz, 1H), 3.40 (d, J = 13.6 Hz, 1H), 3.36 (d, J = 12.9 Hz, 1H), 3.32 – 3.29 (m, 2H), 3.12 – 
2.99 (m, 3H), 2.85 (dd, J = 14.0, 8.5 Hz, 1H), 2.51 – 2.42 (m, 1H), 2.41 – 2.34 (m, 1H), 2.35 – 
2.27 (m, 1H), 1.90 (s, 3H), 1.81 – 1.68 (m, 2H), 1.68 – 1.60 (m, 1H), 1.16 (s, 6H), 1.15 (d, J = 5.1 
Hz, 3H), 0.95 (d, J = 6.5 Hz, 3H), 0.92 (d, J = 6.5 Hz, 3H).13C NMR (150 MHz, CD3OD) δ 199.11, 
175.43, 172.24, 172.00, 166.71, 153.95, 148.72, 146.35, 141.80, 138.12, 130.47, 130.25, 128.38, 
127.99, 124.78, 121.81, 120.98, 112.00, 77.38, 73.59, 55.18, 54.90, 46.35, 43.26, 42.85, 40.51, 
38.43, 37.49, 36.43, 27.30, 24.44, 22.06, 21.83, 21.75, 21.16, 20.52, 15.77; C38H51ClN4O8S [M+H] 
759.3189, found 759.3186. 
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(S)-1-((2-acetamidoethyl)thio)-4-methyl-1-oxopentan-2-yl 
(R)-3-((R)-3-(3-chloro-4-methoxyphenyl)-2-
((2E,5S,6R,7E)-5-hydroxy-6-methyl-8-(pyrazin-2-yl)octa-
2,7-dienamido)propanamido)-2-methylpropanoate (2.28g). Reaction was run as per general 
coupling procedure, and purified by flash chromatography (1-10% MeOH/DCM) Rf = 0.65 (10% 
MeOH/DCM). This was then deprotected as per general deprotection procedure and purified by 
flash chromatography (2 – 15% MeOH/DCM) to afford the final product 2.28g (xx, xx% yield 
over 3 steps) as a clear and colorless oil: Rf = 0.25 (10% MeOH/DCM); 1H NMR (400 MHz, 
CD3OD) δ 8.62 (s, 1H), 8.51 (s, 1H), 8.39 (d, J = 2.6 Hz, 1H), 7.26 (d, J = 2.0 Hz, 1H), 7.14 (dd, 
J = 8.5, 2.1 Hz, 1H), 6.97 (d, J = 8.4 Hz, 1H), 6.93 (dd, J = 15.9, 8.5 Hz, 1H), 6.81 (dt, J = 14.9, 
7.3 Hz, 1H), 6.57 (d, J = 16.0 Hz, 1H), 6.02 (d, J = 15.4 Hz, 1H), 5.21 (dd, J = 9.4, 3.9 Hz, 1H), 
4.58 (t, J = 7.5 Hz, 1H), 3.69 (dt, J = 9.0, 4.7 Hz, 1H), 3.48 (dd, J = 13.4, 6.6 Hz, 1H), 3.37 – 3.24 
(m, 2H), 3.20 (dd, J = 13.5, 7.1 Hz, 1H), 3.07 – 2.97 (m, 1H), 3.03 (t, J = 6.8 Hz, 2H), 2.85 (dd, J 
= 13.7, 8.2 Hz, 1H), 2.70 (apparent q, J = 6.9 Hz, 1H), 2.56 – 2.28 (m, 3H), 1.91 (s, 3H), 1.82 – 
1.68 (m, 2H), 1.68 – 1.56 (m, 1H), 1.19 (d, J = 6.8 Hz, 3H), 1.10 (d, J = 7.0 Hz, 3H), 0.95 (d, J = 
6.3 Hz, 4H), 0.92 (d, J = 6.3 Hz, 3H).13C NMR (151 MHz, cd3od) δ 200.34, 175.08, 173.47, 
173.42, 168.03, 155.42, 153.09, 145.39, 143.89, 143.46, 143.20, 141.38, 131.91, 131.54, 129.86, 
128.22, 126.28, 123.24, 113.42, 78.67, 75.01, 56.62, 56.24, 49.00, 44.21, 42.75, 41.97, 40.60, 
39.86, 38.80, 38.09, 28.61, 25.76, 23.46, 22.54, 21.99, 16.99, 14.86. HRMS (ESI) calcd for 
C37H50ClN5O8S [M+H] 760.3141, found 760.3143. 
 
 
(S)-1-((2-acetamidoethyl)thio)-4-methyl-1-oxopentan-2-yl 
(R)-3-((R)-3-(3-chloro-4-methoxyphenyl)-2-
((2E,5S,6R,7E)-5-hydroxy-6-methyl-8-(1-methyl-1H-
pyrazol-5-yl)octa-2,7-dienamido)propanamido)-2-
methylpropanoate (2.28h). Reaction was run as per general coupling procedure, and purified by 
flash chromatography (1-10% MeOH/DCM) Rf = 0.65 (10% MeOH/DCM). This was then 
deprotected as per general deprotection procedure and purified by flash chromatography (2 – 15% 
MeOH/DCM) to afford the final product 2.28h (xx, xx% yield over 3 steps) as a clear and colorless 
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oil: Rf = 0.25 (10% MeOH/DCM); 1H NMR (600 MHz, CD3OD) δ 7.34 (d, J = 2.2 Hz, 1H), 7.25 
(d, J = 2.2 Hz, 1H), 7.14 (dd, J = 8.4, 2.2 Hz, 1H), 6.97 (d, J = 8.5 Hz, 1H), 6.81 (dt, J = 15.0, 7.3 
Hz, 1H), 6.42 (d, J = 15.9 Hz, 1H), 6.38 (d, J = 2.1 Hz, 1H), 6.25 (dd, J = 15.9, 8.6 Hz, 1H), 6.01 
(dd, J = 15.4, 1.5 Hz, 1H), 5.21 (dd, J = 9.5, 3.9 Hz, 1H), 4.58 (dd, J = 8.1, 7.0 Hz, 1H), 3.84 (s, 
3H), 3.82 (s, 3H), 3.65 (dt, J = 8.0, 4.6 Hz, 1H), 3.48 (dd, J = 13.5, 6.6 Hz, 1H), 3.33 – 3.30 (m, 
2H) 3.20 (dd, J = 13.5, 7.0 Hz, 1H), 3.03 (td, J = 6.6, 1.8 Hz, 2H), 3.03 – 3.00 (m, 1H) 2.85 (dd, J 
= 13.8, 8.1 Hz, 1H), 2.70 (h, J = 6.9 Hz, 1H), 2.50 – 2.36 (m, 2H), 2.36 – 2.28 (m, 1H), 1.91 (s, 
3H), 1.82 – 1.68 (m, 2H), 1.63 (ddd, J = 13.2, 8.1, 3.9 Hz, 1H), 1.15 (d, J = 6.9 Hz, 3H), 1.10 (d, 
J = 7.1 Hz, 3H), 0.95 (d, J = 6.4 Hz, 3H), 0.92 (d, J = 6.5 Hz, 3H). 13C NMR: (150 MHz, CD3OD) 
δ 200.35, 175.08, 173.48, 173.44, 168.04, 155.42, 143.25, 142.85, 139.10, 137.95, 131.90, 131.50, 
129.85, 126.20, 123.21, 118.41, 113.39, 103.55, 78.65, 75.00, 56.59, 56.25, 44.35, 42.74, 41.97, 
40.59, 39.86, 38.87, 38.08, 36.45, 28.59, 25.76, 23.48, 22.54, 21.97, 17.32, 14.86. HRMS (ESI) 
calcd for C37H52ClN5O8S [M+H] 762.3298, found 762.3295. 
 
 (S)-1-((2-acetamidoethyl)thio)-4-methyl-1-oxopentan-2-
yl (R)-3-((R)-3-(3-chloro-4-methoxyphenyl)-2-
((2E,5S,6R,7E)-5-hydroxy-6-methyl-8-(1-methyl-1H-
pyrazol-3-yl)octa-2,7-dienamido)propanamido)-2-
methylpropanoate (2.28i). Reaction was run as per general coupling procedure, and purified by 
flash chromatography (1-10% MeOH/DCM) Rf = 0.65 (10% MeOH/DCM). This was then 
deprotected as per general deprotection procedure and purified by flash chromatography (2 – 15% 
MeOH/DCM) to afford the final product 2.28i (0.019, 34% yield over 3 steps) as a clear and 
colorless oil: Rf = 0.25 (10% MeOH/DCM); 1H NMR (600 MHz, CD3OD) δ 7.34 (d, J = 2.2 Hz, 
1H), 7.25 (d, J = 2.2 Hz, 1H), 7.14 (dd, J = 8.5, 2.1 Hz, 1H), 6.97 (d, J = 8.5 Hz, 1H), 6.81 (dt, J 
= 15.0, 7.3 Hz, 1H), 6.42 (d, J = 15.9 Hz, 1H), 6.38 (d, J = 2.1 Hz, 1H), 6.25 (dd, J = 15.9, 8.6 Hz, 
1H), 6.01 (dd, J = 15.4, 1.5 Hz, 1H), 5.21 (dd, J = 9.5, 3.9 Hz, 1H), 4.58 (dd, J = 8.0, 7.0 Hz, 1H), 
3.84 (s, 3H), 3.82 (s, 3H), 3.65 (dt, J = 8.0, 4.6 Hz, 1H), 3.48 (dd, J = 13.5, 6.6 Hz, 1H), 3.32 – 
3.30 (m, 3H), 3.20 (dd, J = 13.5, 7.0 Hz, 1H), 3.05 – 2.98 (m, 3H), 2.85 (dd, J = 13.8, 8.1 Hz, 1H), 
2.70 (h, J = 6.9 Hz, 1H), 2.49 – 2.36 (m, 1H), 2.36 – 2.28 (m, 1H), 1.91 (s, 3H), 1.80 – 1.68 (m, 
2H), 1.67 – 1.60 (m, 1H), 1.15 (d, J = 6.9 Hz, 3H), 1.10 (d, J = 7.1 Hz, 3H), 0.95 (d, J = 6.4 Hz, 
3H), 0.92 (d, J = 6.5 Hz, 3H). 13C NMR: (150 MHz, CD3OD) δ 200.35, 175.08, 173.48, 173.44, 
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168.04, 155.42, 143.25, 142.85, 139.10, 137.95, 131.90, 131.50, 129.85, 126.19, 123.21, 118.41, 
113.39, 103.55, 78.65, 75.00, 56.59, 56.25, 44.35, 42.74, 41.97, 40.59, 39.86, 38.87, 38.08, 36.45, 
28.59, 25.76, 23.48, 22.54, 21.97, 17.32, 14.86. HRMS (ESI) calcd for C37H52ClN5O8S [M+H] 
762.3298, found 762.3295. 
 
(S)-1-((2-acetamidoethyl)thio)-4-methyl-1-oxopentan-2-yl 
(R)-3-((R)-3-(3-chloro-4-methoxyphenyl)-2-((2E,5S,6R,7E)-
5-hydroxy-6-methyl-8-(1-methyl-1H-pyrazol-4-yl)octa-2,7-
dienamido)propanamido)-2-methylpropanoate (2.28j). Reaction was run as per general 
coupling procedure, and purified by flash chromatography (1-10% MeOH/DCM) Rf = 0.65 (10% 
MeOH/DCM). This was then deprotected as per general deprotection procedure and purified by 
flash chromatography (2 – 15% MeOH/DCM) to afford the final product 2.28j (0.039, 55% yield 
over 3 steps) as a clear and colorless oil: Rf = 0.25 (10% MeOH/DCM); 1H NMR (600 MHz, 
CD3OD) δ 7.54 (s, 1H), 7.50 (s, 1H), 7.25 (d, J = 2.1 Hz, 1H), 7.13 (dd, J = 8.2, 2.1 Hz, 1H), 6.97 
(d, J = 8.3 Hz, 1H), 6.80 (dt, J = 15.0, 7.3 Hz, 1H), 6.22 (d, J = 16.0 Hz, 1H), 6.00 (d, J = 16.1, 
1H), 5.94 (dd, J = 16.0, 8.4 Hz, 1H), 5.21 (dd, J = 9.5, 4.0 Hz, 1H), 4.58 (t, J = 7.5 Hz, 1H), 3.84 
(s, 3H), 3.84 (s, 3H), 3.60 (dt, J = 8.5, 4.5 Hz, 1H), 3.48 (dd, J = 13.5, 6.6 Hz, 1H), 3.33-3.30 (m, 
2H), 3.20 (dd, J = 13.5, 6.9 Hz, 1H), 3.03 (t, J = 5.8 Hz, 2H), 3.03 – 3.00 (m, 1H), 2.85 (dd, J = 
13.7, 8.2 Hz, 1H), 2.70 (q, J = 7.0 Hz, 1H), 2.40 – 2.23 (m, 3H), 1.91 (s, 3H), 1.81 – 1.68 (m, 2H), 
1.67 – 1.58 (m, 1H), 1.10 (d, J = 7.0 Hz, 6H), 0.95 (d, J = 6.3 Hz, 3H), 0.92 (d, J = 6.3 Hz, 4H).13C 
NMR (150 MHz, CD3OD): HRMS (ESI) calcd for C37H52ClN5O8S [M+H] 762.3298, found 
762.3294. 
 
(S)-1-((2-acetamidoethyl)thio)-4-methyl-1-oxopentan-2-yl 
3-((R)-3-(3-chloro-4-methoxyphenyl)-2-((2E,5S,6R,7E)-5-
hydroxy-6-methyl-8-(1-methyl-1H-pyrazol-4-yl)octa-2,7-
dienamido)propanamido)-2,2-dimethylpropanoate (2.28k). Reaction was run as per general 
coupling procedure, and purified by flash chromatography (1-10% MeOH/DCM) Rf = 0.65 (10% 
MeOH/DCM). This was then deprotected as per general deprotection procedure and purified by 
flash chromatography (2 – 15% MeOH/DCM) to afford the final product 2.28k (0.019, 44% yield 
over 3 steps) as a clear and colorless oil: Rf = 0.25 (10% MeOH/DCM); 1H NMR (600MHz, 
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CD3OD) δ 7.55 (s, 1H), 7.50 (s, 1H), 7.28 (d, J = 2.1 Hz, 1H), 7.15 (dd, J = 8.5, 2.2 Hz, 1H), 6.96 
(d, J = 8.5 Hz, 1H), 6.79 (dt, J = 14.9, 7.3 Hz, 1H), 6.21 (d, J = 16.1 Hz, 1H), 5.99 (d, J = 15.4 Hz, 
1H), 5.93 (dd, J = 16.0, 8.4 Hz, 1H), 5.20 (dd, J = 9.6, 3.9 Hz, 1H), 4.65 (dd, J = 8.6, 6.5 Hz, 1H), 
3.84 (s, 3H), 3.83 (s, 3H), 3.60 (dt, J = 8.8, 4.6 Hz, 1H), 3.44 – 3.32 (m, 2H), 3.12 – 2.98 (m, 3H), 
2.85 (dd, J = 13.9, 8.6 Hz, 1H), 2.32 (m, 3H), 1.91 (s, 3H), 1.83 – 1.68 (m, 2H), 1.64 (ddd, J = 
12.8, 8.4, 3.8 Hz, 1H), 1.16 (s, 6H), 1.10 (d, J = 6.9 Hz, 3H), 0.96 (d, J = 6.5 Hz, 3H), 0.92 (d, J = 
6.5 Hz, 3H). 13C NMR (150 MHz, CD3OD) δ 200.54, 176.85, 173.68, 173.44, 168.22, 155.38, 
143.62, 137.71, 131.90, 131.68, 130.86, 129.81, 129.39, 126.00, 123.23, 122.47, 121.60, 113.40, 
78.80, 75.37, 56.60, 56.35, 47.77, 44.68, 44.12, 41.94, 39.86, 38.72, 38.67, 37.85, 28.73, 25.87, 
23.49, 23.25, 23.17, 22.59, 21.94, 17.40. HRMS (ESI) calcd for C38H54ClN5O8S [M+H] xx, found 
x. 
 
(S)-1-((2-acetamidoethyl)thio)-4-methyl-1-oxopentan-2-yl 
(R)-3-((R)-3-(3-chloro-4-methoxyphenyl)-2-
((2E,5S,6R,7E)-5-hydroxy-8-(1-isopropyl-1H-pyrazol-4-
yl)-6-methylocta-2,7-dienamido)propanamido)-2-methylpropanoate (2.28l). Reaction was run 
as per general coupling procedure, and purified by flash chromatography (1-10% MeOH/DCM) 
Rf = 0.65 (10% MeOH/DCM). This was then deprotected as per general deprotection procedure 
and purified by flash chromatography (2 – 15% MeOH/DCM) to afford the final product 2.28l (xx, 
xx% yield over 3 steps) as a clear and colorless oil: Rf = 0.25 (10% MeOH/DCM); 1H NMR (600 
MHz, CD3OD) δ 7.64 (s, 1H), 7.51 (s, 1H), 7.25 (d, J = 2.2 Hz, 1H), 7.14 (dd, J = 8.4, 2.2 Hz, 1H), 
6.97 (d, J = 8.4 Hz, 1H), 6.80 (dt, J = 15.0, 7.3 Hz, 1H), 6.23 (d, J = 16.0 Hz, 1H), 6.00 (d, J = 
15.4 Hz, 1H), 5.94 (dd, J = 16.0, 8.5 Hz, 1H), 5.21 (dd, J = 9.5, 4.0 Hz, 1H), 4.58 (t, J = 7.5 Hz, 
1H), 4.46 (hept, J = 6.6 Hz, 1H), 3.84 (s, 3H), 3.61 (dt, J = 8.6, 4.5 Hz, 1H), 3.48 (dd, J = 13.5, 
6.6 Hz, 1H), 3.33 – 3.30 (m, 2H), 3.20 (dd, J = 13.5, 7.0 Hz, 1H), 3.03 (t, J = 6.6 Hz, 2H), 3.03 – 
3.00 (m, 1H), 2.85 (dd, J = 13.8, 8.1 Hz, 1H), 2.70 (h, J = 6.9 Hz, 1H), 2.43 – 2.23 (m, 3H), 1.91 
(s, 3H), 1.82 – 1.69 (m, 2H), 1.63 (ddd, J = 13.2, 8.1, 3.9 Hz, 1H), 1.47 (d, J = 6.7 Hz, 6H), 1.11 
(d, J = 6.9 Hz, 3H), 1.10 (d, J = 7.1 Hz, 3H), 0.95 (d, J = 6.4 Hz, 3H), 0.92 (d, J = 6.4 Hz, 3H).13C 
NMR (150 MHz, CD3OD) δ 200.36, 175.08, 173.49, 173.44, 168.11, 155.42, 143.59, 137.30, 
131.92, 131.52, 130.64, 129.85, 126.04 (2), 123.22, 121.90, 121.82, 113.39, 78.65, 75.41, 56.59, 
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56.24, 54.99, 44.15, 42.74, 41.97, 40.59, 39.86, 38.67, 38.07, 28.59, 25.76, 23.48, 23.08 (2) , 22.54, 
21.97, 17.44, 14.86. HRMS (ESI) calcd for C39H56ClN5O8S [M+H] 790.3611, found 790.3608. 
 
 
(S)-1-((2-acetamidoethyl)thio)-4-methyl-1-oxopentan-2-
yl (R)-3-((R)-3-(3-chloro-4-methoxyphenyl)-2-
((2E,5S,6R,7E)-8-(3,5-dimethylisoxazol-4-yl)-5-hydroxy-
6-methylocta-2,7-dienamido)propanamido)-2-methylpropanoate (2.28m). Reaction was run 
as per general coupling procedure, and purified by flash chromatography (1-10% MeOH/DCM) 
Rf = 0.65 (10% MeOH/DCM). This was then deprotected as per general deprotection procedure 
and purified by flash chromatography (2 – 15% MeOH/DCM) to afford the final product 2.28m 
(15, 43% yield over 3 steps) as a clear and colorless oil: Rf = 0.25 (10% MeOH/DCM); 1H NMR 
(600 MHz, CD3OD) δ 7.25 (d, J = 2.1 Hz, 1H), 7.14 (dd, J = 8.4, 2.2 Hz, 1H), 6.97 (d, J = 8.4 Hz, 
1H), 6.81 (dt, J = 15.0, 7.3 Hz, 1H), 6.14 (d, J = 16.3 Hz, 1H), 6.01 (d, J = 15.4 Hz, 1H), 5.93 (dd, 
J = 16.3, 8.5 Hz, 1H), 5.21 (dd, J = 9.5, 4.0 Hz, 1H), 4.57 (t, J = 7.5 Hz, 1H), 3.84 (s, 3H), 3.63 
(dt, J = 8.5, 4.7 Hz, 1H), 3.48 (dd, J = 13.5, 6.6 Hz, 1H), 3.33 – 3.30 (m, 2H) 3.20 (dd, J = 13.5, 
7.0 Hz, 1H), 3.03 (t, J = 6.8 Hz, 2H), 3.02 – 2.99 (m, 1H) 2.85 (dd, J = 13.7, 8.1 Hz, 1H), 2.70 (h, 
J = 7.0 Hz, 1H), 2.39 (s, 3H), 2.38 – 2.30 (m, 3H), 2.28 (s, 3H), 1.91 (s, 3H), 1.82 – 1.67 (m, 2H), 
1.63 (ddd, J = 12.6, 8.2, 3.9 Hz, 1H), 1.14 (d, J = 6.8 Hz, 3H), 1.10 (d, J = 7.1 Hz, 3H), 0.95 (d, J 
= 6.4 Hz, 3H), 0.92 (d, J = 6.4 Hz, 3H). 13C NMR (150 MHz, CD3OD) δ 200.36, 175.08, 173.49, 
173.44, 168.04, 166.54, 159.73, 155.42, 143.35, 135.53, 131.90, 131.50, 129.85, 126.13, 123.22, 
119.18, 114.25, 113.38, 78.65, 75.09, 56.59, 56.26, 48.57, 44.85, 42.74, 41.97, 40.59, 39.86, 38.94, 
38.09, 28.59, 25.76, 23.48, 22.53, 21.97, 17.69, 14.86, 11.47, 11.29. HRMS (ESI) calcd for 
C38H53ClN4O9S [M+H] 777.3295, found 777.3293. 
 
6.2 CrpTE Mediated Cyclization Experimentals and Characterization  
*CrpTE was purified as described in section 6.3  
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General Analytical CrpTE Cyclization Procedure. Seco cryptophycins 2.28a-m as a 10 mM 
soluiton in DMSO (xx, final conc. 50 uM) were added to 100 mM sodium phosphate buffer (150 
uL). The reaction medium was supplemented with DMSO to 5 v/v% and CrpTE as a 50 uM 
solution in reaction storage buffer (see buffer recipies) was added (0.5 uM final concentration). 
The reaction was shaken at 120 rpm for 12 hours at 37 °C prior to extraction with 300 uL of ethyl 
acetate. 100 uL of the organic layer was dried into an HPLC vial, taken up in 50 uL of MeOH and 
analyzed by Qtof MS, results are summarized in Figure 2.xx.  
General Semi-Preparative CrpTE Cyclization Procedure. To a 250 mL Erlenmeyer flask was 
added DMSO (5%), and substrate 2.28a-m (75 uM) suspended in DMSO. This was diluted with 
phosphate buffer (pH = 7.2, 100 mM) and warmed to 30 ºC for 20 min prior to treatment with 
CrpTE enzyme (0.5 uM). The reaction was allowed to shake at 120 RPM overnight, prior to 1:1v/v 
dilution with acetone and chilling to – 20 °C in the freezer. The precipitated protein was filtered 
through celite, washing with acetone, organics removed under reduced pressure, and the remaining 
aqueous layer was extracted with DCM 3 x 20 mL. The organics were combined, dried over 
sodium sulfate and concentrated. The reactions were purified using a HydroRP C18 (need 
dimensions) using a 20 – 80% water/acetonitrile gradient with a flow rate of 3 mL/min.  
 
Heterocyclic Cryptophycin Experimentals  
 
(3S,6R,10R,16S,E)-10-(3-chloro-4-methoxybenzyl)-3-isobutyl-6-
methyl-16-((R,E)-4-(pyridin-2-yl)but-3-en-2-yl)-1,4-dioxa-8,11-
diazacyclohexadec-13-ene-2,5,9,12-tetraone (2.28b). Reaction was 
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run and purified as general procedure for semi-preparative scale reaction. 1H NMR (600 MHz, 
CD3OD) δ 8.46 (dd, J = 5.0, 0.9 Hz, 1H), 7.78 (td, J = 7.7, 1.8 Hz, 1H), 7.48 (d, J = 7.9 Hz, 1H), 
7.28 (d, J = 2.2 Hz, 1H), 7.26 (ddd, J = 7.5, 5.0, 1.1 Hz, 1H), 7.17 (dd, J = 8.5, 2.2 Hz, 1H), 6.98 
(d, J = 8.5 Hz, 1H), 6.71 (ddd, J = 15.1, 11.1, 3.9 Hz, 1H), 6.61 – 6.57 (m, 2H), 5.93 (dd, J = 15.1, 
1.9 Hz, 1H), 5.09 (ddd, J = 11.3, 6.9, 1.9 Hz, 1H), 4.93 (dd, J = 9.9, 3.6 Hz, 1H), 4.52 (dd, J = 
11.3, 3.9 Hz, 1H), 3.84 (s, 3H), 3.58 (dd, J = 13.8, 3.3 Hz, 1H), 3.27 (dd, J = 13.8, 3.0 Hz, 1H), 
3.18 (dd, J = 14.5, 3.9 Hz, 1H), 2.80 – 2.73 (m, 2H), 2.73 – 2.65 (m, 2H), 2.39 (dt, J = 14.5, 11.2 
Hz, 1H), 1.69 – 1.52 (m, 2H), 1.34 (ddd, J = 14.1, 8.8, 3.6 Hz, 1H), 1.18 (d, J = 7.1 Hz, 6H), 0.74 
(d, J = 6.5 Hz, 3H), 0.71 (d, J = 6.6 Hz, 3H).13C NMR (151 MHz, CD3OD) δ 177.53, 174.04, 
172.22, 168.33, 156.60, 155.36, 149.99, 143.41, 138.74, 137.58, 132.23, 132.10, 131.49, 129.28, 
125.62, 123.71, 123.27, 122.82, 113.50, 78.48, 72.86, 57.35, 56.60, 43.46, 41.19, 40.88, 38.98, 
37.99, 36.36, 2 5.62, 23.20, 21.66, 17.53, 15.06. HRMS (ESI) calcd for C34H42ClN3O7 [M+H] 
640.2784, found 640.2787. 
(3S,6R,10R,16S,E)-10-(3-chloro-4-methoxybenzyl)-3-isobutyl-
6-methyl-16-((R,E)-4-(pyridin-3-yl)but-3-en-2-yl)-1,4-dioxa-
8,11-diazacyclohexadec-13-ene-2,5,9,12-tetraone (2.28c). 
Reaction was run and purified as general procedure for semi-preparative scale reaction.1H NMR 
(600 MHz, CD3OD) δ 8.53 (d, J = 2.2 Hz, 1H), 8.38 (dd, J = 4.8, 1.6 Hz, 1H), 7.92 (d, J = 8.0 Hz, 
1H), 7.40 (dd, J = 8.0, 4.9 Hz, 1H), 7.28 (d, J = 2.2 Hz, 1H), 7.17 (dd, J = 8.4, 2.2 Hz, 1H), 6.98 
(d, J = 8.4 Hz, 1H), 6.71 (ddd, J = 15.1, 11.2, 3.9 Hz, 1H), 6.53 (d, J = 15.9 Hz, 1H), 6.30 (dd, J = 
15.9, 8.9 Hz, 1H), 5.93 (dd, J = 15.2, 1.9 Hz, 1H), 5.08 (ddd, J = 11.2, 7.2, 1.9 Hz, 1H), 4.93 (dd, 
J = 9.9, 3.7 Hz, 1H), 4.52 (dd, J = 11.2, 3.9 Hz, 1H), 3.84 (s, 3H), 3.58 (dd, J = 13.8, 3.3 Hz, 1H), 
3.27 (dd, J = 13.8, 3.0 Hz, 1H), 3.18 (dd, J = 14.5, 3.9 Hz, 1H), 2.80 – 2.63 (m, 4H), 2.37 (dt, J = 
14.4, 11.1 Hz, 1H), 1.69 – 1.55 (m, 2H), 1.31 (ddd, J = 14.1, 8.9, 3.7 Hz, 1H), 1.19 (d, J = 3.5 Hz, 
3H), 1.18 (d, J = 2.9 Hz, 3H), 0.74 (d, J = 6.5 Hz, 3H), 0.70 (d, J = 6.5 Hz, 3H). 13C NMR (150 
MHz, CD3OD) δ 180.30, 177.53, 174.03, 172.21, 168.33, 155.36, 148.71, 148.40, 143.42, 135.55, 
134.96, 134.86, 132.21, 131.49, 129.28, 128.77, 125.62, 125.40, 113.49, 78.47, 72.80, 57.36, 
56.60, 43.75, 41.18, 40.94, 38.97, 37.88, 36.35, 25.60, 23.18, 21.69, 17.50, 15.06. HRMS (ESI) 
calcd for C34H42ClN3O7 [M+H] 640.2784, found 640.2789. 
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 (3S,10R,16S,E)-10-(3-chloro-4-methoxybenzyl)-3-isobutyl-6,6-
dimethyl-16-((R,E)-4-(pyridin-3-yl)but-3-en-2-yl)-1,4-dioxa-
8,11-diazacyclohexadec-13-ene-2,5,9,12-tetraone (2.28d). 
Reaction was run and purified as general procedure for semi-preparative scale reaction. 1H NMR 
(600MHz, CD3OD) δ 8.53 (s, 1H), 8.38 (d, J = 4.7 Hz, 1H), 7.92 (dt, J = 8.0, 1.9 Hz, 1H), 7.40 
(dd, J = 8.0, 4.8 Hz, 1H), 7.28 (d, J = 2.2 Hz, 1H), 7.17 (dd, J = 8.4, 2.2 Hz, 1H), 6.98 (d, J = 8.4 
Hz, 1H), 6.72 (ddd, J = 15.2, 11.2, 3.9 Hz, 1H), 6.53 (d, J = 15.9 Hz, 1H), 6.30 (dd, J = 16.0, 8.9 
Hz, 1H), 5.92 (dd, J = 15.1, 1.9 Hz, 1H), 5.07 (ddd, J = 11.1, 7.2, 1.8 Hz, 2H), 4.96 (dd, J = 9.9, 
3.4 Hz, 1H), 4.51 (dd, J = 11.3, 3.8 Hz, 1H), 3.84 (s, 3H), 3.46 (d, J = 13.6 Hz, 1H), 3.18 (dd, J = 
14.5, 3.8 Hz, 1H), 3.08 (d, J = 13.7 Hz, 1H), 2.74 (dd, J = 14.5, 11.4 Hz, 1H), 2.74 – 2.62 (m, 2H), 
2.36 (dt, J = 14.4, 11.2 Hz, 1H), 1.66 – 1.55 (m, 2H), 1.37 – 1.26 (m, 3H), 1.20 (s, 3H), 1.16 (s, 
3H), 0.74 (d, J = 6.4 Hz, 3H), 0.70 (d, J = 6.4 Hz, 3H). 13C NMR (150 MHz, CD3OD) δ 180.03, 
178.94, 173.68, 172.01, 168.22, 155.37, 148.71, 148.40, 143.63, 135.55, 134.85, 132.17, 131.46, 
129.26, 128.78, 125.43, 123.28, 113.50, 78.43, 72.58, 57.48, 56.60, 47.39, 44.02, 43.75, 40.92, 
37.92, 36.48, 31.64, 25.85, 23.32, 23.29, 23.22, 21.65, 17.49. HRMS (ESI) calcd for 
C35H44ClN3O7 [M+H] 654.2941, found 654.2940. 
 
 
(3S,6R,10R,16S,E)-10-(3-chloro-4-methoxybenzyl)-3-isobutyl-6-
methyl-16-((R,E)-4-(pyridin-4-yl)but-3-en-2-yl)-1,4-dioxa-8,11-
diazacyclohexadec-13-ene-2,5,9,12-tetraone (2.28e). Reaction was run and purified as general 
procedure for semi-preparative scale reaction. 1H NMR (600MHz, CD3OD) δ 8.43 (d, J = 6.2 Hz, 
2H), 7.42 (d, J = 6.3 Hz, 2H), 7.27 (d, J = 2.1 Hz, 1H), 7.15 (dd, J = 8.5, 2.1 Hz, 1H), 6.96 (d, J = 
8.4 Hz, 1H), 6.69 (ddd, J = 15.1, 11.1, 3.9 Hz, 1H), 6.50 – 6.47 (m, 2H), 5.91 (dd, J = 15.2, 1.8 
Hz, 1H), 5.08 (dd, J = 10.7, 8.3 Hz, 1H), 4.90 (dd, J = 9.9, 3.6 Hz, 1H), 4.51 (dd, J = 11.2, 3.9 Hz, 
1H), 3.82 (s, 3H), 3.56 (dd, J = 13.8, 3.3 Hz, 1H), 3.25 (dd, J = 13.8, 2.9 Hz, 1H), 3.16 (dd, J = 
14.5, 3.9 Hz, 1H), 2.77 – 2.62 (m, 4H), 2.34 (dt, J = 14.7, 11.2 Hz, 1H), 1.67 – 1.51 (m, 2H), 1.28 
(ddd, J = 12.9, 8.7, 3.5 Hz, 1H), 1.17 (d, J = 2.6 Hz, 3H), 1.16 (d, J = 2.0 Hz, 3H), 0.72 (d, J = 6.4 
Hz, 3H), 0.68 (d, J = 6.5 Hz, 3H). 13C NMR (150 MHz, CD3OD) δ 177.55, 174.02, 172.17, 168.31, 
155.36, 150.42, 147.12, 143.33, 138.63, 132.21, 131.49, 130.23, 129.28, 125.66, 123.27, 122.49, 
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113.49, 78.35, 72.78, 57.36, 56.60, 43.67, 41.17, 40.91, 38.96, 37.88, 36.35, 25.60, 23.15, 21.66, 
17.35, 15.06. HRMS (ESI) calcd for C34H42ClN3O7 [M+H] 640.2784, found 640.2787. 
 
(3S,10R,16S,E)-10-(3-chloro-4-methoxybenzyl)-3-isobutyl-6,6-
dimethyl-16-((R,E)-4-(pyridin-4-yl)but-3-en-2-yl)-1,4-dioxa-
8,11-diazacyclohexadec-13-ene-2,5,9,12-tetraone (2.28f). 
Reaction was run and purified as general procedure for semi-preparative scale reaction. 1H NMR 
(600MHz, CD3OD) δ 8.45 (d, J = 5.7 Hz, 2H), 7.44 (d, J = 6.3 Hz, 2H), 7.28 (d, J = 2.2 Hz, 1H), 
7.17 (dd, J = 8.4, 2.2 Hz, 1H), 6.98 (d, J = 8.5 Hz, 1H), 6.72 (ddd, J = 15.1, 11.2, 3.9 Hz, 1H), 6.51 
(s, 1H), 6.50 (d, J = 4.6 Hz, 1H), 5.92 (dd, J = 15.1, 1.9 Hz, 1H), 5.09 (ddd, J = 11.3, 7.2, 1.9 Hz, 
1H), 4.95 (dd, J = 9.9, 3.3 Hz, 1H), 4.51 (dd, J = 11.3, 3.7 Hz, 1H), 3.84 (s, 3H), 3.46 (d, J = 13.6 
Hz, 1H), 3.18 (dd, J = 14.6, 3.8 Hz, 1H), 3.08 (d, J = 13.6 Hz, 1H), 2.74 (dd, J = 14.5, 11.3 Hz, 
1H), 2.74 – 2.66 (m, 2H), 2.35 (dt, J = 14.5, 11.2 Hz, 1H), 1.67 – 1.54 (m, 2H), 1.37 – 1.24 (m, 
1H), 1.19 (s, 3H), 1.16 (s, 3H), 0.74 (d, J = 6.3 Hz, 3H), 0.71 (d, J = 6.4 Hz, 3H). 13C NMR (150 
MHz, CD3OD) δ 177.59, 174.05, 172.32, 168.36, 155.34, 143.63, 137.86, 132.21, 131.48, 130.26, 
129.63, 129.28, 125.50, 123.24, 122.46, 121.98, 113.46, 78.68, 72.91, 57.37, 56.58, 43.68, 41.18, 
40.87, 38.95, 38.75, 37.84, 36.36, 25.64, 23.18, 21.67, 17.75, 15.07. HRMS (ESI) calcd for 
C35H44ClN3O7 [M+H] 654.2941, found 654.2945. 
 
(3S,6R,10R,16S,E)-10-(3-chloro-4-methoxybenzyl)-3-isobutyl-
6-methyl-16-((R,E)-4-(pyrazin-2-yl)but-3-en-2-yl)-1,4-dioxa-
8,11-diazacyclohexadec-13-ene-2,5,9,12-tetraone (2.28g). 
Reaction was run and purified as general procedure for semi-preparative scale reaction. 1H NMR 
(600MHz, CD3OD) δ 8.61 (d, J = 1.5 Hz, 1H), 8.54 (dd, J = 2.6, 1.5 Hz, 1H), 8.42 (d, J = 2.6 Hz, 
1H), 7.28 (d, J = 2.2 Hz, 1H), 7.17 (dd, J = 8.4, 2.2 Hz, 1H), 6.98 (d, J = 8.5 Hz, 1H), 6.84 (dd, J 
= 15.7, 8.9 Hz, 1H), 6.71 (ddd, J = 15.2, 11.2, 3.9 Hz, 1H), 6.64 (d, J = 15.7 Hz, 1H), 5.93 (dd, J 
= 15.1, 1.9 Hz, 1H), 5.11 (ddd, J = 11.3, 6.8, 2.0 Hz, 1H), 4.94 (dd, J = 9.7, 3.7 Hz, 1H), 4.53 (dd, 
J = 11.2, 3.9 Hz, 1H), 3.84 (s, 3H), 3.58 (dd, J = 13.8, 3.4 Hz, 1H), 3.27 (dd, J = 13.7, 3.0 Hz, 1H), 
3.18 (dd, J = 14.5, 3.9 Hz, 1H), 2.81 – 2.72 (m, 3H), 2.69 (ddd, J = 12.6, 4.0, 2.0 Hz, 1H), 2.38 
(dt, J = 14.6, 11.2 Hz, 1H), 1.70 – 1.57 (m, 2H), 1.36 (ddd, J = 14.1, 8.7, 3.7 Hz, 1H), 1.19 (d, J = 
6.9 Hz, 3H), 1.19 (d, J = 7.5 Hz, 3H), 0.76 (d, J = 6.5 Hz, 3H). 13C NMR (150 MHz, CD3OD) δ 
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177.53, 174.03, 172.18, 168.32, 155.36, 152.52, 145.69, 144.15, 143.92, 143.33, 140.15, 132.22, 
131.48, 129.28, 128.83, 125.65, 123.27, 113.50, 78.45, 72.83, 57.35, 56.60, 43.37, 41.19, 40.91, 
38.98, 38.03, 36.35, 25.65, 23.23, 21.74, 17.37, 15.07. HRMS (ESI) calcd for [M+H] xx, found 
xx. 
 
(3S,6R,10R,16S,E)-10-(3-chloro-4-methoxybenzyl)-3-isobutyl-6-
methyl-16-((R,E)-4-(1-methyl-1H-pyrazol-5-yl)but-3-en-2-yl)-
1,4-dioxa-8,11-diazacyclohexadec-13-ene-2,5,9,12-tetraone 
(2.28h). Reaction was run and purified as general procedure for semi-preparative scale reaction. 
1H NMR (600 MHz, CD3OD) δ 7.36 (d, J = 2.1 Hz, 1H), 7.28 (d, J = 2.2 Hz, 1H), 7.17 (dd, J = 
8.5, 2.2 Hz, 1H), 6.98 (d, J = 8.4 Hz, 1H), 6.71 (ddd, J = 15.1, 11.2, 3.9 Hz, 1H), 6.52 (d, J = 15.8 
Hz, 1H), 6.42 (d, J = 2.1 Hz, 1H), 6.14 (dd, J = 15.8, 9.0 Hz, 1H), 5.93 (dd, J = 15.1, 1.9 Hz, 1H), 
5.07 (ddd, J = 11.3, 6.9, 1.9 Hz, 1H), 4.93 (dd, J = 9.8, 3.6 Hz, 1H), 4.52 (dd, J = 11.3, 3.9 Hz, 
1H), 3.84 (s, 6H), 3.59 (dd, J = 13.8, 3.3 Hz, 1H), 3.27 (dd, J = 13.8, 3.0 Hz, 1H), 3.18 (dd, J = 
14.5, 3.9 Hz, 1H), 2.79 – 2.73 (m, 2H), 2.73 – 2.62 (m, 2H), 2.35 (dt, J = 14.6, 11.2 Hz, 1H), 1.71 
– 1.57 (m, 2H), 1.35 (ddd, J = 14.0, 8.6, 3.5 Hz, 1H), 1.19 (d, J = 7.4 Hz, 3H), 1.17 (d, J = 6.9 Hz, 
3H), 0.77 (d, J = 6.4 Hz, 6H). 13C NMR: (150 MHz, CD3OD) δ 177.58, 174.04, 172.22, 168.32, 
155.35, 143.40, 142.29, 139.27, 136.81, 132.20, 131.48, 129.28, 125.61, 123.24, 119.18, 113.46, 
103.68, 78.39, 72.84, 57.39, 56.58, 43.68, 41.16, 40.96, 38.96, 37.96, 36.51, 36.36, 25.69, 23.25, 
21.76, 17.53, 15.08. HRMS (ESI) calcd for C33H43ClN4O7 [M+H] 643.2893, found 643.2890. 
 
(3S,6R,10R,16S,E)-10-(3-chloro-4-methoxybenzyl)-3-isobutyl-
6-methyl-16-((R,E)-4-(1-methyl-1H-pyrazol-3-yl)but-3-en-2-
yl)-1,4-dioxa-8,11-diazacyclohexadec-13-ene-2,5,9,12-tetraone 
(2.28i). Reaction was run and purified as general procedure for semi-preparative scale reaction. 1H 
NMR (600 MHz, CD3OD) δ 7.70 (s, 1H), 7.53 (s, 1H), 7.28 (d, J = 2.2 Hz, 1H), 7.17 (dd, J = 8.4, 
2.2 Hz, 1H), 6.98 (d, J = 8.5 Hz, 1H), 6.70 (ddd, J = 15.1, 11.2, 3.9 Hz, 1H), 6.28 (d, J = 15.8 Hz, 
1H), 5.92 (dd, J = 15.2, 1.9 Hz, 1H), 5.79 (dd, J = 15.9, 8.9 Hz, 1H), 4.98 (ddd, J = 11.2, 7.5, 2.0 
Hz, 1H), 4.91 (dd, J = 10.0, 3.5 Hz, 1H), 4.52 (dd, J = 11.2, 3.8 Hz, 1H), 4.47 (p, J = 6.7 Hz, 1H), 
3.84 (s, 3H), 3.58 (dd, J = 13.8, 3.3 Hz, 1H), 3.27 (dd, J = 13.7, 3.0 Hz, 1H), 3.18 (dd, J = 14.5, 
3.8 Hz, 1H), 2.79 – 2.71 (m, 2H), 2.71 – 2.63 (m, 1H), 2.50 (h, J = 7.2 Hz, 1H), 2.33 (dt, J = 14.5, 
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11.2 Hz, 1H), 1.72 – 1.54 (m, 2H), 1.46 (d, J = 6.7 Hz, 6H), 1.37 (ddd, J = 14.2, 9.0, 3.6 Hz, 1H), 
1.18 (d, J = 7.4 Hz, 3H), 1.12 (d, J = 6.9 Hz, 3H), 0.77 (d, J = 6.5 Hz, 3H), 0.74 (d, J = 6.6 Hz, 
3H). 13C NMR (150 MHz, CD3OD) δ 177.60, 174.05, 172.33, 168.37, 155.35, 143.64, 137.40, 
132.21, 131.48, 130.12, 129.28, 126.34, 125.51, 123.25, 122.67, 121.38, 113.46, 78.67, 72.93, 
57.38, 56.59, 55.07, 43.80, 41.18, 40.87, 38.96, 37.85, 36.37, 25.64, 23.31, 23.09, 21.70, 17.79, 
15.07. HRMS (ESI) calcd for C35H47ClN4O7 [M+H] 671.3206, found 671.3025. 
 
 (3S,6R,10R,16S,E)-10-(3-chloro-4-methoxybenzyl)-3-
isobutyl-6-methyl-16-((R,E)-4-(1-methyl-1H-pyrazol-4-
yl)but-3-en-2-yl)-1,4-dioxa-8,11-diazacyclohexadec-13-ene-
2,5,9,12-tetraone (2.28j). Reaction was run and purified as general procedure for semi-preparative 
scale reaction. 1H NMR (600 MHz, CD3OD) δ 7.61 (s, 1H), 7.51 (s, 1H), 7.28 (d, J = 2.2 Hz, 1H), 
7.17 (dd, J = 8.4, 2.2 Hz, 1H), 6.98 (d, J = 8.4 Hz, 1H), 6.70 (ddd, J = 15.2, 11.2, 3.9 Hz, 1H), 6.27 
(d, J = 15.9 Hz, 1H), 5.92 (dd, J = 15.2, 1.9 Hz, 1H), 5.80 (dd, J = 15.9, 8.9 Hz, 1H), 4.99 (ddd, J 
= 11.3, 7.1, 1.9 Hz, 1H), 4.92 (dd, J = 10.0, 3.6 Hz, 1H), 4.52 (dd, J = 11.3, 3.8 Hz, 1H), 3.84 (d, 
J = 1.8 Hz, 6H), 3.58 (dd, J = 13.8, 3.3 Hz, 1H), 3.27 (dd, J = 13.8, 2.9 Hz, 1H), 3.18 (dd, J = 14.5, 
3.8 Hz, 1H), 2.81 – 2.70 (m, 2H), 2.69 – 2.60 (m, 1H), 2.50 (p, J = 7.1 Hz, 1H), 2.33 (dt, J = 14.5, 
11.2 Hz, 1H), 1.71 – 1.56 (m, 2H), 1.38 (ddd, J = 13.2, 9.0, 3.6 Hz, 1H), 1.18 (d, J = 7.5 Hz, 3H), 
1.11 (d, J = 6.8 Hz, 3H), 0.78 (d, J = 6.5 Hz, 3H), 0.76 (d, J = 6.6 Hz, 3H). 13C NMR (150 MHz, 
CD3OD) δ 177.59, 174.05, 172.32, 168.36, 155.34, 143.63, 137.86, 132.21, 131.48, 130.26, 
129.63, 129.28, 125.50, 123.24, 122.46, 121.98, 113.46, 78.68, 72.91, 57.37, 56.58, 43.68, 41.18, 
40.87, 38.95, 38.75, 37.84, 36.36, 25.64, 23.18, 21.67, 17.75, 15.07. HRMS (ESI) calcd for 
C33H43ClN4O7 [M+H] 643.2893, found 643.2890. 
 
(3S,10R,16S,E)-10-(3-chloro-4-methoxybenzyl)-3-isobutyl-6,6-
dimethyl-16-((R,E)-4-(1-methyl-1H-pyrazol-4-yl)but-3-en-2-
yl)-1,4-dioxa-8,11-diazacyclohexadec-13-ene-2,5,9,12-tetraone 
(2.28k). Reaction was run and purified as general procedure for semi-preparative scale reaction. 
1H NMR (600MHz, CD3OD) 7.60 (s, 1H), 7.51 (s, 1H), 7.27 (d, J = 2.1 Hz, 1H), 7.16 (dd, J = 8.5, 
2.2 Hz, 1H), 6.97 (d, J = 8.5 Hz, 1H), 6.70 (ddd, J = 15.2, 11.2, 3.9 Hz, 1H), 6.27 (d, J = 15.9 Hz, 
1H), 5.90 (dd, J = 15.1, 1.9 Hz, 1H), 5.79 (dd, J = 15.9, 8.9 Hz, 1H), 4.97 (ddd, J = 11.3, 7.1, 1.6 
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Hz, 1H), 4.94 (dd, J = 9.9, 3.4 Hz, 1H), 4.50 (dd, J = 11.4, 3.7 Hz, 1H), 3.83 (s, 3H), 3.83 (s, 3H), 
3.45 (d, J = 13.6 Hz, 1H), 3.17 (dd, J = 14.5, 3.7 Hz, 1H), 3.07 (d, J = 13.6 Hz, 1H), 2.73 (dd, J = 
14.5, 11.4 Hz, 1H), 2.65 (dt, J = 14.7, 2.4 Hz, 1H), 2.50 (h, J = 7.2 Hz, 1H), 2.32 (dt, J = 14.4, 
11.2 Hz, 1H), 1.68 – 1.57 (m, 2H), 1.43 – 1.36 (m, 1H), 1.19 (s, 3H), 1.15 (s, 3H), 1.11 (d, J = 6.9 
Hz, 3H), 0.77 (t, J = 6.7 Hz, 6H). 13C NMR (150 MHz, CD3OD) δ 178.97, 173.70, 172.12, 168.25, 
155.37, 143.83, 137.86, 132.17, 131.46, 130.26, 129.63, 129.26, 125.33, 123.27, 122.48, 121.98, 
113.49, 78.65, 72.69, 57.47, 56.59, 47.40, 44.01, 43.68, 40.85, 38.75, 37.88, 36.49, 25.90, 23.32, 
23.28, 23.20, 21.64, 17.74. HRMS (ESI) calcd for C34H45ClN4O7 [M+H] 643.2893, found 
643.2893. 
 
(3S,6R,10R,16S,E)-10-(3-chloro-4-methoxybenzyl)-3-isobutyl-
16-((R,E)-4-(1-isopropyl-1H-pyrazol-4-yl)but-3-en-2-yl)-6-
methyl-1,4-dioxa-8,11-diazacyclohexadec-13-ene-2,5,9,12-
tetraone (2.28l). Reaction was run and purified as general procedure for semi-preparative scale 
reaction. 1H NMR (600 MHz, CD3OD) δ 7.70 (s, 1H), 7.53 (s, 1H), 7.28 (d, J = 2.2 Hz, 1H), 7.17 
(dd, J = 8.4, 2.2 Hz, 1H), 6.98 (d, J = 8.5 Hz, 1H), 6.70 (ddd, J = 15.1, 11.2, 3.9 Hz, 1H), 6.28 (d, 
J = 15.8 Hz, 1H), 5.92 (dd, J = 15.2, 1.9 Hz, 1H), 5.79 (dd, J = 15.9, 8.9 Hz, 1H), 4.98 (ddd, J = 
11.2, 7.5, 2.0 Hz, 1H), 4.91 (dd, J = 10.0, 3.5 Hz, 1H), 4.52 (dd, J = 11.2, 3.8 Hz, 1H), 4.47 (p, J 
= 6.7 Hz, 1H), 3.84 (s, 3H), 3.58 (dd, J = 13.8, 3.3 Hz, 1H), 3.27 (dd, J = 13.7, 3.0 Hz, 1H), 3.18 
(dd, J = 14.5, 3.8 Hz, 1H), 2.79 – 2.71 (m, 2H), 2.71 – 2.63 (m, 1H), 2.50 (h, J = 7.2 Hz, 1H), 2.33 
(dt, J = 14.5, 11.2 Hz, 1H), 1.72 – 1.54 (m, 2H), 1.46 (d, J = 6.7 Hz, 6H), 1.37 (ddd, J = 14.2, 9.0, 
3.6 Hz, 1H), 1.18 (d, J = 7.4 Hz, 3H), 1.12 (d, J = 6.9 Hz, 3H), 0.77 (d, J = 6.5 Hz, 3H), 0.74 (d, J 
= 6.6 Hz, 3H). 13C NMR (150 MHz, CD3OD) δ 177.60, 174.05, 172.33, 168.37, 155.35, 143.64, 
137.40, 132.21, 131.48, 130.12, 129.28, 126.34, 125.51, 123.25, 122.67, 121.38, 113.46, 78.67, 
72.93, 57.38, 56.59, 55.07, 43.80, 41.18, 40.87, 38.96, 37.85, 36.37, 25.64, 23.31, 23.09, 21.70, 
17.79, 15.07. HRMS (ESI) calcd for C35H47ClN4O7 [M+H] 671.3206, found 671.3025. 
 
(3S,6R,10R,16S,E)-10-(3-chloro-4-methoxybenzyl)-16-((R,E)-4-
(3,5-dimethylisoxazol-4-yl)but-3-en-2-yl)-3-isobutyl-6-methyl-
1,4-dioxa-8,11-diazacyclohexadec-13-ene-2,5,9,12-tetraone 
(2.28m). Reaction was run and purified as general procedure for semi-preparative scale reaction. 
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1H NMR (600 MHz, CD3OD) δ 7.28 (d, J = 2.2 Hz, 1H), 7.17 (dd, J = 8.4, 2.2 Hz, 1H), 6.98 (d, 
J = 8.4 Hz, 1H), 6.69 (ddd, J = 15.1, 11.1, 3.9 Hz, 1H), 6.23 (d, J = 16.2 Hz, 1H), 5.93 (dd, J = 
15.1, 1.9 Hz, 1H), 5.80 (dd, J = 16.2, 8.9 Hz, 1H), 5.06 (ddd, J = 11.3, 6.7, 1.9 Hz, 1H), 4.93 (dd, 
J = 9.7, 3.8 Hz, 1H), 4.51 (dd, J = 11.2, 3.9 Hz, 1H), 3.84 (s, 3H), 3.57 (dd, J = 13.7, 3.3 Hz, 1H), 
3.27 (dd, J = 13.8, 3.0 Hz, 1H), 3.17 (dd, J = 14.5, 3.9 Hz, 1H), 2.80 – 2.71 (m, 2H), 2.67 (ddt, J 
= 14.6, 4.0, 2.0 Hz, 1H), 2.58 (dt, J = 8.8, 6.6 Hz, 1H), 2.40 (s, 3H), 2.35 (dt, J = 14.5, 11.4 Hz, 
1H), 2.28 (s, 3H), 1.70 – 1.53 (m, 2H), 1.33 (ddd, J = 14.1, 8.7, 3.8 Hz, 1H), 1.18 (d, J = 7.4 Hz, 
3H), 1.15 (d, J = 6.9 Hz, 3H), 0.79 (d, J = 3.7 Hz, 3H), 0.78 (d, J = 3.8 Hz, 3H). 13C NMR (150 
MHz, CD3OD) δ 177.53, 174.04, 172.23, 168.34, 166.95, 159.53, 155.35, 143.40, 134.36, 132.19, 
131.48, 129.29, 125.65, 123.24, 120.19, 113.78, 113.46, 78.53, 72.77, 57.40, 56.58, 44.22, 41.16, 
41.02, 38.95, 37.87, 36.35, 25.62, 23.20, 21.77, 17.83, 15.07, 11.55, 11.45. HRMS (ESI) calcd for 
C34H44ClN3O8 [M+H] 658.2890, found 658.2893. 
 
6.3 Cryptophycin TE Construct Design (Chapter 3) and Protein Expression 
6.3.1 Generation of Mutant Crp TEs 
The mutations of CrpTE were generated from a modified pET28b plasmid containing a 8x his tag 
and a TEV cleavage site in place of the thrombin cleavage site. A quickchange mutagenesis 
(Stratagene) protocol was utilized for the generation of mutants except the plus 7aa, minus 5aa, 
and the minus 10aa which utilized the same conditions except only a forward primer was utilize. 
All new constructs were verified with the UofM Sequencing core.   
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Mutation	  	   Primer	  	  
C145S	   5'-­‐GGATAATGCAAAGTGGATAAGCCGAATGGCTGAGGTTATTG-­‐3'	  
	   5'-­‐CAATAACCTCAGCCATTCGGCTTATCCACTTTGCATTATCC-­‐3'	  
C226S	   5'-­‐CCAATCACTTTGTTTAGCGCGAGGGAGATAAATC-­‐3'	  
	   5'-­‐GATTTATCTCCCTCGCGCTAAACAAAGTGATTGG-­‐3'	  
E61G	   5'-­‐CAAGGTCTTGATGGTGGCACCGAACCTCATAAAAG-­‐3'	  
	   5'-­‐CTTTTATGAGGTTCGGTGCCACCATCAAGACCTTG-­‐3'	  
K66S	   5'	  GTGGCACCGAACCTCATAGCAGTGTTGAAGCAATAGC	  3'	  
	   5'	  GCTATTGCTTCAACACTGCTATGAGGTTCGGTGCCAC	  3'	  
E70A	   5'-­‐CATAAAAGTGTTGAAGCAATAGCCTCCCAACAC-­‐3'	  
	   5'-­‐GTGTTGGGAGGCTATTGCTTCAACACTTTTATG-­‐3'	  
K77A	   5'	  GCAATAGCCTCCCAACACATTGCGGCAATTCAAACAGTTCAACC	  3'	  
	   5'	  GGTTGAACTGTTTGAATTGCCGCAATGTGTTGGGAGGCTATTGC	  3'	  
K195G	   5'-­‐GCCTGCTCAAACAGATATCGGCATTGTTCGTGGTTTATTAC-­‐3'	  
	   5'-­‐GTAATAAACCACGAACAATGCCGATATCTGTTTGAGCAGGC-­‐3'	  
K219A	   5'-­‐CCGGAAAAGACTTATGCGACTCCAATCACTTTG-­‐3'	  
	   5'-­‐CAAAGTGATTGGAGTCGCATAAGTCTTTTCCGG-­‐3'	  
Plus	  7aa	   5'	  CCAACCGCTAGCGAACGACTAGCACTTCTTGTTGGTTCCGATTCCGGAGCCGAACTTTGG	  3'	  
Minus	  5aa	   5'CCAACCGCTAGCGCCGAACTTTGGTCTCCATTAG	  3'	  
Minus	  10aa	   5'	  CCAACCGCTAGCCCATTAGTACCAATTCAATTCAACAAAACG3'	  
S94C	   5’	  CTTGGCTGGTCATTGCTTTGGCAGTCATG	  3’	  	  
	   5’	  CATGACTGCCAAAGCAATGACCAGCCAAG	  3’	  	  
H265Q	   5’	  CATATAGTTCCGGGTAATCGTGTTTCAATGCTGAGTGAG	  3’	  
	   5’	  CTCACTCAGCATTGAAACACGATTACCCGGAACTATATG	  3’	  
H265N	   5’	  CATATAGTTCCGGGTAATCAGGTTTCAATGCTGAGTGAGC	  3’	  	  
	  	   	  5’	  GCTCACTCAGCATTGAAACCTGATTACCCGGAACTATATG	  3’	  
Table 6.1 Primers utilized for generation of CrpTE mutants 
6.3.2 CrpTE Protein Expression and Purification: Crystallography  
Buffers For CrpTE Purification for Reactions and Crystallography 
 HEPES Lysis: 50 mM HEPES pH 8, 300 mM NaCl, 10 mM imidazole 
 HEPES Wash: 50 mM HEPES pH 8, 300 mM NaCl, 30 mM imidazole 
 HEPES Elution: 50 mM HEPES pH 8, 300 mM NaCl, 300 mM imidazole 
 HEPES Storage: 10 mM HEPES pH 7.5, 150 mM NaCl, 0.2 mM TCEP 
 Tris Storage: 10 mM Tris pH = 7.5, 100 mM NaCl, 0.2 mM TCEP 
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General Expression Protocol: Crystallography  
Prior to protein production, a starter culture of E. Coli (BAP1) cells were grown by inoculating 10 
mL of LB broth supplemented with kanamycin (50 mg/L) from freshly transformed colonies and 
grown overnight at 37 °C. Following overnight growth, 4 mL/L was used to inoculate a 1L 
expression culture in TB containing kanamycin (50 mg/L) and grown with shaking at 37 °C until 
an OD600 of 0.8 – 1.2 was reached. At which time the flasks were cooled in an ice bath until an 
internal temperature of 20 °C was reached (~15 min). The flasks were returned to a 20 °C shaker, 
induced with 300 uL of IPTG (1M stock solution), and shaken at 200 RPM at 20 °C for a minimum 
of 18 hours. The cells were harvested by centrifugation (6,000 x g, 25 min, 4 °C). The pellets were 
frozen in liquid nitrogen and stored at -80 °C until purification.  
 
General Protein Purification Protocol  
The frozen cells were suspended in Lysis buffer (7 mL/g cell pellet) and thawed at 4 °C with 
stirring for 1 hour. Benzenase was added and the solution was sonicated on ice (12 x 10s with 50s 
rest periods). The resulting cellular lysate was then pelleted by centrifugation (50,000 x g, 30 min, 
4 °C) and the supernatant was applied to 5 mL of Ni-NTA resin pre-equilibrated with wash buffer. 
After binding, the column was washed with 20 column volumes (100 mL) of wash buffer and the 
protein was subsequently eluted with 15 mL of elution buffer. The eluted fractions were combined, 
concentrated to 2.5 mL and buffer exchanged into storage (Tris for crystallography, HEPES for 
enzymatic reactions) buffer using a pre-equilibrated PD-10 column.  After elution with 3.5 mL of 
storage buffer, the fractions were collected and protein concentration determined by absorption at 
280 nm.  
 Enzymatic reactions: The fractions were pooled and diluted to 50 uM with HEPES storage 
buffer, flash frozen in liquid N2, and stored at -80 °C until use.  
 Crystallography: The fractions were pooled and run over an S75 size exclusion column 
previously equilibrated in Tris storage buffer using an AKTA FPLC system. The populations of 
monomer and dimer were collected and concentrated to 30 mg/mL concentration or higher and 
transferred to the Smith Lab for crystallographic screens.  
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6.3.3 CrpTE Protein Expression and Purification: NMR  
 
*For unlabled Crp TE, expression was conducted as described above for crystallography  
 
Buffers For CrpTE Purification for NMR experiments  
 Phosphate Lysis: 100mM NaPO4 pH 8, 300 mM NaCl, 20 mM imidazole 
 Phosphate Wash: 100 mM NaPO4 pH 8, 300 mM NaCl, 50 mM imidazole 
 Phosphate Elution: 100 mM NaPO4 pH 8, 300 mM NaCl, 300 mM imidazole 
 Phosphate Storage: 100 mM NaPO4 pH 8, 150 mM NaCl  
 NMR Buffer: 100 mM NaPO4 pH 6.0, 150 mM NaCl 
M9 Salts (1L 5x concentration, no NH4Cl) 
 64 g Na2HPO4  
 15 g KH2PO4 
 2.5 gNaCl   
1L 100x Trace Elements  
 5 g EDTA   0.01 g H3BO3 
 0.8 g FeCl3   1.6 g MnCl2 
 0.05 g ZnCl2   0.005 g Ni2SO4 
 0.01 g CuCl2   0.005 g Molybdic Acid 
 0.01 g CoCl2  
Dissolve in 1L water, adjust pH to 7 with NaOH (some precipitation) and sterile filter, store cold 
500 mL 1000x vitamins  
 0.5 g riboflavin 
 0.5 g niacinamide 
 0.5 g pyridoxine monohydrate 
 0.5 g thiamine 
Dissolve in 500 mL water, store cold 
Minimal Expression Media 15N, 15N/13C, or 15N/13C/2H  (per L) 
 1 L M9 Salts (200 mL in 800 mL DI H2O or D2O) 
 2 mL 1M MgSO4 
 20 mL 20% glucose or 20 mL 20% 13C glucose 
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 1 mL Vitamins 100x 
 10 mL trace elements 100x 
 1 g 15NH4Cl 
 Kanamycin 50 mg/L 
  
Labeled Protein Expression Conditions 
Day 1: Bl21 (DE3) E. coli were transformed with the minus 5aa plasmid 
Day 2: Freshly transformed cells were used to inoculate 5 mL of LB containing Kanamycin (50 
mg//L) as a pre-culture which was grown to a high OD600 (6-8 hours). Overnight cultures were 
then inoculated in minimal expression media (15N, 15N/13C, or 15N/13C/2H) with Kanamycin (50 
mg/L) using a 1:100 inoculum. These were grown at 37 °C overnight.  
Day 3:  1L minimal expression media 15N main cultures were inoculated with overnight culture 
(1:100 inoculum, 10 mL per liter culture). These were grown at 37 °C until OD600 0.4 – 0.6 was 
reached, at which time the cells were cooled to 20 °C for 1 h and induced with 100 uL IPTG (1M). 
The cultures were allowed to express for 18 h prior to harvesting (6,000 x g, 25 min), flash freezing 
in liquid N2, and storage at -80 °C.  
 
General Purification Protocol for NMR 
The frozen cells were suspended in Lysis buffer (7 mL/g cell pellet) and thawed at 4 °C with 
stirring for 1 hour. Benzenase was added and the solution was sonicated on ice (12 x 10s with 50s 
rest periods). The resulting cellular lysate was then pelleted by centrifugation (50,000 x g, 30 min, 
4 °C) and the supernatant was applied to 5 mL of Ni-NTA resin pre-equilibrated with wash buffer. 
After binding, the column was washed with 20 column volumes (100 mL) of wash buffer and the 
protein was subsequently eluted with 15 mL of elution buffer. The eluted fractions were combined, 
concentrated to 2.5 mL and buffer exchanged into storage buffer using a pre-equilibrated PD-10 
column. After elution with 3.5 mL of storage buffer, the fractions were collected and protein 
concentration determined by absorption at 280 nm. These were then flash frozen and stored until 
NMR experiments were to be run.  
Prior to NMR experiments, proteins were thawed, and run over an S75 size exclusion column 
previously equilibrated in NMR buffer using an AKTA FPLC system. The dimer was excluded 
and monomeric protein was concentrated to 500 mM (protein would precipitate upon freezing in 
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this buffer so done directly before). This was then spiked with D2O and loaded into a shigemi 
NMR tube for analysis. 
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Chapter 7 
Polyketide Synthase Experimentals 
 
7.1 New Pentaketide Synthetic Procedures and Characterization  
 
*Synthesis previously developend by Hansen et. al.1  
 
 
methyl (S)-3-((tert-butyldimethylsilyl)oxy)-2-methylpropanoate (S7.4): To a stirred solution of 
(S)-Roche ester and imidazole in DMF was added TBSCl and the reaction was stirred at rt 
overnight. The reaction was diluted with 0.5N HCl and the organics separated, extracted with ethyl 
acetate (3 x 50 mL), organics combined, washed with sat. NH4Cl, dried over Na2SO4, and 
concentrated. The crude product was purified by flash chromatography system (2 – 20% Ethyl 
Acetate/Hexanes) to afford xx (4.12 g, 70% yield) as a colorless oil: Rf = 0.7 (10% Ethyl 
Acetate/Hexanes); 1H NMR (600 MHz, CDCl3) δ 3.76 (dd, J = 9.7, 6.9 Hz, 1H), 3.66 (d, J = 1.3 
Hz, 3H), 3.64 (dd, J = 9.7, 6.0 Hz, 1H), 2.64 (h, J = 7.0 Hz, 1H), 1.12 (d, J = 7.0 Hz, 3H), 0.86 (d, 
J = 1.8 Hz, 9H), 0.02 (s, 3H), 0.02 (s, 3H). HRMS (ESI) calcd for C11H24O3Si [M+H] 233.1568, 
found 233.1571. 
 
 
O N
Bn
O O 1. Bu2BOTf, NEt3, DCM 0 C2. Propionaldehyde, -78 C O N
Bn
O O OH TBSOTf, Lutidine CH2Cl2 O N
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(S)-3-((tert-butyldimethylsilyl)oxy)-2-methylpropanoic acid (4.20): S7.5 (1 eq, 4.30 mmol, 1.0 
g) was suspended in a 4:1 mixture of THF/H2O (43 mL, 0.1M) and treated with LiOH (4 eq, 17.21 
mmol, 0.412 g) and stirred for 4 hours. The reaction was quenched with 1 M HCl (50 mL) and the 
organics removed under reduced pressure. The aqueous layer was extracted with ethyl acetate (3 
x 50 mL), organics combined, washed with brine, dried over Na2SO4, and concentrated. The crude 
product was purified by flash chromatography system (10 – 30% Ethyl Acetate/Hexanes + 1% 
AcOH) to afford 4.20  ( 0.81 g, 87% yield) as a clear and colorless oil: Rf = 0.4 (20% Ethyl 
Acetate/Hexanes); 1H NMR (600 MHz, CDCl3) δ 3.79 – 3.66 (m, 2H), 2.65 (td, J = 7.2, 6.0 Hz, 
1H), 1.17 (d, J = 7.1 Hz, 3H), 0.89 (d, J = 0.9 Hz, 9H), 0.07 (d, J = 1.4 Hz, 6H). 13C NMR (15 
MHz, CDCl3) δ 179.21, 64.85, 41.59, 25.71, 18.14, 13.00, -5.55, -5.57. HRMS (ESI) calcd for 
C10H22O3Si [M+H] 219.1411, found 219.1419. 
 
 
S-phenyl (S)-3-((tert-butyldimethylsilyl)oxy)-2-methylpropanethioate (S7.6): To a 25 mL 
flask was added 4.20 (1 eq, 0.92 mmol, 0.20 g) and Ph2S2 (1.1 eq, 1.01 mmol, 0.22 g) in CH2Cl2 
(9.2 mL, 0.1M) and cooled to 0 °C. PBu3 (distilled, 1.1 eq, 1.01 mmol, 250 uL) was added slowly, 
the reaction was stirred for 10 min before it was quenched with sat. NaHCO3. The organics were 
separated, extracted with CH2Cl2 (3 x 20 mL), dried over sodium sulfate, and concentrated. The 
crude product was purified by flash chromatography system (2 – 40% Ethyl Acetate/Hexanes) to 
afford S7.6 (225 mg, 77% yield) as a clear and colorless oil: Rf  = 0.25 (25% Ethyl 
Acetate/Hexanes); 1H NMR (400 MHz, CDCl3) δ 7.40 (s, 5H), 3.87 (dd, J = 9.9, 7.2 Hz, 1H), 3.66 
(dd, J = 10.0, 5.9 Hz, 1H), 2.97 (q, J = 6.7, 6.2 Hz, 1H), 1.21 (d, J = 7.0 Hz, 3H), 0.90 (d, J = 1.2 
Hz, 9H), 0.06 (s, 3H), 0.06 (s, 3H). 13C NMR (150 MHz, CDCl3) δ 199.98, 134.42, 129.17, 129.06, 
127.90, 65.37, 51.06, 25.80, 18.22, 13.98, -5.50. HRMS (ESI) calcd for C16H26O2SSi [M+H] 
311.1496, found 311.1497. 
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O
LiOH, THF/H2O
HO OTBS
O
S7.5 4.20
HO OTBS
O
Ph2S2, PBu3, DCM PhS OTBS
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S-phenyl (S)-3-hydroxy-2-methylpropanethioate (4.22): To an open 20 mL polyethylene vial 
was added S7.7 in CH3CN (4 mL, 1M) and aq. HF (48%, 1 mL). The reaction was monitored by 
TLC and upon completion it was diluted with CH2Cl2 (5 mL) and carefully quenched with sat. 
NaHCO3 (until pH was acidic). The aqueous layer was extracted with CH2Cl2 (3 x 10 mL), 
organics combined, dried over Na2SO4, and concentrated. The crude product was purified by flash 
chromatography system (20 – 60% Ethyl Acetate/Hexanes) to afford 4.22 (0.72 g, 87%) as a clear 
and colorless oil: Rf = (0.25) (25% Ethyl Acetate/Hexanes); 1HNMR (600 MHz, CDCl3) δ 7.41 
(s, 5H), 3.81 (dd, J = 11.2, 7.3 Hz, 1H), 3.73 (dd, J = 11.3, 4.4 Hz, 1H), 2.99 (pd, J = 7.1, 4.5 Hz, 
1H), 1.28 (d, J = 7.2 Hz, 3H). 13C NMR (150 MHz, CDCl3) δ 201.53, 134.54, 129.49, 129.21, 
127.16, 64.69, 50.30, 14.32. HRMS (ESI) calcd for C10H12O2S [M+H] 197.0631, found xx. 
 
 
S-phenyl (S)-3-((tert-butoxycarbonyl)amino)-2-methylpropanethioate (S7.8): To a 25 mL 
flask was added xx (1 eq, 0.98 mmol, 0.20 g) and Ph2S2 (1.1 eq, 1.01 mmol, 0.236 g) in CH2Cl2 
(9.8 mL, 0.1M) and cooled to 0 °C. PBu3 (distilled, 1.1 eq, 1.01 mmol, 270 uL) was added slowly, 
the reaction was stirred for 10 min before it was quenched with sat. NaHCO3. The organics were 
separated, extracted with CH2Cl2 (3 x 20 mL), dried over sodium sulfate, and concentrated. The 
crude product was purified by flash chromatography system (2 – 40% Ethyl Acetate/Hexanes) to 
afford xx (225 mg, 77% yield) as a clear and colorless oil: Rf  = 0.25 (25% Ethyl Acetate/Hexanes); 
1H NMR (400 MHz, CDCl3) δ 7.42 (s, 5H), 4.88 (s, 1H), 3.43 – 3.23 (m, 2H), 3.11 – 2.97 (m, 
1H), 1.44 (s, 9H), 1.28 (d, J = 7.1 Hz, 3H). 13C NMR (150 MHz, CDCl3) δ 201.15, 155.90, 134.48, 
129.45, 129.19, 127.27, 79.44, 48.33, 43.20, 28.35, 15.51. HRMS (ESI) calcd for C15H21NO3S 
[M+H] 296.1315, found 296.1311. 
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S-phenyl (S)-3-amino-2-methylpropanethioate HCl (4.23): To a 4 dram vial with S4.3 was 
added 5 mL of 4M HCl/Dioxane, and the mixture was stirred for 30 min, concentrated and used 
directly.  
 
 
(4R,5R,E)-5-((tert-butyldimethylsilyl)oxy)-4-methylhept-2-enoic acid (4.26): To a long tube 
under N2 was added Hoveyda Grubbs II (0.03 eq, 0.03 mmol, 0.019 g), 2-pentenoic acid (1 eq, 1.0 
mmol, 0.10 g), and 4.25 (4 eq, 4.0 mmol, 0.913 g) in DCM (2 mL, 0.5 M). This was allowed to 
reflux for 12 h, cooled, the solvent was removed under reduced pressure and purified directly by 
flash chromatography (1 – 25% Ethyl Acetate/Hexane + 1% AcOH) to afford 4.26 (0.231 g, 88% 
yield) as a white solid: Rf = 0.4 (20% Ethyl Acetate/Hexanes); 1H NMR (600 MHz, CDCl3) δ 7.11 
(dd, J = 15.8, 7.4 Hz, 1H), 5.80 (d, J = 15.8 Hz, 1H), 3.55 (q, J = 5.5 Hz, 1H), 2.49 (dq, J = 13.0, 
7.0 Hz, 1H), 1.48 (ddd, J = 13.2, 7.2, 5.5 Hz, 1H), 1.38 (dp, J = 14.1, 7.2 Hz, 1H), 1.03 (d, J = 6.8 
Hz, 3H), 0.88 (s, 9H), 0.86 (t, J = 7.4 Hz, 3H), 0.03 (s, 3H), 0.03 (s, 3H). 13C NMR (150 MHz, 
CDCl3) δ 171.63, 155.04, 119.92, 76.20, 41.37, 26.82, 25.84, 18.09, 13.88, 9.64, -4.38, -4.56. 
HRMS (ESI) calcd for C14H28O3Si [M-H] 271.1755, found 271.1759. 
 
 
(S)-2-methyl-3-oxo-3-(phenylthio)propyl(4R,5R,E)-5-((tert-butyldimethylsilyl)oxy)-4-
methylhept-2-enoate (S7.9): To an open flask was added 4.22 (1 eq, 0.31 mmol, 0.060 g) and 
4.26 (1 eq, 0.31 mmol, 0.083 g) suspended in CH2Cl2 (3.1 mL, 0.1M). The mixture was treated 
with DCC (1.2 eq, 0.37 mmol, 0.072 g) and DMAP (0.1 eq, 0.03 mmol, 0.004 g) and stirred at rt 
overnight. The reaction was filtered through celite and concentrated. The crude product was 
purified by flash chromatography system (2 – 40% Ethyl Acetate/Hexanes) to afford S7.9 (43 mg, 
33% yield): Rf = 0.6 (10% Ehtyl Acetate/Hexanes); 1H NMR (600 MHz, CDCl3) δ 7.40 (d, J = 
PhS NHBoc
O
S7.8
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O
Cl
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+ HGII, DCM
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0.6 Hz, 5H), 7.04 (dd, J = 15.8, 7.4 Hz, 1H), 5.81 (dd, J = 15.8, 1.3 Hz, 1H), 4.34 (dd, J = 11.1, 
7.8 Hz, 1H), 4.24 (dd, J = 11.0, 5.6 Hz, 1H), 3.54 (dt, J = 6.5, 5.1 Hz, 1H), 3.15 (pd, J = 7.1, 5.4 
Hz, 1H), 2.52 – 2.43 (m, 1H), 1.46 (dtd, J = 14.8, 7.4, 5.2 Hz, 1H), 1.38 (dp, J = 14.2, 7.3 Hz, 1H), 
1.29 (d, J = 7.0 Hz, 3H), 1.02 (d, J = 6.8 Hz, 3H), 0.88 (s, 9H), 0.85 (t, J = 7.4 Hz, 3H), 0.03 (s, 
3H), 0.02 (s, 3H). 3C NMR (150 MHz, CDCl3) δ 198.85, 166.20, 152.97, 134.41, 129.40, 129.15, 
127.30, 120.11, 76.28, 65.23, 47.37, 41.32, 26.81, 25.86, 18.10, 14.51, 14.04, 9.62, -4.38, -4.50. 
HRMS (ESI) calcd for C24H38O4SSi [M+H] 451.2333, found 451.2334. 
 
 
S-phenyl (S)-3-((4R,5R,E)-5-((tert-butyldimethylsilyl)oxy)-4-methylhept-2-enamido)-2-
methylpropanethioate (S7.10): To an open flask was added acid 4.26 suspended in CH2Cl2 (2 
mL, 0.1M) and treated with HATU (1.2 eq, 0.24 mmol, 0.093 g). Deprotected amine was 
suspended in DCM (0.5 mL) and DIPEA (2.5 eq, 0.51 mmol, 88 uL) and the mixture was added 
to the acid portion and stirred at rt overnight. The reaction was diluted with water and extracted 
with DCM (3 x 20 mL), organics combined, dried over Na2SO4, and concentrated. The crude 
product was purified by flash chromatography system (8 – 40% Ethyl Acetate/Hexanes) to afford 
S7.10 (58 mg, 66% yield) as a colorless oil: Rf = 0.4 (20% Ethyl Acetate/Hexanes); 1H NMR (600 
MHz, CDCl3) δ 7.41 (tq, J = 7.0, 3.7, 2.9 Hz, 5H), 6.83 (dd, J = 15.4, 7.4 Hz, 1H), 5.84 (s, 1H), 
5.69 (dd, J = 15.5, 1.3 Hz, 1H), 3.60 (ddd, J = 13.8, 6.4, 4.2 Hz, 1H), 3.51 (q, J = 5.5 Hz, 1H), 3.46 
(ddd, J = 13.9, 8.0, 6.0 Hz, 1H), 3.10 (pd, J = 7.3, 4.1 Hz, 1H), 2.53 – 2.30 (m, 1H), 1.46 (ddd, J 
= 14.1, 7.4, 5.3 Hz, 1H), 1.39 (tq, J = 14.1, 7.2, 6.4 Hz, 1H), 1.31 (d, J = 7.2 Hz, 3H), 0.99 (d, J = 
6.8 Hz, 3H), 0.87 (s, 9H), 0.84 (t, J = 7.4 Hz, 3H), 0.02 (s, 3H), 0.02 (s, 3H). 13C NMR (150 MHz, 
CDCl3) δ 201.77, 166.04, 147.86, 134.49, 129.53, 129.22, 127.14, 122.74, 76.34, 47.94, 41.67, 
41.00, 26.84, 25.88, 18.12, 15.82, 14.43, 9.47, -4.38, -4.45. HRMS (ESI) calcd for C24H39NO3SSi 
[M+H] 450.2493, found 450.2493. 
 
(S)-2-methyl-3-oxo-3-(phenylthio)propyl (4R,5R,E)-5-hydroxy-4-methylhept-2-enoate 
(4.28): The TBS protected S7.9 was suspended in 1 mL of CH3CN in a polyethylene vial and 
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treated with aq. HF (48%, 250 uL). The reaction was monitored by TLC and upon completion it 
was diluted with CH2Cl2 (5 mL) and carefully quenched with sat. NaHCO3 (until pH was acidic). 
The aqueous layer was extracted with CH2Cl2 (3 x 10 mL), organics combined, dried over Na2SO4, 
and concentrated. The crude product was purified by flash chromatography system (12 – 40% 
Ethyl Acetate/Hexanes) to afford 4.28 (0.035 g, 82% yield) as a clear and colorless oil: Rf = 0.6 
(33% Ethyl Acetate/Hexanes); 1H NMR (600 MHz, CDCl3) δ 7.40 (s, 5H), 6.98 (dd, J = 15.8, 7.8 
Hz, 1H), 5.87 (dd, J = 15.7, 1.3 Hz, 1H), 4.33 (dd, J = 11.0, 7.9 Hz, 1H), 4.25 (dd, J = 11.0, 5.6 
Hz, 1H), 3.48 (h, J = 4.3 Hz, 1H), 3.21 – 3.06 (m, 1H), 2.49 – 2.35 (m, 1H), 1.55 – 1.48 (m, 1H), 
1.41 – 1.33 (m, 1H), 1.29 (d, J = 7.0 Hz, 3H), 1.09 (d, J = 6.8 Hz, 3H), 0.95 (t, J = 7.4 Hz, 3H). 
13C NMR (150 MHz, CDCl3) δ 198.88, 166.04, 152.00, 129.45, 129.19, 127.23, 120.90, 75.85, 
65.35, 47.33, 42.23, 27.37, 14.50, 13.96, 10.22. HRMS (ESI) calcd for C18H24O4S [M+H] 
337.1468, found 337.1466. 
 
 
S-phenyl (S)-3-((4R,5R,E)-5-hydroxy-4-methylhept-2-enamido)-2-methylpropanethioate 
(4.27): The TBS protected xx was suspended in 1 mL of CH3CN in a polyethylene vial and treated 
with aq. HF (48%, 250 uL). The reaction was monitored by TLC and upon completion it was 
diluted with CH2Cl2 (5 mL) and carefully quenched with sat. NaHCO3 (until pH was acidic). The 
aqueous layer was extracted with CH2Cl2 (3 x 10 mL), organics combined, dried over Na2SO4, and 
concentrated. The crude product was purified by flash chromatography system (20 – 60% Ethyl 
Acetate/Hexanes) to afford 4.27 (0.045 g, 85% yield) as a clear and colorless oil: Rf = 0.55 (50% 
Ethyl Acetate/Hexanes);  1H NMR (600 MHz, CDCl3) δ 7.40 (dq, J = 7.5, 4.1 Hz, 5H), 6.80 (dd, 
J = 15.4, 7.8 Hz, 1H), 6.01 (t, J = 6.3 Hz, 1H), 5.76 (dd, J = 15.4, 1.3 Hz, 1H), 3.57 (ddd, J = 13.8, 
6.4, 4.3 Hz, 1H), 3.49 – 3.39 (m, 2H), 3.09 (pd, J = 7.3, 4.2 Hz, 1H), 2.38 (hept, J = 6.3 Hz, 1H), 
1.51 (dqd, J = 14.9, 7.5, 3.8 Hz, 1H), 1.43 – 1.32 (m, 1H), 1.30 (d, J = 7.2 Hz, 3H), 1.05 (d, J = 
6.8 Hz, 3H), 0.93 (t, J = 7.4 Hz, 3H). 13C NMR (150 MHz, CDCl3) δ 201.75, 165.95, 147.14, 
134.49, 129.56, 129.24, 127.08, 123.52, 75.87, 47.87, 41.93, 41.73, 27.25, 15.82, 13.99, 10.30. 
HRMS (ESI) calcd for C18H25NO3S [M+H]336.1628, found 336.1622. 
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methyl 5-(methoxy(methyl)amino)-5-oxopentanoate (4.33): A solution of glutaric anhydride (1 
eq, 42.82 mmol, 5.0 g) and N,O-dimethylhydroxylamine hydrochloride (1 eq, 43.82 mmol, 4.27 
g) in CH2Cl2 (0.4M, 110 mL) was cooled to 0 °C and treated dropwise with pyridine (2.2 eq, 96.41 
mmol, 7.78 mL). The resulting solution was warmed to rt and stirred overnight. The reaction was 
then concentrated under reduced pressure. The crude product was dissolved in 4:1 Toluene/MeOH 
(15 mL) and treated dropwise with TMS diazomethane (2M in diethyl ether, 10 mL). Upon 
persistence of yellow color, the reaction was quenched with a 10% Acetic Acid in CH2Cl2. This 
was concentrated under reduced pressure and the crude product was purified by flash 
chromatography system (30 – 80% Ethyl Acetate/Hexanes) to afford xx (6.05 g, 80% yield); 1H 
NMR (400 MHz, CDCl3) δ 3.66 (d, J = 0.8 Hz, 3H), 3.66 (s, 3H), 3.16 (s, 3H), 2.48 (t, J = 7.3 Hz, 
2H), 2.39 (t, J = 7.2 Hz, 2H), 1.95 (p, J = 7.3 Hz, 2H). 13C NMR (100 MHz, CDCl3) δ 173.69, xx 
61.19, 51.51, 33.22, 30.82, 19.76. HRMS (ESI) calcd for C8H15NO4 [M+H] 190.1074, found 
190.1070. 
 
 
methyl 5-oxohept-6-enoate (4.34): To a flame dried 25 mL flask under N2 was added 4.33 (1 eq, 
1.32 mmol, 0.25 g) in dry THF (0.2 M, 6.5 mL) and the mixture was cooled to 0 °C. Vinyl 
Magnesium Bromide (0.8 M THF, freshly titrated, 1.2 eq, 1.98 mL) was added slowly and the 
reaction was allowed to stir at 0 °C for 30 min. The reaction was quenched with half 0.5 N HCl 
(10 mL) and the aqueous layer was extracted with CH2Cl2 (3x20 mL), organics combined, dried 
over Na2SO4, and concentrated. The crude product was purified by flash chromatography system 
(10 – 50% Ethyl Acetate/Hexanes) to afford 4.34 (105 mg, 51% yield) as a clear and colorless oil 
(being careful not to pull this off on a high vacuum as it is volatile): Rf = 0.3 (25% Ethyl 
Acetate/Hexanes);  1H NMR (400 MHz, CDCl3) δ 6.34 (dd, J = 17.7, 10.4 Hz, 1H), 6.22 (dd, J = 
17.7, 1.3 Hz, 1H), 5.84 (dd, J = 10.4, 1.3 Hz, 1H), 3.67 (s, 3H), 2.67 (t, J = 7.2 Hz, 2H), 2.37 (t, J 
= 7.2 Hz, 2H), 1.95 (p, J = 7.2 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 199.87, 173.60, 136.42, 
O OO 1. Pyridien, CH2Cl2 2. TMSCHN2, Toluene/MeOH+
H
N O
Cl MeO
O
N O
O
4.29 4.31 4.33
MeO N
OO
MeO
OO
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128.26, 51.56, 38.33, 33.00, 18.96. 13C NMR (100 MHz, CDCl3) δ 199.87, 173.60, 136.42, 128.26, 
51.56, 38.33, 33.00, 18.96. HRMS (ESI) calcd for C8H12O3 [M+H] 157.0862, found 157.0866. 
 
 
methyl (8R,9R,E)-9-((tert-butyldimethylsilyl)oxy)-8-methyl-5-oxoundec-6-enoate (4.35): To a 
long tube under N2 was added Hoveyda Grubbs II (0.03 eq, 0.02 mmol, 0.012 g), ester 4.34 (1 eq, 
0.58 mmol, 0.09 g), and 4.25 (4 eq, 1.73 mmol, 0.395g) in DCM (2 mL, 0.5 M). This was allowed 
to reflux for 12 h, cooled, the solvent was removed under reduced pressure and purified directly 
by flash chromatography (1 – 15% Ethyl Acetate/Hexane) to afford 4.35 (0.152 g, 74% yield) as 
a colorless oil: Rf = 0.25 (10% Ethyl Acetate/Hexanes); 1H NMR (600 MHz, CDCl3) δ 6.86 (dd, 
J = 16.1, 7.3 Hz, 1H), 6.05 (dd, J = 16.1, 1.3 Hz, 1H), 3.65 (s, 3H), 3.54 (q, J = 5.4 Hz, 1H), 2.60 
(t, J = 7.2 Hz, 2H), 2.46 (dq, J = 13.2, 6.5 Hz, 1H), 2.35 (t, J = 7.3 Hz, 2H), 1.93 (p, J = 7.2 Hz, 
2H), 1.47 (ddd, J = 13.2, 7.5, 5.6 Hz, 1H), 1.35 (dp, J = 14.2, 7.2 Hz, 1H), 1.01 (d, J = 6.8 Hz, 
3H), 0.88 (s, 9H), 0.85 (t, J = 7.5 Hz, 3H), 0.03 (s, 3H), 0.01 (s, 3H). 13C NMR (150 MHz, CDCl3) 
δ 195.67, 169.71, 146.41, 125.61, 72.38, 47.58, 37.46, 34.66, 29.19, 22.83, 21.94, 15.24, 14.16, 
10.12, 5.71, -8.31, -8.43. HRMS (ESI) calcd for C19H36O4Si [M+H] 357.2456, found xx. 
 
 
(8R,9R,E)-9-((tert-butyldimethylsilyl)oxy)-8-methyl-5-oxoundec-6-enoic acid (4.36): 4.35 (1 
eq, 0.30 mmol, 0.106 g) was suspended in a 4:1 mixture of THF/H2O (43 mL, 0.1M) and treated 
with LiOH (3 eq, 0.89 mmol, 0.037 g) and stirred for 4 hours. The reaction was quenched with 1 
M HCl (50 mL) and the organics removed under reduced pressure. The aqueous layer was 
extracted with ethyl acetate (3 x 50 mL), organics combined, washed with brine, dried over 
Na2SO4, and concentrated. The crude product was purified by flash chromatography system (10 – 
40% Ethyl Acetate/Hexanes + 1% AcOH) to afford 4.36 (89 mg, 87% yield) as a clear and 
colorless oil: Rf = 0.15 (25% Ethyl Acetate/Hexane) 1H NMR (600 MHz, CDCl3) δ 6.87 (dd, J = 
16.1, 7.3 Hz, 1H), 6.06 (dd, J = 16.1, 1.3 Hz, 1H), 3.55 (q, J = 5.5 Hz, 1H), 2.63 (t, J = 7.2 Hz, 
2H), 2.47 (dp, J = 13.1, 6.3 Hz, 1H), 2.41 (t, J = 7.2 Hz, 2H), 2.16 (d, J = 0.7 Hz, 3H), 1.98 – 1.87 
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(m, 2H), 1.47 (ddd, J = 13.3, 7.4, 5.5 Hz, 1H), 1.35 (dp, J = 14.1, 7.2 Hz, 1H), 1.01 (d, J = 6.8 Hz, 
3H), 0.88 (s, 9H), 0.85 (t, J = 7.4 Hz, 3H), 0.03 (s, 2H), 0.01 (s, 3H). 13C NMR (150 MHz, CDCl3) 
δ 195.64, 174.68, 146.63, 125.56, 72.37, 37.47, 34.51, 29.03, 28.95, 26.98, 22.84, 22.84, 14.94, 
14.15, 10.13, 5.73, -8.30, -8.50. HRMS (ESI) calcd for C18H34O4Si [M+H] 343.2299, found 
343.2292. 
 
 
S-phenyl (8R,9R,E)-9-((tert-butyldimethylsilyl)oxy)-8-methyl-5-oxoundec-6-enethioate 
(S7.11): To a 25 mL flask was added 4.36 (1 eq, 0.37 mmol, 0.126 g) and Ph2S2 (1.1 eq, 0.4 mmol, 
0.088 g) in CH2Cl2 (4 mL, 0.1M) and cooled to 0 °C. PBu3 (distilled, 1.1 eq, 0.40 mmol, 100 uL) 
was added slowly, the reaction was stirred for 10 min before it was quenched with sat. NaHCO3. 
The organics were separated, extracted with CH2Cl2 (3 x 20 mL), dried over sodium sulfate, and 
concentrated. The crude product was purified by flash chromatography system (0 – 10% Ethyl 
Acetate/Hexanes) to afford S7.11 (0.042 g, 82% yield) as a clear and colorless oil: Rf = 0.6 (10% 
Ethyl Acetate/Hexanes).  
 
 
S-phenyl (8R,9R,E)-9-hydroxy-8-methyl-5-oxoundec-6-enethioate (4.37): The TBS protected 
S7.11 was suspended in 1 mL of CH3CN in a polyethylene vial and treated with aq. HF (48%, 250 
uL). The reaction was monitored by TLC and upon completion it was diluted with CH2Cl2 (5 mL) 
and carefully quenched with sat. NaHCO3 (until pH was acidic). The aqueous layer was extracted 
with CH2Cl2 (3 x 10 mL), organics combined, dried over Na2SO4, and concentrated. The crude 
product was purified by flash chromatography system (12 – 40% Ethyl Acetate/Hexanes) to afford 
4.37 (0.036, 92%) as a clear and colorless oil: Rf = 0.3 (33% Ethyl Acetate/Hexanes);1H NMR 
(600 MHz, CDCl3) δ 7.40 (s, 5H), 6.82 (dd, J = 16.0, 7.7 Hz, 1H), 6.11 (dd, J = 16.0, 1.2 Hz, 1H), 
3.49 (dq, J = 9.1, 4.8 Hz, 1H), 2.72 (t, J = 7.1 Hz, 2H), 2.66 (t, J = 7.1 Hz, 2H), 2.42 (h, J = 6.8, 
6.3 Hz, 1H), 2.01 (p, J = 7.1 Hz, 2H), 1.57 – 1.48 (m, 2H), 1.38 (ddt, J = 16.1, 14.5, 7.4 Hz, 1H), 
1.08 (d, J = 6.8 Hz, 3H), 0.95 (t, J = 7.4 Hz, 3H).13C NMR (150 MHz, CDCl3) δ 199.27, 197.22, 
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149.42, 134.44, 129.93, 129.38, 129.17, 127.62, 75.90, 42.50, 42.28, 38.65, 27.40, 19.67, 13.91, 
10.25. HRMS (ESI) calcd for C18H24O3S [M+H] 321.1519, found 321.1516. 
 
 
methyl 5-(methoxy(methyl)amino)-2,2-dimethyl-5-oxopentanoate (S7.13): A solution of 
dimethyl glutaric anhydride (1 eq, 7.03 mmol, 1.0 g) and N,O-dimethylhydroxylamine 
hydrochloride (1 eq, 7.03 mmol, 1.0 g) in CH2Cl2 (0.4M, 17 mL) was cooled to 0 °C and treated 
dropwise with pyridine (2.2 eq, 15.48 mmol, 1.25 mL). The resulting solution was warmed to rt 
and stirred overnight. The reaction was then concentrated under reduced pressure. The crude 
product was dissolved in 4:1 Toluene/MeOH (15 mL) and treated dropwise with TMS 
diazomethane (2M in diethyl ether, 3 mL). Upon persistence of yellow color, the reaction was 
quenched with a 10% Acetic Acid in CH2Cl2. This was concentrated under reduced pressure and 
the crude product was purified by flash chromatography system (30 – 70% Ethyl Acetate/Hexanes) 
to afford S7.13 (1.36 g, 90% yield) as a clear and colorless oil: Rf = 0.65 (50% Ethyl 
Acetate/Hexanes); 1H NMR (600 MHz, CDCl3) δ 3.66 (s, 3H), 3.65 (s, 3H), 3.15 (s, 3H), 2.36 (t, 
J = 8.4 Hz, 2H), 1.93 – 1.80 (m, 2H), 1.19 (s, 6H). 13C NMR (150 MHz, CDCl3) δ 177.91, 174.02, 
61.18, 51.75, 41.77, 34.97, 27.73, 25.08. HRMS (ESI) calcd for C10H19NO4 [M+H] 218.1387, 
found 218.1288. 
 
 
methyl 2,2-dimethyl-5-oxohept-6-enoate (S7.14): To a flame dried 25 mL flask under N2 was 
added S7.13 (1 eq, 0.81 mmol, 0.175 g) in dry THF (0.2 M, 4 mL) and the mixture was cooled to 
0 °C. Vinyl Magnesium Bromide (0.8 M THF, freshly titrated, 1.2 eq, 1.21 mL) was added slowly 
and the reaction was allowed to stir at 0 °C for 30 min. The reaction was quenched with half 0.5 
N HCl (10 mL) and the aqueous layer was extracted with CH2Cl2 (3x20 mL), organics combined, 
dried over Na2SO4, and concentrated. The crude product was purified by flash chromatography 
system (5 – 50% Ethyl Acetate/Hexanes) to afford S7.14 (90 mg, 62% yield) as a clear and 
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colorless oil (being careful not to pull this off on a high vacuum as it is volatile): Rf = 0.5 (25% 
Ethyl Acetate/Hexanes); 1H NMR (600 MHz, CDCl3) δ 6.32 (dd, J = 17.9, 10.4 Hz, 1H), 6.21 (d, 
J = 17.7 Hz, 1H), 5.81 (d, J = 10.6 Hz, 1H), 3.65 (d, J = 0.8 Hz, 3H), 2.57 – 2.51 (m, 2H), 1.87 – 
1.82 (m, 2H), 1.18 (s, 6H). 13C NMR (150 MHz, CDCl3) δ 200.14, 177.84, 136.33, 128.18, 51.81, 
41.67, 35.44, 34.12, 25.16. HRMS (ESI) calcd for C10H16O3 [M+H] 185.1172, found185.1172. 
 
 
methyl (8R,9R,E)-9-((tert-butyldimethylsilyl)oxy)-2,2,8-trimethyl-5-oxoundec-6-enoate 
(S7.15): To a long tube under N2 was added Hoveyda Grubbs II (0.03 eq, 0.01 mmol, 0.009 g), 
ester S7.14 (1 eq, 0.49 mmol, 0.09 g), and 4.25 (3 eq, 1.47 mmol, 0.335 g) in DCM (2 mL, 0.5 M). 
This was allowed to reflux for 12 h, cooled, the solvent was removed under reduced pressure and 
purified directly by flash chromatography (0 – 15% Ethyl Acetate/Hexane) to afford S7.15 (0.102 
g, 53% yield) as a colorless oil: Rf = 0.25 (10% Ethyl Acetate/Hexanes); 1H NMR (600 MHz, 
CDCl3) δ 6.85 (dd, J = 16.1, 7.3 Hz, 1H), 6.05 (d, J = 16.0 Hz, 0H), 3.65 (s, 3H), 3.54 (q, J = 5.5 
Hz, 1H), 2.52 – 2.46 (m, 2H), 2.50 – 2.42 (m, 1H), 1.87 – 1.80 (m, 2H), 1.52 – 1.41 (m, 1H), 1.41 
– 1.30 (m, 1H), 1.18 (s, 6H), 1.01 (d, J = 6.8 Hz, 3H), 0.88 (s, 9H), 0.85 (t, J = 7.4 Hz, 3H), 0.03 
(s, 3H), 0.02 (s, 3H). 13C NMR (150 MHz, CDCl3) δ 199.90, 177.90, 150.25, 129.48, 76.32, 51.78, 
41.68, 41.37, 35.63, 34.31, 26.78, 25.84, 25.14, 18.10, 14.05, 9.66, -4.33, -4.52. HRMS (ESI) 
calcd for C21H40O4Si [M+H] 385.2769, found xx. 
 
 
(8R,9R,E)-9-((tert-butyldimethylsilyl)oxy)-2,2,8-trimethyl-5-oxoundec-6-enoic acid (S7.16): 
Ester S7.15 (1 eq, 0.25 mmol, 0.095 g) was dissolved in 1,2 dichloroehtane  (2.4 mL, 0.1M) and 
after the addition of trimethyltin hydroxide (10 eq, 2.55 mmol, 0.304 g), the mixture was heated 
to 70 °C, and monitored by TLC until completion (~4 h). After completion, the reaction was cooled 
and concentrated. The residue was taken up in ethyl acetate (20 mL) and washed with 1N HCl (20 
mL), brine (20 mL), dried over Na2SO4, and concentrated. The crude concentrate was purified by 
flash chromatography system (5 – 50% Ethyl Acetate/Hexanes + 1% acetic acid) to afford S7.16 
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(75 mg, 83% yield): Rf = 0.1 (10% Ethyl Acetate/Hexanes + 1% AcOH);  1H NMR (400 MHz, 
CDCl3) δ 6.88 (dd, J = 16.2, 7.3 Hz, 1H), 6.07 (d, J = 16.1 Hz, 1H), 3.56 (q, J = 5.6 Hz, 1H), 2.62 
– 2.53 (m, 2H), 2.46 (dt, J = 13.6, 6.1 Hz, 2H), 1.92 – 1.82 (m, 2H), 1.54 – 1.41 (m, 1H), 1.45 – 
1.29 (m, 1H), 1.24 – 1.20 (m, 6H), 1.02 (d, J = 6.8 Hz, 3H), 0.89 (d, J = 0.9 Hz, 9H), 0.85 (d, J = 
7.4 Hz, 3H), 0.04 (s, 3H), 0.03 (s, 3H). HRMS (ESI) calcd for C20H38O4Si [M+H] 371.2612, found 
371.2610. 
 
 
S-phenyl (8R,9R,E)-9-((tert-butyldimethylsilyl)oxy)-2,2,8-trimethyl-5-oxoundec-6-
enethioate (S7.17): To a 25 mL flask was added S7.16 (1 eq, 0.09 mmol, 0.035 g) and Ph2S2 (1.1 
eq, 0.1 mmol, 0.023 g) in CH2Cl2 (1 mL, 0.1M) and cooled to 0 °C. PBu3 (distilled, 1.1 eq, 0.10 
mmol, 30 uL) was added slowly, the reaction was stirred for 10 min before it was quenched with 
sat. NaHCO3. The organics were separated, extracted with CH2Cl2 (3 x 20 mL), dried over sodium 
sulfate, and concentrated. The crude product was purified by flash chromatography system (0 – 
10% Ethyl Acetate/Hexanes) to afford S7.17 as a mixture of product and thiophenol byproducts: 
Rf = 0.6 (10% Ethyl Acetate/Hexanes). This was inseparable from thiophenol byproducts and was 
carried through to deprotection. 
 
 
S-phenyl (8R,9R,E)-9-hydroxy-2,2,8-trimethyl-5-oxoundec-6-enethioate (4.38): The TBS 
protected S7.17 was suspended in 1 mL of CH3CN in a polyethylene vial and treated with aq. HF 
(48%, 250 uL). The reaction was monitored by TLC and upon completion it was diluted with 
CH2Cl2 (5 mL) and carefully quenched with sat. NaHCO3 (until pH was acidic). The aqueous layer 
was extracted with CH2Cl2 (3 x 10 mL), organics combined, dried over Na2SO4, and concentrated. 
The crude product was purified by flash chromatography system (12 – 40% Ethyl 
Acetate/Hexanes) to afford 7.38 (0.027 g, 81% yield) as a clear and colorless oil: Rf = 0.4 (10% 
Ethyl Acetate/Hexanes); 1H NMR (600 MHz, CDCl3) δ 7.44 – 7.33 (m, 5H), 6.82 (dd, J = 16.0, 
7.7 Hz, 1H), 6.11 (d, J = 15.9 Hz, 1H), 3.49 (dt, J = 9.0, 4.6 Hz, 1H), 2.60 – 2.53 (m, 2H), 2.42 (h, 
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J = 6.7 Hz, 1H), 1.99 – 1.94 (m, 2H), 1.55 – 1.47 (m, 1H), 1.42 – 1.33 (m, 1H), 1.32 (s, 6H), 1.07 
(d, J = 6.9 Hz, 3H), 0.95 (t, J = 7.4 Hz, 3H). 13C NMR (151 MHz, cdcl3) δ 204.03, 199.53, 149.36, 
134.92, 129.83, 129.25, 129.12, 127.69, 75.88, 49.64, 42.27, 35.77, 34.74, 27.39, 25.43, 13.87, 
10.27. HRMS (ESI) calcd for C20H28O3S [M+H] 349.1832, found 349.1831. 
 
3-oxabicyclo[3.3.1]nonane-2,4-dione (S7.19): 1,3-cyclohexanedicarboxylic acid (1 eq, 9.70 
mmol, 1.67 g) in acetic anhydride (0.5M, 20 mL) was heated to 140 °C and stirred for 10 h. The 
reaction was cooled and the solvent removed under reduced pressure. The residual white solid was 
dissolved in CH2Cl2, filtered, and concentrated, yielding S7.19 (1.27 g, 84% yield). 1H NMR (600 
MHz, CDCl3) δ 3.06 (d, J = 3.3 Hz, 2H), 2.29 – 2.19 (m, 1H), 2.14 – 2.04 (m, 2H), 1.88 – 1.81 (m, 
1H), 1.81 – 1.69 (m, 3H), 1.55 – 1.41 (m, 1H).13C NMR (150 MHz, CDCl3) δ 169.91, 36.41, 
28.56, 27.26, 19.99. HRMS (ESI) calcd for C8H10O3 [M+H] 155.2703, found 155.2705. 
 
 
methyl 3-(methoxy(methyl)carbamoyl)cyclohexane-1-carboxylate (S7.21): A solution of 
S7.20 anhydride (1 eq, 3.24 mmol, 0.5 g) and N,O-dimethylhydroxylamine hydrochloride (1 eq, 
3.24 mmol, 0.5 g) in CH2Cl2 (0.4M, 8 mL) was cooled to 0 °C and treated dropwise with pyridine 
(2.2 eq, 7.14 mmol, 0.58 mL). The resulting solution was warmed to rt and stirred overnight. The 
reaction was then concentrated under reduced pressure. The crude product was dissolved in 4:1 
Toluene/MeOH (15 mL) and treated dropwise with TMS diazomethane (2M in diethyl ether, 3 
mL). Upon persistence of yellow color, the reaction was quenched with a 10% Acetic Acid in 
CH2Cl2. This was concentrated under reduced pressure and the crude product was purified by flash 
chromatography system (30 – 70% Ethyl Acetate/Hexanes) to afford S7.21 (0.66 g, 89% yield) as 
a clear and colorless oil: Rf = 0.65 (50% Ethyl Acetate/Hexanes); 
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methyl 3-acryloylcyclohexane-1-carboxylate (S7.22): To a flame dried 25 mL flask under N2 
was added S7.21 (1 eq, 0.65 mmol, 0.150 g) in dry THF (0.2 M, 6 mL) and the mixture was cooled 
to 0 °C. Vinyl Magnesium Bromide (0.8 M THF, freshly titrated, 1.2 eq, 0.92 mL) was added 
slowly and the reaction was allowed to stir at 0 °C for 30 min. The reaction was quenched with 
half 0.5 N HCl (10 mL) and the aqueous layer was extracted with CH2Cl2 (3x20 mL), organics 
combined, dried over Na2SO4, and concentrated. The crude product was purified by flash 
chromatography system (5 – 50% Ethyl Acetate/Hexanes) to afford S7.22 (65 mg, 51% yield) as 
a clear and colorless oil (being careful not to pull this off on a high vacuum as it is volatile): Rf = 
0.5 (20% Ethyl Acetate/Hexanes); 1H NMR (600 MHz, CD3COCD3) δ 6.49 (dd, J = 17.5, 10.6 
Hz, 1H), 6.27 (dd, J = 17.5, 1.4 Hz, 1H), 5.81 (dd, J = 10.6, 1.4 Hz, 1H), 2.84 (tt, J = 12.1, 3.2 Hz, 
1H), 2.43 (tt, J = 12.4, 3.6 Hz, 1H), 2.07 – 2.01 (m, 2H), 1.96 (dtt, J = 14.9, 3.5, 1.9 Hz, 1H), 1.91 
– 1.83 (m, 2H), 1.50 – 1.37 (m, 2H), 1.31 (tdd, J = 13.2, 12.3, 3.5 Hz, 1H), 1.26 – 1.16 (m, 1H). 
13C NMR (150 MHz, CD3COCD3) δ 201.32, 174.91, 135.05, 127.35, 50.77, 46.43, 42.10, 30.50, 
28.46, 27.93, 24.67. HRMS (ESI) calcd for C11H16O3 [M+H] 197.1172, found 197.1179. 
 
 
methyl 3-((4R,5R,E)-5-((tert-butyldimethylsilyl)oxy)-4-methylhept-2-enoyl)cyclohexane-1-
carboxylate (S7.24): To a long tube under N2 was added Hoveyda Grubbs II (0.03 eq, 0.01 mmol, 
0.006 g), ester S7.23 (1 eq, 0.31 mmol, 0.060 g), and 4.25 (3 eq, 1.22 mmol, 0.279 g) in DCM (2 
mL, 0.5 M). This was allowed to reflux for 12 h, cooled, the solvent was removed under reduced 
pressure and purified directly by flash chromatography (0 – 15% Ethyl Acetate/Hexane) to afford 
xx (0.099 g, 82% yield) as a colorless oil: Rf = 0.2 (10% Ethyl Acetate/Hexanes); 1H NMR (600 
MHz, CD3COCD3) δ 6.95 (dd, J = 15.9, 7.4 Hz, 1H), 6.23 (dd, J = 16.0, 1.4 Hz, 1H), 3.70 (q, J = 
5.5 Hz, 1H), 3.62 (s, 3H), 2.76 (ttd, J = 12.1, 3.4, 1.9 Hz, 1H), 2.59 – 2.49 (m, 1H), 2.41 (ttd, J = 
12.4, 3.5, 1.3 Hz, 1H), 2.05 – 2.00 (m, 1H), 1.95 (dtd, J = 14.4, 3.5, 1.9 Hz, 1H), 1.91 – 1.80 (m, 
2H), 1.54 (dtd, J = 14.9, 7.4, 5.4 Hz, 1H), 1.48 – 1.36 (m, 3H), 1.31 (qd, J = 12.9, 3.5 Hz, 1H), 
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1.23 (qt, J = 12.6, 4.2 Hz, 1H), 1.06 (d, J = 6.8 Hz, 3H), 0.92 (s, 9H), 0.89 (t, J = 7.4 Hz, 3H), 0.09 
(s, 3H), 0.08 (s, 3H). 13C NMR (150 MHz, CD3COCD3) δ 200.75, 174.92, 149.45, 127.92, 76.30, 
50.75, 46.92, 42.24, 41.15, (30.77 or 30.69), 28.48, (28.17 or 28.09), 26.65, 25.40, 24.75, 17.79, 
13.43, 9.06, -5.03, -5.21. HRMS (ESI) calcd for C22H40O4Si [M+H] 397.2769, found 397.2772. 
 
 
3-((4R,5R,E)-5-((tert-butyldimethylsilyl)oxy)-4-methylhept-2-enoyl)cyclohexane-1-
carboxylic acid (S7.25): S7.24 (1 eq, 0.13 mmol, 0.052 g) was suspended in a 4:1 mixture of 
THF/H2O (1 mL, 0.1M) and treated with LiOH (3 eq, 0.39 mmol, 0.017 g) and stirred for 4 hours. 
The reaction was quenched with 1 M HCl (2 mL) and the organics removed under reduced 
pressure. The aqueous layer was extracted with ethyl acetate (3 x 10 mL), organics combined, 
washed with brine, dried over Na2SO4, and concentrated. The crude product was purified by flash 
chromatography system (10 – 30% Ethyl Acetate/Hexanes + 1% AcOH) to afford S7.25 (20 mg, 
40% yield) as a clear and colorless oil: Rf = 0.15 (10% Ethyl Acetate/Hexanes + 1% AcOH);  ; 1H 
NMR (400 MHz, CD3COCD3) δ 6.96 (dd, J = 15.9, 7.3 Hz, 1H), 6.24 (dd, J = 16.0, 1.4 Hz, 1H), 
3.70 (dt, J = 6.4, 5.1 Hz, 1H), 2.77 (tt, J = 11.8, 2.6 Hz, 2H), 2.55 (h, J = 6.7 Hz, 1H), 2.39 (tt, J = 
12.2, 4.0 Hz, 1H), 2.12 – 1.95 (m, 1H), 1.94 – 1.81 (m, 2H), 1.62 – 1.17 (m, 6H), 1.06 (d, J = 6.8 
Hz, 3H), 0.92 (s, 9H), 0.90 (t, J = 7.5 Hz, 7H), 0.08 (s, 3H), 0.08 (s, 3H). HRMS (ESI) calcd for 
C21H38O4Si [M+H] 383.2612, found 383.2612. 
 
 
S-phenyl 3-((4R,5R,E)-5-((tert-butyldimethylsilyl)oxy)-4-methylhept-2-enoyl)cyclohexane-1-
carbothioate (S7.26): To a 25 mL flask was added xx (1 eq, 0.05 mmol, 0.018 g) and Ph2S2 (1.1 
eq, 0.05 mmol, 0.011 g) in CH2Cl2 (1 mL, 0.1M) and cooled to 0 °C. PBu3 (distilled, 1.1 eq, 0.05 
mmol, 15 uL) was added slowly, the reaction was stirred for 10 min before it was quenched with 
sat. NaHCO3. The organics were separated, extracted with CH2Cl2 (3 x 10 mL), dried over sodium 
sulfate, and concentrated. The crude product was purified by flash chromatography system (0 – 
10% Ethyl Acetate/Hexanes) to afford S7.26 as a mixture of product and thiophenol byproducts: 
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Rf = 0.6 (10% Ethyl Acetate/Hexanes). This was inseparable from thiophenol byproducts and was 
carried through to deprotection. 
 
 
S-phenyl 3-((4R,5R,E)-5-hydroxy-4-methylhept-2-enoyl)cyclohexane-1-carbothioate (4.39): 
The TBS protected S7.26 was suspended in 1 mL of CH3CN in a polyethylene vial and treated 
with aq. HF (48%, 250 uL). The reaction was monitored by TLC and upon completion it was 
diluted with CH2Cl2 (5 mL) and carefully quenched with sat. NaHCO3 (until pH was acidic). The 
aqueous layer was extracted with CH2Cl2 (3 x 10 mL), organics combined, dried over Na2SO4, and 
concentrated. The crude product was purified by flash chromatography system (5 – 25% Ethyl 
Acetate/Hexanes) to afford 4.39 (0.09 g, 74% yield) as a clear and colorless oil: Rf = 0.4; 1H NMR 
(400 MHz, CD3COCD3) δ 7.49 – 7.37 (m, 5H), 6.94 (dd, J = 15.9, 8.0 Hz, 1H), 6.23 (dd, J = 15.9, 
1.2 Hz, 1H), 3.69 (d, J = 5.7 Hz, 1H), 3.45 (td, J = 9.1, 5.5 Hz, 1H), 2.87 (tt, J = 12.1, 3.3 Hz, 1H), 
2.80 – 2.75 (m, 1H), 2.50 – 2.35 (m, 1H), 2.11 (d, J = 14.1 Hz, 1H), 1.99 – 1.83 (m, 2H), 1.61 – 
1.17 (m, 7H), 1.09 (d, J = 6.8 Hz, 3H), 0.94 (t, J = 7.4 Hz, 3H). HRMS (ESI) calcd for C21H28O3S 
[M+H] 361.1832, found 361.1833. 
 
 
(2R,3R)-3-((tert-butyldimethylsilyl)oxy)-2-methylpentyl 4-methylbenzenesulfonate (S7.27): 
To a stirred solution of alcohol (1 eq, 3.44 mmol, 0.80 g) in pyridine (100 eq, 28 mL) was added 
p-toluenesulfonyl chloride (1.3 eq, 4.47 mmol, 0.85 g) at 0 °C. The reaction was warmed to rt and 
stirred for 3 h, the reaction was quenching with sat. NH4Cl (30 mL) and concentrated under 
reduced pressure. The remaining oil was diluted with water and Ethyl Acetate and the aqueous 
layer was extracted (3 x 30 mL), organics combined, dried over Na2SO4 and concentrated. The 
crude product was purified by flash chromatography system (2 – 15% hexane/Ethyl Acetate) to 
afford S7.27 (1.13g, 85% yield) as a pale yellow oil: Rf = 0.7 (10% Ethyl Acetate/Hexanes);  1H 
NMR (400 MHz, CDCl3) δ 7.78 (d, J = 8.2 Hz, 2H), 7.33 (d, J = 8.0 Hz, 2H), 4.00 (dd, J = 9.2, 
PhS
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6.3 Hz, 1H), 3.84 (dd, J = 9.2, 7.4 Hz, 1H), 3.57 (td, J = 6.7, 3.0 Hz, 1H), 2.44 (s, 3H), 1.93 (qd, J 
= 6.8, 3.0 Hz, 1H), 1.50 – 1.28 (m, 2H), 0.82 (d, J = 7.0 Hz, 4H), 0.80 (s, 9H), 0.77 (d, J = 7.5 Hz, 
3H), -0.00 (s, 3H), -0.06 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 144.58, 133.11, 129.76, 127.92, 
73.21, 73.05, 36.88, 26.60, 25.77, 21.60, 17.98, 10.41, 10.08, -4.20, -4.87. HRMS (ESI) calcd for 
C19H34O4SSi [M+H] 387.2020, found387.2022. 
 
 
(3R,4R)-4-((tert-butyldimethylsilyl)oxy)-3-methylhexanenitrile (4.42): To a flame dried flask 
under N2 was added tosylate (1 eq, 2.92 mmol, 1.13 g) in anhydrous DMSO (20 mL)  and treated 
with a solution of NaCN (4 eq, 11.69 mmol, 0.573) in DMSO (10 mL). The reaction was then 
heated to 60 °C for 12h. Upon completion of the reaction, it was cooled, diluted with water and 
the aqueous layer extracted with Et2O (3 x 25 mL). The organics were combined, dried over 
Na2SO4, concentrated under reduced pressure and purified by flash purification system (0 – 10% 
Ethyl Acetate/Hexanes) to afford 4.42 (577 mg, 81%) as a clear and colorless oil: Rf = 0.75 (10% 
Ethyl Acetate/Hexanes); 1H NMR (600 MHz, CDCl3) δ 3.59 (td, J = 6.5, 3.2 Hz, 1H), 2.43 (dd, J 
= 16.6, 6.3 Hz, 1H), 2.20 (dd, J = 16.7, 8.3 Hz, 1H), 2.05 – 1.95 (m, 1H), 1.52 – 1.34 (m, 2H), 1.00 
(d, J = 6.9 Hz, 3H), 0.89 (s, 9H), 0.86 (t, J = 7.5 Hz, 3H), 0.07 (d, J = 1.2 Hz, 6H). 13C NMR (150 
MHz, CDCl3) δ 75.10, 35.05, 26.07, 25.81, 20.81, 18.05, 13.52, 10.06, -4.23, -4.68. HRMS (ESI) 
calcd for C13H27NOSi [M+H] 242.1935, found 242.1929. 
 
 
(2S,3R)-3-((tert-butyldimethylsilyl)oxy)-2-methylpentanal (S2.28): To a flame dried flask 
under N2 was added 4.42 (1 eq, 0.83 mmol, 0.201 g) in toluene (0.2 M, 4.2 mL) and cooled to -78 
°C. A solution of DIBAL (2M in Hexanes, 1.05 eq, 0.87 mL) was added and the reaction was 
stirred at -78 °C for 4 h. The solution was then warmed to 0 °C and poured into a mixture of 
potassium sodium tartrate (20 mL) and Et2O (20 mL) followed by stirring for 1 h until the phases 
became almost clear. The aqueous layer was extracted with Et2O (3 x 40 mL), organics combined, 
TsO
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NC
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4.42
NC
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O
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dried over sodium sulfate and concentrated. The crude product was purified by flash 
chromatography system (0 – 5% Ether/Pentane) to afford S2.28 (126 mg, 62% yield) as a clear 
and colorless oil: Rf = 0.5 (5% Ethyl Acetate/Hexanes).  1H NMR (400 MHz, CDCl3) δ 9.49 (t, J 
= 1.9 Hz, 1H), 3.35 (td, J = 6.7, 3.5 Hz, 1H), 2.31 (dd, J = 16.7, 4.9 Hz, 1H), 2.21 – 2.03 (m, 1H), 
1.88 (ddd, J = 16.6, 8.5, 2.1 Hz, 1H), 1.37 – 1.21 (m, J = 6.6 Hz, 2H), 1.00 (s, 9H), 0.83 (t, J = 7.4 
Hz, 3H), 0.78 (d, J = 6.9 Hz, 3H), 0.05 (s, 3H), 0.03 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 
200.42, 127.85, 127.62, 76.50, 46.89, 32.34, 25.81, 18.02, 14.41, 10.29, -4.51, -4.64. HRMS (ESI) 
calcd for C13H28O2Si [M+H] 245.1932, found xx. 
 
 
tert-butyldimethyl(((3R,4R)-4-methylhept-6-en-3-yl)oxy)silane (4.43): To a flame dried flask 
under N2 was added MePPh3Br (1.1 eq, 1.53 mmol, 0.55 g) and suspended in anhydrous THF (0.2 
M, 10 mL) and cooled to 0 °C. To this n-BuLi was added dropwise (the solution turned orange as 
the precipitant disappeared) and the reaction was allowed to warm to room temperature and stirred 
for a minimum of 1h. The flask was then recooled to -78 °C and a solution of aldehyde xx (1 eq, 
1.39 mmol, 0.34 g) in THF (5 mL) was added dropwise to the prepared ylide. The solution was 
stirred at -78 °C for 30 min, warmed to 0 °C and stirred for an additional 30 min at 0 °C. The 
reaction was quenched with half sat. NH4Cl and extracted with pentane (3x 40 mL), dried over 
Na2SO4 and concentrated. The crude product was purified by flash chromatography (0 – 5% 
Diethyl Ether/Pentane) to afford 4.43 (204 mg, 60% yield) as a clear and colorless oil: Rf = 0.9 
(5% Ethyl Acetate/Hexanes):  1H NMR (400 MHz, CDCl3) δ 5.78 (dddd, J = 16.9, 10.2, 7.7, 6.5 
Hz, 1H), 5.00 (d, J = 15.1 Hz, 2H), 4.97 (d, J = 6.9 Hz, 1H), 3.47 (td, J = 6.2, 3.5 Hz, 1H), 2.24 
(ddd, J = 12.4, 8.7, 4.6 Hz, 1H), 1.88 – 1.75 (m, 1H), 1.68 – 1.57 (m, 1H), 1.53 – 1.32 (m, 2H), 
0.89 (s, 9H), 0.87 (d, J = 12.5 Hz, 3H), 0.87 – 0.79 (m, 3H), 0.04 (s, 3H), 0.03 (s, 3H). 13C NMR 
(100 MHz, CDCl3) δ 138.34, 115.24, 76.81, 37.34, 37.15, 26.18, 25.93, 18.16, 13.89, 10.26, -4.19, 
-4.49. HRMS (ESI) calcd for C14H30OSi [M+H] 243.2139, found 243.2131. 
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*Synthesis previously described by Hansen et al.1  
 
 
 
(2S,4R,9R,10R,E)-10-((tert-butyldimethylsilyl)oxy)-2,4,9-trimethyl-5-oxododec-6-enoic acid 
(4.45): To a long tube under N2 was added Hoveyda Grubbs II (0.03 eq, 0.01 mmol, 0.006 g), Acid 
4.44 (1 eq, 0.31 mmol, 0.060 g), and 4.43 (3 eq, 1.22 mmol, 0.279 g) in DCM (2 mL, 0.5 M). This 
was allowed to reflux for 12 h, cooled, the solvent was removed under reduced pressure and 
purified directly by flash chromatography (0 – 15% Ethyl Acetate/Hexane) to afford 4.45 (0.099 
g, 82% yield) as a colorless oil: Rf = 0.2 (10% Ethyl Acetate/Hexanes);1H NMR (600 MHz,CD-
3COCD3) δ 6.91 (ddd, J = 15.8, 7.8, 6.9 Hz, 1H), 6.20 (dt, J = 15.8, 1.5 Hz, 1H), 3.59 (td, J = 6.3, 
3.4 Hz, 1H), 2.92 (dt, J = 14.2, 6.9 Hz, 1H), 2.51 – 2.39 (m, 2H), 2.09 – 2.05 (m, 1H), 1.87 – 1.75 
(m, 1H), 1.51 (ddd, J = 13.4, 7.5, 6.0 Hz, 1H), 1.45 (tt, J = 14.1, 7.2 Hz, 1H), 1.32 (ddd, J = 13.8, 
7.8, 6.2 Hz, 1H), 1.13 (d, J = 7.0 Hz, 3H), 1.06 (d, J = 6.8 Hz, 3H), 0.91 (s, 9H), 0.88 (t, J = 7.3 
Hz, 3H), 0.87 (d, J=7.0 Hz, 3H), 0.08 (s, 3H), 0.07 (s, 3H). 13C NMR (150 MHz, CD3COCD3) δ 
201.58, 146.34, 129.91, 76.61, 40.82, 37.02, 36.72, 36.65, 35.59, 25.98, 25.42, 17.81, 17.06, 15.80, 
13.47, 9.63, -4.91, -5.15. HRMS (ESI) calcd for C15H26O4 [M+H] 271.1904, found 271.1900. 
 
7.2 Pikromycin PKS Expression and Purification Protocols 
The cloning and expression of Pik AIII, Pik AIV, and Pik AIIITE as well as Pik AIIITE S148C 
have been reported previously as well as Juv E4 and Juv E5. Buffers used for all purifications 
include: 
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Buffers:  
[Lysis] –  HEPES (50 mM), NaCl (300 mM), imidazole (10 mM), glycerol (10% v/v), pH 8 
[Wash] – HEPES (50 mM), NaCl (300 mM), imidazole (30 mM), glycerol (10% v/v), pH 8 
[Elution] –  HEPES (50 mM), NaCl (300 mM), imidazole (300 mM), glycerol (10% v/v), pH 8 
[Storage] – HEPES (50 mM), NaCl (150 mM), glycerol (20% v/v), pH 7.2 
[Reaction Buffer] – Sodium Phosphate (800 mM), NaCl (150 mM), pH 7.2 
 
Bap1 pRARE cells were freshly transformed with the desired plasmid and grown overnight on 
LB agar plates supplemented with 50 ug/mL Kanamycin overnight at 37 °C. Multiple colonies 
were picked and grown in 15 mL of LB with kanamycin (50 ug/mL), and grown overnight at 37 
°C. The following morning, TB media (Kan 50 mg/L) were then inoculated with 4 mL of 
overnight culture and grown at 37 °C until OD600 reached 1.0. These were then flash cooled in 
ice baths for ~15 min until the internal temperature hit 20 °C, at which time the flasks were 
returned to a 20 °C shaker, and induced with IPTG (300 uL of 1 M solution) and shaken at 180 
RPM at 20 °C for 18 h. The cells were then pelleted at 6500 rpm (4 °C) for 30 min, and flash 
frozen for future purification.  
 
Frozen overexpression cultures were suspended in 5 mL of lysis buffer per gram of pellet and 
aloud to thaw at 4 °C with stirring. Cells were treated with 8 units/mL of benzonase and aloud to 
stir for 20 min prior to sonication (6 x 10s with 50 s rest periouds). Cellular debris was pelleted 
by centrifugation (55,000 x g, 25 min, 4 °C) and the supernatant was passed through a 0.45 uM 
filter and applied to the top of 5 mL of Ni-NTA resin, pre-equilibrated with wash buffer. This 
was allowed to gravity flow through, washed with 50 mL of wash buffer, and eluted with 15 mL 
of elution buffer. Fractions containing protein were assessed via their 280 nm absorbance and 
were concentrated using a 30 kDa centrifugal filter until volume reached 2.5 mL. These were 
then deslated on a storage buffer equilibrated PD-10 column, the concentration adjusted to 50 
uM, and flash frozen in liquid nitrogen prior to storage in the -80 °C.  
 
7.2.1 Enzymatic Reaction Experimental Procedures  
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General Analytical Enzymatic Reactions 
 
All Enzymatic reactions were performed at 50 uL volumes. To a PCR tube was added 12.5 uL 
reaction buffer, 26 uL water, NADP (50 mM, 0.5 uL), glucose-6-phosphate (500 mM, 1 uL), and 
glucose-6-phosphate dehydrogenase (100 miliunits/uL, 1 uL) which was allowed to sit at room 
temperature for 10 min. To this was added MeMal (500 mM, 2 uL), AIII (50 uM, 3 uL), AIV (50 
uM, 3 uL) and substrate in DMSO (50 mM, 1 uL). These were aloud to stand at rt for 2.5 hours. 
The reactions were quenched by the addition of 150 uL Methanol and clarified by centrifugation 
(17,000 x g 20 min, 4 °C). The supernatant was then loaded into an HPLC vial and analyzed via 
TOF-MS [Gradient from 20% - 100% Acetonitrile over 12 minutes. 
 
General Semi-Preparative Enzymatic Conditions  
To a 50 mL falcon tube was added phosphate buffer, water, NADP, glucose-6-phosphate, and 
glucose-6-phosphate dehydrogenase which was allowed to incubated at room temperature for 10 
min. To this was added Methyl Malonyl, desired PKS protein (AIIITE or AIII/AIV), and 
substrate prior to incubation at room temperature for 2.5 hours. The reaction was quenched by 
pouring into cold acetone (3x) and incubating at – 20 °C for 1 hour, filtered through celite, and 
the organics removed. The remaining aqueous layer was extracted with methylene chloride (3 x 
20 mL) and concentrated. The remaining residue was purified by reverse phase HPLC.  
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7.3 New Macrolactone Characterization  
 
Figure 7.1 HMBC correlations for amide narbonolide as blue arrows. 
 
Position	   H	   C	   COSY	   HMBC	  
1	   	  	   170.99	   	  	   	  	  
2	   3.78	  (q,	  J	  =	  7.1	  Hz,	  1H)	   48.17	   16	   1,	  3,	  16	  
3	   	  	   205.66	   	  	   	  	  
4	   2.55	  (p,	  J	  =	  7.0	  Hz,	  1H)	   50.29	   5,	  17	   3,	  5,	  6,	  17	  
5	   3.49	  (m,	  1H)	   72.24	   4,6	   7,	  4	  
6	   1.76	  (tq,	  J	  =	  7.1,	  3.7	  Hz,	  1H)	   37.32	   5,	  7',	  19	   	  	  
7	   3.29	  (dt,	  J	  =	  14.0,	  7.1	  Hz,	  1H)	   40.34	   6,	  7'',8	   9,6,19	  	  	   3.35	  (m,	  1H)	   7',8	   5	  
8	   6.98	  (s,	  1H)	   	  	   7',7''	   	  	  
9	   	  	   168.02	   	  	   	  	  
10	   5.97	  (dd,	  J	  =	  16.1,	  1.9	  Hz,	  1H)	   123.91	   11	   9,12	  
11	   6.67	  (dd,	  J	  =	  16.2,	  4.2	  Hz,	  1H)	   146.26	   10,	  12	   9,10,13,12,20	  
12	   2.77	  (m,	  1H)	   38.23	   11,	  13,20	   	  	  
13	   5.09	  (ddd,	  J	  =	  9.3,	  4.6,	  2.6	  Hz,	  1H)	   77.66	  
12,	  14',	  
14''	   	  	  
14	   1.64	  1.64	  (ddt,	  J	  =	  14.1,	  7.3,	  5.0	  Hz,	  1H)	   24.82	   13,	  15	   15	  	  	   1.71	  (ddt,	  J	  =	  14.9,	  9.8,	  7.4	  Hz,	  1H)	   13,	  15	   13,15	  
15	   0.90	  (d,	  J	  =	  7.1	  Hz,	  3H)	   9.92	   14',	  14''	   14',14''	  
16	   1.25	  (d,	  J	  =	  7.0	  Hz,	  3H)	   14.45	   2	   1,2,3	  
17	   1.06	  (d,	  J	  =	  7.0	  Hz,	  3H)	   12.16	   4	   3,4,5	  
18	   	  	   	  	   	  	   	  	  
19	   0.94	  (d,	  J	  =	  7.1	  Hz,	  3H)	   17.17	   6	   5,6,7	  
20	   1.09	  (d,	  J	  =	  6.9	  Hz,	  3H)	   8.93	   12	   11,12,13,14	  
 
Table 7.1 Amide narbonolide assignments and correlations.  
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Figure 7.2 HMBC correlations for ester narbonolide as blue arrows. 
 
Position	   H	   C	   COSY	   HMBC	  
1	   	  	   171.55	   	  	   	  	  
2	   3.3	  (q,	  J	  =	  7.1	  Hz,	  1H)	   49.51	   16	   1,	  16	  
3	   	  	   204.74	   	  	   	  	  
4	   2.45	  –	  2.35	  (m,	  1H)	   50.98	   5,	  17	   3,	  5,	  17	  
5	   3.91	  (t,	  J	  =	  5.5	  Hz,	  1H)	   70.96	   4,	  6	   4,	  6,	  7	  
6	   1.83	  –	  1.76	  (m,	  1H)	   36.48	   5,	  7,	  19	   	  	  
7	   4.06	  (dd,	  J	  =	  10.9,	  5.3	  Hz,	  1H)	   65.19	   6,	  7''	   9,	  5,	  6,	  19	  
	  	   4.44	  (dd,	  J	  =	  10.9,	  3.3	  Hz,	  1H)	   6,	  7'	   9,	  6,	  19	  
8	   	  	   	  	   	  	   	  	  
9	   	  	   165.67	   	  	   	  	  
10	   5.71	  (dd,	  J	  =	  15.9,	  1.4	  Hz,	  1H)	   121.53	   11	   9,	  12	  
11	   6.86	  (dd,	  J	  =	  15.9,	  6.7	  Hz,	  1H)	   150.73	   10,	  12	   9,	  12,	  13,	  20	  
12	   1.87	  –	  1.81	  (m,	  1H)	   38.51	   11,	  13,	  20	   11	  
13	   4.79	  (ddd,	  J	  =	  9.5,	  4.4,	  2.9	  Hz,	  1H)	   77.53	   12,	  14	   	  	  
14	   0.91	  (ddd,	  J	  =	  14.3,	  6.9,	  4.5	  Hz,	  1H)	   24.61	   13,	  14'',	  15	   	  	  
	  	   1.26	  –	  1.17	  (m,	  1H)	   13,14',	  15	   13	  
15	   0.52	  (t,	  J	  =	  7.4	  Hz,	  3H)	   9.73	   14	   13,	  14	  
16	   1.23	  (d,	  J	  =	  7.1	  Hz,	  3H)	   14.33	   2	   1,	  2,	  3	  
17	   1.03	  (d,	  J	  =	  6.9	  Hz,	  3H)	   10.24	   4	   3,	  4,	  5	  
18	   	  	   	  	   	  	   	  	  
19	   0.72	  (d,	  J	  =	  7.2	  Hz,	  3H)	   15.61	   6	   5,	  6,	  7	  
20	   0.67	  (d,	  J	  =	  6.5	  Hz,	  3H)	   9.86	   12	   11,	  12,	  13	  
 
Table 7.2 Ester narbonolide assignments and correlations.  
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Figure 7.3 Desmethyl narbonolide structure. 
Position	   H	   C	   COSY	   HMBC	  
1	   	  	   170.1	   	  	   	  	  
2	   3.15	  (q,	  J	  =	  7.3	  Hz,	  1H)	   51.9	   	  	   	  	  
3	   	  	   208.81	   	  	   	  	  
4	   2.26	  –	  2.16	  (m,	  1H)	   39.01	   5,	  17	   	  	  
5	   3.71	  (dt,	  J	  =	  8.7,	  4.3	  Hz,	  1H)	   69.03	   4,	  6	   	  	  
6	   1.39	  –	  1.31	  (m,	  1H)	   31.88	   5,7	   	  	  
7	   1.71	  (ddt,	  J	  =	  18.6,	  13.6,	  4.0	  Hz,	  2H)	   21.85	   6,	  8	   	  	  
8	   2.03	  (dt,	  J	  =	  13.3,	  5.5	  Hz,	  1H)	   36.83	   7,	  8''	   	  	  
	  	   2.57	  (ddd,	  J	  =	  13.5,	  10.0,	  5.4	  Hz,	  1H)	   7,	  8'	   	  	  
9	   	  	   199.89	   	  	   	  	  
10	   5.97	  (dd,	  J	  =	  16.0,	  1.5	  Hz,	  1H)	   131.9	   11	   	  	  
11	   6.50	  (dd,	  J	  =	  16.0,	  7.0	  Hz,	  1H)	   146.59	   10,	  12	   	  	  
12	   2.26	  –	  2.16	  (m,	  1H)	   51.4	   11,	  20,	  13	   	  	  
13	   4.83	  (dt,	  J	  =	  10.1,	  3.6	  Hz,	  1H)	   77.91	   12,	  14	   	  	  
14	   1.06	  (ddd,	  J	  =	  14.3,	  7.2,	  3.9	  Hz,	  1H)	   22.68	   15	   	  	  
	  	   1.20	  (ddd,	  J	  =	  14.6,	  10.0,	  7.3	  Hz,	  1H)	   13,	  15	   	  	  
15	   0.63	  (d,	  J	  =	  6.9	  Hz,	  3H)	   10.14	   14	   	  	  
16	   1.15	  (d,	  J	  =	  7.2	  Hz,	  3H)	   12.92	   2	   	  	  
17	   0.92	  (d,	  J	  =	  7.0	  Hz,	  3H)	   10.69	   4	   	  	  
18	   OH	  Not	  Seen	   	  	   	  	   	  	  
19	   	  	   	  	   	  	   	  	  
20	   0.60	  (d,	  J	  =	  7.3	  Hz,	  3H)	   12.33	   12	   	  	  
 
Table 7.3 Desmethyl narbonolide assignments and correlations.  
O
O
O O
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1
2
3
4
5
6
7
8910
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15
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17
20
* Tentative assignments, will confirm
upon secondary scale up with HMBC
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